| 1 | (+)-(s)-2-(6-methoxynaphthalen-2-yl) propanoic acid | Propanoic acid | [1] D02310D02310 💬 | - | - | 271[1] 271 💬 | 
| 2 | (2r)-2-propyloctanoic acid | - | - | - | - | 002[1]  2  💬 | 
| 3 | (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | - | - | - | - | 309[1] 309 💬 | 
| 4 | (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | - | - | - | - | 309[1] 309 💬 | 
| 5 | (6r)-4, 5, 6, 7 - tetrahydro-n6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 002[1]  2  💬 | 
| 6 | (6s)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 006[1]  6  💬 | 
| 7 | (r)-(-)-2-propyloctaroic acid | - | - | - | - | 002[1]  2  💬 | 
| 8 | (r)-3-(1-oxo-propoxy)-4-(n,n,n-trimethyl amonium chloride)-butanoic acid | Butyric Acid | [1] D05866D05866 💬 | - | - | 097[1] 97 💬 | 
| 9 | (s)- 2- amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | 006[1]  6  💬 | 
| 10 | (s)-3-((3-(1-((6-(3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium | - | - | - | - | 086[1] 86 💬 | 
| 11 | **comment**- imp inhalation solution identical to ventavis inhalation solution, but imp is in a different volume presentation. please see covering letter. | - | - | - | - | 086[1] 86 💬 | 
| 12 | 0 mg prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 044[1] 44 💬 | 
| 13 | 0,5 mg prevenar i.m. | - | - | - | - | 051[1] 51 💬 | 
| 14 | 10% nifedipine cream | Nifedipine | [1] D00437D00437 💬 | CACNA1C[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | Adrenergic signaling in cardiomyocytes[36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 050[1] 50 💬 | 
| 15 | 10% nitroglycerine in propylene glycol, usp | Nitroglycerin | [2] D00078D00078, D00515D00515 💬 | - | - | 051[1] 51 💬 | 
| 16 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 075[1] 75 💬 | 
| 17 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 075[1] 75 💬 | 
| 18 | 1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 006[1]  6  💬 | 
| 19 | 1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 006[1]  6  💬 | 
| 20 | 1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 006[1]  6  💬 | 
| 21 | 1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 006[1]  6  💬 | 
| 22 | 2'-o-(2-methoxyethyl)-d-ribose antisense oligonucleotide targeting glial fibrillary acidic protein messenger ribonucleic acid | Ribose | - | - | - | 131[1] 131 💬 | 
| 23 | 2-(2-(2-amino-9h-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | - | - | - | - | 013[1] 13 💬 | 
| 24 | 3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid | Pyrazole | - | - | - | 028[1] 28 💬 | 
| 25 | 5 mg prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 044[1] 44 💬 | 
| 26 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | Estradiol | [11] D00105D00105, D00358D00358, D01413D01413, D01617D01617, D01953D01953, D02086D02086, D04061D04061, D04063D04063, D04064D04064, D04065D04065, D08127D08127 💬 | ESR1[7] ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[12] Adrenergic signaling in cardiomyocytes, Breast cancer, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway | 226[1] 226 💬 | 
| 27 | 5-aminosalicylic acid(5-asa) and/or prednisone | Aminosalicylic acid | [3] D00162D00162, D00377D00377, D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 28 | 5-probe cocktail | - | - | - | - | 254[1] 254 💬 | 
| 29 | 68ga-bnota-prgd2 | - | - | - | - | 046[1] 46 💬 | 
| 30 | 90 mg hydrocortisone acetate suppository with sephure suppository applicator | Acetate | [2] D00088D00088, D00165D00165 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 31 | [rvt-1601 (in precedenza pa101b)] | - | - | - | - | 085[1] 85 💬 | 
| 32 | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (cbus) | - | - | - | - | 060[1] 60 💬 | 
| 33 | A multistrain probiotic product (dsf) | - | - | - | - | 097[1] 97 💬 | 
| 34 | Abatacept prefilled syringe | Abatacept | [1] D03203D03203 💬 | CD80[2] CD80, CD86 💬 | Allograft rejection[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis | 046[1] 46 💬 | 
| 35 | Abp 959 - proposed biosimilar to eculizumab | Eculizumab | [1] D03940D03940 💬 | C5[1] C5 💬 | Complement and coagulation cascades[9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus | 062[1] 62 💬 | 
| 36 | Access program - sildenafil citrate, viagra, revatio | Sildenafil | [2] D02229D02229, D08514D08514 💬 | PDE5A[1] PDE5A 💬 | Metabolic pathways[3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway | 086[1] 86 💬 | 
| 37 | Act-385781a (actelion epoprostenol) | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 38 | Acthar injectable product | - | - | - | - | 046[1] 46 💬 | 
| 39 | Adalimumab prn | Adalimumab | [1] D02597D02597 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 096[1] 96 💬 | 
| 40 | Adalimumab, plus prednisone | Adalimumab | [2] D00473D00473, D02597D02597 💬 | NR3C1[2] NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 41 | Adalimumab, solution for injection 40 mg/ (0.8 ml) pre-filled syringe | Adalimumab | [1] D02597D02597 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 42 | Adeno-associated viral (aav) serotype 8 (aav2/8) vector with liver-specific thyroxine-binding globulin (tbg) promoter, driving the expression of the human arsb gene | Levothyroxine | [2] D01010D01010, D08125D08125 💬 | THRA[2] THRA, THRB 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | 019[1] 19 💬 | 
| 43 | Advagraf prolonged-release hard capsules | - | - | - | - | 299[1] 299 💬 | 
| 44 | Agua para preparaciones inyectables | - | - | - | - | 078[1] 78 💬 | 
| 45 | Aldesleukin | Aldesleukin | [1] D00748D00748 💬 | IL2RA[3] IL2RA, IL2RB, IL2RG 💬 | Cytokine-cytokine receptor interaction[14] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor | 049[4] 49, 65, 96, 97 💬 | 
| 46 | Alirocumab | Alirocumab | [1] D10335D10335 💬 | PCSK9[1] PCSK9 💬 | Cholesterol metabolism[1] Cholesterol metabolism | 079[1] 79 💬 | 
| 47 | Alirocumab sar236553 (regn727) | Alirocumab | [1] D10335D10335 💬 | PCSK9[1] PCSK9 💬 | Cholesterol metabolism[1] Cholesterol metabolism | 079[1] 79 💬 | 
| 48 | Alkalinized lidocaine-heparin | Heparin | [4] D00358D00358, D02086D02086, D07510D07510, D08127D08127 💬 | SCN1A[6] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 | Adrenergic signaling in cardiomyocytes[4] Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction | 226[1] 226 💬 | 
| 49 | Allogeneic mesenchymal precursor cells | - | - | - | - | 046[1] 46 💬 | 
| 50 | Allogeneic neural retina-derived human neural retinal progenitor cells ex vivo expanded | - | - | - | - | 090[1] 90 💬 | 
| 51 | Alpha 1-proteinase inhibitor | Alpha-1-proteinase inhibitor | - | - | - | 231[1] 231 💬 | 
| 52 | Alpha 1-proteinase inhibitor (human) | Alpha-1-proteinase inhibitor | - | - | - | 231[1] 231 💬 | 
| 53 | Alpha-1 proteinase inhibitor (human) | - | - | - | - | 231[1] 231 💬 | 
| 54 | Alpha1-proteinase inhibitor | Alpha-1-proteinase inhibitor | - | - | - | 231[2] 231, 299 💬 | 
| 55 | Alpha1-proteinase inhibitor (human) | Alpha-1-proteinase inhibitor | - | - | - | 231[2] 231, 299 💬 | 
| 56 | Alprostadil | Alprostadil | [2] D00180D00180, D02705D02705 💬 | PTGER1[1] PTGER1 💬 | Calcium signaling pathway[4] Calcium signaling pathway, Human cytomegalovirus infection, Neuroactive ligand-receptor interaction, Pathways in cancer | 051[2] 51, 70 💬 | 
| 57 | Ambrisentan 5mg film-coated tablets [marketed product] | Ambrisentan | [1] D07077D07077 💬 | EDNRA[1] EDNRA 💬 | Calcium signaling pathway[7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 086[1] 86 💬 | 
| 58 | Amitriptyline, fluoxetine and tramadol alone (control group) | Amitriptyline | [6] D00326D00326, D00809D00809, D00823D00823, D01355D01355, D07448D07448, D08623D08623 💬 | OPRM1[3] OPRM1, SLC6A2, SLC6A4 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle | 078[1] 78 💬 | 
| 59 | Amorphous calcium carbonate | Calcium | [2] D00932D00932, D10802D10802 💬 | - | - | 235[1] 235 💬 | 
| 60 | Androgel 10 grams of gel containing 100 mg of testosterone | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 013[1] 13 💬 | 
| 61 | Antioxidant plus pregabalin | Pregabalin | [1] D02716D02716 💬 | CACNA2D1[4] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 💬 | Adrenergic signaling in cardiomyocytes[7] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway | 298[1] 298 💬 | 
| 62 | Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed | Apomorphine | [2] D02004D02004, D07460D07460 💬 | DRD1[2] DRD1, DRD2 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 63 | Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed | Apomorphine | [2] D02004D02004, D07460D07460 💬 | DRD1[2] DRD1, DRD2 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 64 | Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed | Apomorphine | [2] D02004D02004, D07460D07460 💬 | DRD1[2] DRD1, DRD2 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 65 | Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed | Apomorphine | [2] D02004D02004, D07460D07460 💬 | DRD1[2] DRD1, DRD2 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 66 | Atenolol or propranolol | Atenolol | [3] D00235D00235, D00483D00483, D08443D08443 💬 | ADRB1[3] ADRB1, ADRB2, ADRB3 💬 | Adrenergic signaling in cardiomyocytes[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway | 167[1] 167 💬 | 
| 67 | Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv) | Adenosine | [1] D00045D00045 💬 | ADORA1[4] ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | Alcoholism[12] Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 065[1] 65 💬 | 
| 68 | Autologous mesenchymal cell product | - | - | - | - | 013[1] 13 💬 | 
| 69 | Avatrombopag (proposed) | Avatrombopag | [1] D10306D10306 💬 | - | - | 063[1] 63 💬 | 
| 70 | Avxs-101 (previously known as scaav9.cb.smn) | - | - | - | - | 003[1]  3  💬 | 
| 71 | Azathioprine/prednisone | Azathioprine | [3] D00238D00238, D00473D00473, D03033D03033 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 085[1] 85 💬 | 
| 72 | Azd4017 and prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 075[1] 75 💬 | 
| 73 | Bacteriophage preparation | - | - | - | - | 096[1] 96 💬 | 
| 74 | Bascial prescription plus or minus herbs depend on symptoms | - | - | - | - | 097[1] 97 💬 | 
| 75 | Befizal l.p. 400 mg, comprimé enrobé à libération prolongée | - | - | - | - | 094[1] 94 💬 | 
| 76 | Behavioral: 6 months weight resistance and balance program | Isoxaflutole | - | - | - | 013[1] 13 💬 | 
| 77 | Behavioral: administration of probiotic (l. rhamnosus and l. acidophilus) | Lactobacillus acidophilus | [1] D04349D04349 💬 | - | - | 097[1] 97 💬 | 
| 78 | Behavioral: co-op treatment protocol | - | - | - | - | 006[1]  6  💬 | 
| 79 | Behavioral: gait and balance training program | Isoxaflutole | - | - | - | 006[1]  6  💬 | 
| 80 | Behavioral: heart health educational program | - | - | - | - | 049[1] 49 💬 | 
| 81 | Behavioral: protein and calorie controlled diet | - | - | - | - | 251[1] 251 💬 | 
| 82 | Betamethasone | Betamethasone | [7] D00244D00244, D00972D00972, D01357D01357, D01402D01402, D01637D01637, D02032D02032, D02286D02286 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 002[6]  2 , 28, 46, 90, 96, 235 💬 | 
| 83 | Betamethasone acibutate | Betamethasone | [7] D00244D00244, D00972D00972, D01357D01357, D01402D01402, D01637D01637, D02032D02032, D02286D02286 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 84 | Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days | Acetate | [7] D00244D00244, D00972D00972, D01357D01357, D01402D01402, D01637D01637, D02032D02032, D02286D02286 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 002[1]  2  💬 | 
| 85 | Bi 695501 prefilled syringe | - | - | - | - | 046[1] 46 💬 | 
| 86 | Biib019 (daclizumab high yield process) | Daclizumab | [1] D03639D03639 💬 | IL2RA[1] IL2RA 💬 | Cytokine-cytokine receptor interaction[11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor | 013[1] 13 💬 | 
| 87 | Biib041 (pr fampridine) | Dalfampridine | [1] D04127D04127 💬 | KCNA4[4] KCNA4, KCNC3, KCND2, KCND3 💬 | Cortisol synthesis and secretion[4] Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia | 013[1] 13 💬 | 
| 88 | Bio-25 probiotic | - | - | - | - | 299[1] 299 💬 | 
| 89 | Biosimilar product to adalimumab | Adalimumab | [1] D02597D02597 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 90 | Bladder instillation with heparin/ lidocaine | Heparin | [4] D00358D00358, D02086D02086, D07510D07510, D08127D08127 💬 | SCN1A[6] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 | Adrenergic signaling in cardiomyocytes[4] Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction | 226[1] 226 💬 | 
| 91 | Bladder instillation with triamcinolone acetonide | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 226[1] 226 💬 | 
| 92 | Bladder instillation without triamcinolone acetonide | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 226[1] 226 💬 | 
| 93 | Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin) | Digoxin | [13] D00298D00298, D00330D00330, D00455D00455, D00529D00529, D00550D00550, D00696D00696, D01207D01207, D01475D01475, D02290D02290, D05028D05028, D05259D05259, D05261D05261, D08229D08229 💬 | ATP1A1[25] ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP4A, ATP4B, CYSLTR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, PTGS1, PTGS2 💬 | Adrenergic signaling in cardiomyocytes[49] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis, Collecting duct acid secretion, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway | 046[1] 46 💬 | 
| 94 | Bortezomib/dexamethasone | Bortezomib | [10] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D03150D03150 💬 | NR3C1[2] NR3C1, PSMB5 💬 | Alzheimer disease[9] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia | 283[1] 283 💬 | 
| 95 | Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone | Bortezomib | [10] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D03150D03150 💬 | NR3C1[2] NR3C1, PSMB5 💬 | Alzheimer disease[9] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia | 028[1] 28 💬 | 
| 96 | Botox 100 unites allergan (pr1) | - | - | - | - | 002[1]  2  💬 | 
| 97 | Btt1023 iv infusion 20 mg/ml, 5 ml drug product | - | - | - | - | 094[1] 94 💬 | 
| 98 | Budesonide 6 mg capsules, hard (bux-pvii prototype) | Budesonide | [1] D00246D00246 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 99 | Budesonide 6 mg prolonged-release capsule, hard (bux-pvii prototype) | Budesonide | [1] D00246D00246 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 100 | Budesonide 6 mg prolonged-release capsules, hard (bux-pvii prototype) | Budesonide | [1] D00246D00246 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 101 | Budesonide 9 mg capsules, hard (bux-pvii prototype) | Budesonide | [1] D00246D00246 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 102 | Budesonide 9 mg prolonged-release capsule, hard (bux-pvii prototype) | Budesonide | [1] D00246D00246 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 103 | Budesonide 9 mg prolonged-release capsules, hard (bux-pvii prototype) | Budesonide | [1] D00246D00246 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 104 | Budesonide plus prevacid | Budesonide | [1] D00246D00246 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 098[1] 98 💬 | 
| 105 | Bupivacaine/epinephrine/dexamethasone | Bupivacaine | [14] D00095D00095, D00292D00292, D00975D00975, D00996D00996, D01450D01450, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02149D02149, D02174D02174, D02591D02591, D02592D02592, D07552D07552 💬 | ADRA1A[15] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, NR3C1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | AMPK signaling pathway[15] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 096[1] 96 💬 | 
| 106 | Buprenorphine | Buprenorphine | [2] D00836D00836, D07132D07132 💬 | OPRK1[2] OPRK1, OPRM1 💬 | Estrogen signaling pathway[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction | 046[2] 46, 70 💬 | 
| 107 | Buprenorphine transdermal patch | Buprenorphine | [2] D00836D00836, D07132D07132 💬 | OPRK1[2] OPRK1, OPRM1 💬 | Estrogen signaling pathway[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 108 | Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf | Busulfan | [8] D00107D00107, D00142D00142, D00248D00248, D01907D01907, D02115D02115, D03235D03235, D07966D07966, D08556D08556 💬 | CSF3R[9] CSF3R, DHFR, DHFR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, RRM1 💬 | Alzheimer disease[46] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Axon guidance, B cell receptor signaling pathway, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Drug metabolism - other enzymes, Folate biosynthesis, Glucagon signaling pathway, Glutamatergic synapse, Glutathione metabolism, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, One carbon pool by folate, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Pyrimidine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 060[1] 60 💬 | 
| 109 | Bydureon 2 mg powder and solvent for prolonged-release suspension | - | - | - | - | 006[1]  6  💬 | 
| 110 | C326, il-6 inhibitory avimer protein | - | - | - | - | 096[1] 96 💬 | 
| 111 | Calcium carbonate | Calcium | [2] D00932D00932, D10802D10802 💬 | - | - | 013[8] 13, 19, 46, 53, 75, 96, 235, 299 💬 | 
| 112 | Calcium carbonate and alphacalcidol | Calcium | [2] D00932D00932, D10802D10802 💬 | - | - | 235[1] 235 💬 | 
| 113 | Calcium carbonate d | Calcium | [2] D00932D00932, D10802D10802 💬 | - | - | 053[1] 53 💬 | 
| 114 | Calcium lactate | Calcium | [2] D00936D00936, D02254D02254 💬 | - | - | 235[1] 235 💬 | 
| 115 | Canakinumab (proposed) | Canakinumab | [1] D09315D09315 💬 | IL1B[1] IL1B 💬 | AGE-RAGE signaling pathway in diabetic complications[42] AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection | 046[1] 46 💬 | 
| 116 | Cardiovascular profile | - | - | - | - | 113[1] 113 💬 | 
| 117 | Caveolin-1-scaffolding-protein-derived peptide (lti-03) | - | - | - | - | 085[1] 85 💬 | 
| 118 | Cd34+ enriched, t cell depleted donor stem cell product | - | - | - | - | 326[1] 326 💬 | 
| 119 | Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg) | Certolizumab pegol | [1] D03441D03441 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 120 | Cgmp protein | - | - | - | - | 097[1] 97 💬 | 
| 121 | Chinese herb prescription granule plus prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 122 | Cipro (ciprofloxacin, bayq3939) | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 123 | Ciprofloxacin | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 002[5]  2 , 60, 96, 97, 299 💬 | 
| 124 | Ciprofloxacin (bayq3939) dry powder for inhalation | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 125 | Ciprofloxacin (cipro inhale, bayq3939) | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 126 | Ciprofloxacin (cipro, bayq3939) | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 127 | Ciprofloxacin (ciproxin) | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 128 | Ciprofloxacin dispersion for inhalation | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 129 | Ciprofloxacin dpi | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 130 | Ciprofloxacin dpi (bayq3939) | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 131 | Ciprofloxacin for inhalation | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 132 | Ciprofloxacin hydrochloride | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 096[2] 96, 299 💬 | 
| 133 | Ciprofloxacin hydrochloride monohydrate | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 134 | Ciprofloxacin inhale | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 135 | Circadin 2 mg comprimidos de liberación prolongada | - | - | - | - | 090[1] 90 💬 | 
| 136 | Cis-4-hydroxy-l-proline | Proline | [1] D00035D00035 💬 | - | - | 094[1] 94 💬 | 
| 137 | Cisapride | Cisapride | [2] D00274D00274, D02092D02092 💬 | HTR2A[3] HTR2A, HTR3A, HTR4 💬 | Calcium signaling pathway[7] Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway | 013[1] 13 💬 | 
| 138 | Clartihromycin, amoxicillin, and omeprazole | Amoxicillin | [7] D00229D00229, D00455D00455, D01207D01207, D02925D02925, D05259D05259, D05261D05261, D07452D07452 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 006[1]  6  💬 | 
| 139 | Clobetasol propionate | Clobetasol | [2] D01272D01272, D07715D07715 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[2] 46, 162 💬 | 
| 140 | Clobetasol propionate + methotrexate | Clobetasol | [4] D00142D00142, D01272D01272, D02115D02115, D07715D07715 💬 | DHFR[3] DHFR, DHFR2, NR3C1 💬 | Antifolate resistance[6] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate | 162[1] 162 💬 | 
| 141 | Clobetasol propionate alone | Clobetasol | [2] D01272D01272, D07715D07715 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 162[1] 162 💬 | 
| 142 | Clobetasol propionate cream treatment | Clobetasol | [2] D01272D01272, D07715D07715 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 162[1] 162 💬 | 
| 143 | Coenzyme q10 and lisinopril | Lisinopril | [3] D00362D00362, D01065D01065, D08131D08131 💬 | ACE[1] ACE 💬 | Chagas disease[6] Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system | 113[1] 113 💬 | 
| 144 | Colal pred | - | - | - | - | 097[1] 97 💬 | 
| 145 | Colal-pred | - | - | - | - | 097[1] 97 💬 | 
| 146 | Colal-pred® | - | - | - | - | 097[1] 97 💬 | 
| 147 | Colistimethate sodium (promixin) | Colistimethate | [1] D02049D02049 💬 | - | - | 299[1] 299 💬 | 
| 148 | Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine | Azathioprine | [12] D00238D00238, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D02994D02994, D03033D03033 💬 | MS4A1[2] MS4A1, NR3C1 💬 | Hematopoietic cell lineage[2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction | 035[1] 35 💬 | 
| 149 | Combination oral budesonide and rectal hydrocortisone | Budesonide | [2] D00088D00088, D00246D00246 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 150 | Combination product (natpara) and drug or supplements [disease and drug registry] | - | - | - | - | 235[1] 235 💬 | 
| 151 | Combination product:  device: axially oscillating sphere dry powder inhaler (aos dpi) | - | - | - | - | 086[1] 86 💬 | 
| 152 | Combination product: active treatment with dual therapy | - | - | - | - | 002[1]  2  💬 | 
| 153 | Combination product: beclomethasone dipropionate in addition to mc-evoo | Beclomethasone dipropionate | [2] D00689D00689, D07495D07495 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 154 | Combination product: beclomethasone dipropionate in addition to refined oil | Beclomethasone dipropionate | [2] D00689D00689, D07495D07495 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 155 | Combination product: belimumab | Belimumab | [1] D03068D03068 💬 | TNFSF13B[1] TNFSF13B 💬 | Cytokine-cytokine receptor interaction[4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis | 049[1] 49 💬 | 
| 156 | Combination product: goldic serum | - | - | - | - | 070[1] 70 💬 | 
| 157 | Combination product: hyperbaric oxygen therapy- | Oxygen | [1] D00003D00003 💬 | - | - | 226[1] 226 💬 | 
| 158 | Combination product: implantable system for remodulin (treprostinil) | Treprostinil | [1] D06213D06213 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 159 | Combination product: l-dopa 140 mg | Levodopa | [1] D00059D00059 💬 | DRD1[5] DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 160 | Combination product: l-dopa 35 mg | Levodopa | [1] D00059D00059 💬 | DRD1[5] DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 161 | Combination product: l-dopa 70mg | Levodopa | [1] D00059D00059 💬 | DRD1[5] DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 162 | Combination product: l-dopa 70mg/carbidopa 7mg | Carbidopa | [2] D00059D00059, D00558D00558 💬 | DDC[6] DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism[16] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway | 006[1]  6  💬 | 
| 163 | Combination product: mavrilimumab | Mavrilimumab | [1] D09930D09930 💬 | CSF2RA[1] CSF2RA 💬 | Cytokine-cytokine receptor interaction[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer | 041[1] 41 💬 | 
| 164 | Combination product: methotrexate | Methotrexate | [2] D00142D00142, D02115D02115 💬 | DHFR[2] DHFR, DHFR2 💬 | Antifolate resistance[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 046[1] 46 💬 | 
| 165 | Combination product: nd0612 solution for sc infusion | - | - | - | - | 006[1]  6  💬 | 
| 166 | Combination product: ofatumumab with ai | Ofatumumab | [1] D09314D09314 💬 | MS4A1[1] MS4A1 💬 | Hematopoietic cell lineage[1] Hematopoietic cell lineage | 013[1] 13 💬 | 
| 167 | Combination product: ofatumumab with prf | Ofatumumab | [1] D09314D09314 💬 | MS4A1[1] MS4A1 💬 | Hematopoietic cell lineage[1] Hematopoietic cell lineage | 013[1] 13 💬 | 
| 168 | Combination product: prp combined magnovision | - | - | - | - | 090[1] 90 💬 | 
| 169 | Combination product: transcon pth | - | - | - | - | 235[1] 235 💬 | 
| 170 | Combination product: treprostinil via implanted pump | Treprostinil | [1] D06213D06213 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 171 | Combination product: twice daily 90 mg hydrocortisone acetate suppository administered with sephure applicator | Acetate | [2] D00088D00088, D00165D00165 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 172 | Combination therapy with vigabatrin and prednisolone | Prednisolone | [9] D00472D00472, D00535D00535, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | ABAT[2] ABAT, NR3C1 💬 | Alanine, aspartate and glutamate metabolism[8] Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism | 145[1] 145 💬 | 
| 173 | Continuation of current haart (boosted protease inhibitor [pi] combination + 2 nrtis) | - | - | - | - | 265[1] 265 💬 | 
| 174 | Control intervention (no dexamethasone) | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 175 | Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) | Acetate | [21] D00088D00088, D00292D00292, D00472D00472, D00473D00473, D00973D00973, D00975D00975, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D01998D01998, D02156D02156, D02174D02174, D02591D02591, D02592D02592, D03301D03301, D07749D07749 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 176 | Copaxone - 20 mg/ml soluzione iniettabile in siringhe preriempite 30 siringhe | - | - | - | - | 013[1] 13 💬 | 
| 177 | Copaxone - 40 mg/ml soluzione iniettabile in siringa preriempita 12 siringhe preriempite da 1 ml con ago | - | - | - | - | 013[1] 13 💬 | 
| 178 | Copaxone 20 mg/ml solución inyectable en jeringa precargada | - | - | - | - | 013[1] 13 💬 | 
| 179 | Copaxone 20 mg/ml solución para inyección en jeringa precargada | - | - | - | - | 013[1] 13 💬 | 
| 180 | Copaxone 20 mg/ml solution for injection, pre-filled syringe | - | - | - | - | 013[1] 13 💬 | 
| 181 | Copaxone 20 mg/ml, solution for injection, pre-filled syringes | - | - | - | - | 013[1] 13 💬 | 
| 182 | Copaxone 20mg/ml solution for injection, pre-filled syringe | - | - | - | - | 013[1] 13 💬 | 
| 183 | Copaxone 40 mg/ml solution for injection, pre-filled syringe | - | - | - | - | 013[1] 13 💬 | 
| 184 | Cortef (hydrocortisone) | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 083[1] 83 💬 | 
| 185 | Corticosteroid (prednisolone) | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 085[1] 85 💬 | 
| 186 | Corticosteroid treatment (methylprednisolone or prednisolone) | Methylprednisolone | [14] D00407D00407, D00472D00472, D00751D00751, D00979D00979, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 064[1] 64 💬 | 
| 187 | Corticosteroids (prednisone or prednisolone) | Prednisolone | [9] D00472D00472, D00473D00473, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 049[1] 49 💬 | 
| 188 | Current marketed flolan (epoprostenol sodium) | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 189 | Cyclo[l-alanyl-l-seryl-l-isoleucyl-l-prolyl-l-prolyl-l-glutaminyl-l-lysyl-l-tyrosyl-d-prolyl-l-prolyl-(2s)-2-aminodecanoyl-l-alpha-glutamyl-l-threonyl] | - | - | - | - | 299[1] 299 💬 | 
| 190 | Cyclophosphamide + pred | Cyclophosphamide | [2] D00287D00287, D07760D07760 💬 | - | - | 283[1] 283 💬 | 
| 191 | Cyclophosphamide, azathioprine,prednisone,methylprednisolone | Azathioprine | [11] D00238D00238, D00287D00287, D00407D00407, D00473D00473, D00751D00751, D00979D00979, D03033D03033, D05000D05000, D05001D05001, D05002D05002, D07760D07760 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 042[3] 42, 43, 45 💬 | 
| 192 | Cyclophosphamide, bortezomib, and dexamethasone (cybord) | Bortezomib | [12] D00287D00287, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D03150D03150, D07760D07760 💬 | NR3C1[2] NR3C1, PSMB5 💬 | Alzheimer disease[9] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia | 028[1] 28 💬 | 
| 193 | Cyclophosphamide, bortezomib, dexamethasone | Bortezomib | [12] D00287D00287, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D03150D03150, D07760D07760 💬 | NR3C1[2] NR3C1, PSMB5 💬 | Alzheimer disease[9] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia | 028[1] 28 💬 | 
| 194 | Cyclophosphamide, bortezomib, dexamethasone plus daratumumab | Bortezomib | [13] D00287D00287, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D03150D03150, D07760D07760, D10777D10777 💬 | CD38[3] CD38, NR3C1, PSMB5 💬 | Alzheimer disease[16] Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Hematopoietic cell lineage, Huntington disease, Metabolic pathways, Neuroactive ligand-receptor interaction, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Salivary secretion, Spinocerebellar ataxia | 028[1] 28 💬 | 
| 195 | Cyclophosphamide-prednisone-azathioprine | Azathioprine | [5] D00238D00238, D00287D00287, D00473D00473, D03033D03033, D07760D07760 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 049[1] 49 💬 | 
| 196 | Cyclosporin, methotrexate (gvhd prophylaxis) | Cyclosporine | [3] D00142D00142, D00184D00184, D02115D02115 💬 | DHFR[7] DHFR, DHFR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[37] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Axon guidance, B cell receptor signaling pathway, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Folate biosynthesis, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, One carbon pool by folate, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 326[1] 326 💬 | 
| 197 | Cyclosporine oral product | Cyclosporine | [1] D00184D00184 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 060[1] 60 💬 | 
| 198 | D-proline | D-Proline | [1] D00035D00035 💬 | - | - | 097[1] 97 💬 | 
| 199 | D.3.2 product code where applicable13: | - | - | - | - | 193[1] 193 💬 | 
| 200 | Dabigatran etexilate | Dabigatran | [2] D07144D07144, D09707D09707 💬 | F2[1] F2 💬 | Complement and coagulation cascades[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, Neuroactive ligand-receptor interaction, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Platelet activation, Regulation of actin cytoskeleton | 051[1] 51 💬 | 
| 201 | Daclizumab high yield process | Daclizumab | [1] D03639D03639 💬 | IL2RA[1] IL2RA 💬 | Cytokine-cytokine receptor interaction[11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor | 013[1] 13 💬 | 
| 202 | Decortin (prednisona) 5 mg comprimidos | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 203 | Denosumab | Denosumab | [1] D03684D03684 💬 | TNFSF11[1] TNFSF11 💬 | Breast cancer[7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis | 046[7] 46, 50, 93, 95, 96, 274, 299 💬 | 
| 204 | Denosumab - - immunoglobulin g2 human monoclonal antibody to rank ligand | Denosumab | [1] D03684D03684 💬 | TNFSF11[1] TNFSF11 💬 | Breast cancer[7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis | 274[1] 274 💬 | 
| 205 | Denosumab - immunoglobulin g2 human monoclonal antibody to rank ligand | Denosumab | [1] D03684D03684 💬 | TNFSF11[1] TNFSF11 💬 | Breast cancer[7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis | 274[1] 274 💬 | 
| 206 | Device: abatacept combination product (acp) | Abatacept | [1] D03203D03203 💬 | CD80[2] CD80, CD86 💬 | Allograft rejection[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis | 046[1] 46 💬 | 
| 207 | Device: avonex prefilled syringe via manual im injection | - | - | - | - | 013[1] 13 💬 | 
| 208 | Device: biib017 (peginterferon beta-1a) pre-filled syringe (pfs) | Peginterferon beta-1a | [1] D10483D10483 💬 | IFNAR1[2] IFNAR1, IFNAR2 💬 | Coronavirus disease - COVID-19[18] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway | 013[1] 13 💬 | 
| 209 | Device: blood pressure | - | - | - | - | 084[1] 84 💬 | 
| 210 | Device: cell processing for tcrabeta+/cd19+ depletion | - | - | - | - | 065[1] 65 💬 | 
| 211 | Device: cell processing for tcraß+/cd19+ depletion | - | - | - | - | 065[1] 65 💬 | 
| 212 | Device: cic using lofric primo | - | - | - | - | 013[1] 13 💬 | 
| 213 | Device: dexamethasone injection | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 090[1] 90 💬 | 
| 214 | Device: heparin-induced extracorporeal ldl precipitation | Heparin | [1] D07510D07510 💬 | SERPINC1[1] SERPINC1 💬 | Complement and coagulation cascades[1] Complement and coagulation cascades | 079[1] 79 💬 | 
| 215 | Device: iowa oral pressure instrument | - | - | - | - | 002[1]  2  💬 | 
| 216 | Device: micro mouth pressure meter | - | - | - | - | 002[1]  2  💬 | 
| 217 | Device: nocturnal oxygen , nocturnal bi-level positive pressure ventilation | Oxygen | [1] D00003D00003 💬 | - | - | 299[1] 299 💬 | 
| 218 | Device: positive expiratory pressure | - | - | - | - | 299[1] 299 💬 | 
| 219 | Device: pre-filled syringe (pfs) | - | - | - | - | 046[1] 46 💬 | 
| 220 | Device: primus fgti (flexible great toe implant) | Florasulam | - | - | - | 046[1] 46 💬 | 
| 221 | Device: propofol dosage | Propofol | [1] D00549D00549 💬 | GABRA1[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | GABAergic synapse[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction | 084[1] 84 💬 | 
| 222 | Device: reciprocating procedure device (rpd) - avanca re no. 1091001 | - | - | - | - | 046[1] 46 💬 | 
| 223 | Device: single-use autoinjector with a prefilled liquid avonex syringe | - | - | - | - | 013[1] 13 💬 | 
| 224 | Device: the ozone generator device (human pro medic, german) | Ozone | - | - | - | 051[1] 51 💬 | 
| 225 | Dexamethasone | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 013[25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 162, 222, 235, 283, 296, 299 💬 | 
| 226 | Dexamethasone (1 cycle) | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 063[1] 63 💬 | 
| 227 | Dexamethasone (4 cycles) | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 063[1] 63 💬 | 
| 228 | Dexamethasone (50mg 1dd6, 3 consecutive days/month) | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 035[1] 35 💬 | 
| 229 | Dexamethasone 0,1 mg tablets | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 230 | Dexamethasone 0,5mg | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 084[1] 84 💬 | 
| 231 | Dexamethasone 0.5mg tablet | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 232 | Dexamethasone 0.5mg/5ml solution | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 035[2] 35, 162 💬 | 
| 233 | Dexamethasone 0.5mg/5ml solution in mucolox™ | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 035[2] 35, 162 💬 | 
| 234 | Dexamethasone 1,5 mg tablets | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 235 | Dexamethasone 21-dihydrogen phosphate | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 065[1] 65 💬 | 
| 236 | Dexamethasone 21-phosphate | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 237 | Dexamethasone 2mg tablets | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 238 | Dexamethasone 4 mg jenapharm | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 028[1] 28 💬 | 
| 239 | Dexamethasone abcur | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 063[1] 63 💬 | 
| 240 | Dexamethasone and rituximab | Dexamethasone | [10] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D02994D02994 💬 | MS4A1[2] MS4A1, NR3C1 💬 | Hematopoietic cell lineage[2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction | 063[1] 63 💬 | 
| 241 | Dexamethasone oral tablet 8mg (dexamethasone krka tablets(8mg), warsaw, poland). | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 235[1] 235 💬 | 
| 242 | Dexamethasone parotid irrigation | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 053[1] 53 💬 | 
| 243 | Dexamethasone sodium phosphate | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 065[3] 65, 70, 96 💬 | 
| 244 | Dexamethasone sodium phosphate 250 mg/ 10 ml | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 096[1] 96 💬 | 
| 245 | Dexamethasone sodium phosphate 250 mg/10 ml solution | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 299[1] 299 💬 | 
| 246 | Dexamethasone sodium phosphate ph. eur. | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 065[1] 65 💬 | 
| 247 | Dexamethasone sodium sulfate | Dexamethasone | [11] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01732D01732, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D05877D05877 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 028[1] 28 💬 | 
| 248 | Dexamethasone soduim phosphate | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 013[1] 13 💬 | 
| 249 | Dexamethasone, 40 mg | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 028[1] 28 💬 | 
| 250 | Dexmedetomidine | Dexmedetomidine | [2] D00514D00514, D01205D01205 💬 | ADRA2A[3] ADRA2A, ADRA2B, ADRA2C 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 002[12]  2 ,  4 ,  6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬 | 
| 251 | Dexmedetomidine 1 | Dexmedetomidine | [2] D00514D00514, D01205D01205 💬 | ADRA2A[3] ADRA2A, ADRA2B, ADRA2C 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 280[1] 280 💬 | 
| 252 | Dexmedetomidine 2 | Dexmedetomidine | [2] D00514D00514, D01205D01205 💬 | ADRA2A[3] ADRA2A, ADRA2B, ADRA2C 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 280[1] 280 💬 | 
| 253 | Dexmedetomidine 3 | Dexmedetomidine | [2] D00514D00514, D01205D01205 💬 | ADRA2A[3] ADRA2A, ADRA2B, ADRA2C 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 280[1] 280 💬 | 
| 254 | Dexmedetomidine group | Dexmedetomidine | [2] D00514D00514, D01205D01205 💬 | ADRA2A[3] ADRA2A, ADRA2B, ADRA2C 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 070[1] 70 💬 | 
| 255 | Dexmedetomidine hydrochloride | Dexmedetomidine | [2] D00514D00514, D01205D01205 💬 | ADRA2A[3] ADRA2A, ADRA2B, ADRA2C 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 070[1] 70 💬 | 
| 256 | Dexmedetomidine hydrochloride infusion | Dexmedetomidine | [2] D00514D00514, D01205D01205 💬 | ADRA2A[3] ADRA2A, ADRA2B, ADRA2C 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 006[1]  6  💬 | 
| 257 | Dexmedetomidine with ropivacaine | Dexmedetomidine | [4] D00514D00514, D01205D01205, D04048D04048, D08490D08490 💬 | ADRA2A[8] ADRA2A, ADRA2B, ADRA2C, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[5] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction, cGMP-PKG signaling pathway | 070[1] 70 💬 | 
| 258 | Diagnostic test: beam test to predict falls | Tricyclazole | - | - | - | 006[1]  6  💬 | 
| 259 | Diagnostic test: biotherapy prescription with sinnotest® software | - | - | - | - | 046[1] 46 💬 | 
| 260 | Diagnostic test: dexamethasone test | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 075[1] 75 💬 | 
| 261 | Diagnostic test: fecal microbiome probiotic | - | - | - | - | 294[1] 294 💬 | 
| 262 | Diagnostic test: preoparative blood laboratory tests | - | - | - | - | 235[1] 235 💬 | 
| 263 | Diagnostic test: pressure pain threshold | - | - | - | - | 113[1] 113 💬 | 
| 264 | Diagnostic test: pulmonary microbiome probiotic | - | - | - | - | 294[1] 294 💬 | 
| 265 | Diagnostic test: retrospective evaluation of endoscopy prior to study drug | - | - | - | - | 098[1] 98 💬 | 
| 266 | Diagnostic test: voc probiotic | - | - | - | - | 294[1] 294 💬 | 
| 267 | Diazoxide | Diazoxide | [1] D00294D00294 💬 | ABCC8[2] ABCC8, KCNJ11 💬 | ABC transporters[4] ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus | 013[2] 13, 193 💬 | 
| 268 | Diazoxide choline | Choline | [2] D00294D00294, D07690D07690 💬 | ABCC8[2] ABCC8, KCNJ11 💬 | ABC transporters[4] ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus | 193[1] 193 💬 | 
| 269 | Diazoxide choline controlled-release tablet | Choline | [2] D00294D00294, D07690D07690 💬 | ABCC8[2] ABCC8, KCNJ11 💬 | ABC transporters[4] ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus | 193[1] 193 💬 | 
| 270 | Diclofenac + omeprazole | Diclofenac | [7] D00455D00455, D00903D00903, D00904D00904, D01207D01207, D05259D05259, D05261D05261, D07816D07816 💬 | ATP4A[4] ATP4A, ATP4B, PTGS1, PTGS2 💬 | Alzheimer disease[26] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway | 046[1] 46 💬 | 
| 271 | Dimebon + omeprazole | Latrepirdine | [5] D00455D00455, D01207D01207, D05259D05259, D05261D05261, D09917D09917 💬 | ACHE[8] ACHE, ATP4A, ATP4B, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | Alcoholism[26] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Dopaminergic synapse, Gastric acid secretion, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Metabolic pathways, Neuroactive ligand-receptor interaction, Nicotine addiction, Oxidative phosphorylation, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway | 008[1]  8  💬 | 
| 272 | Dopamine agonists (pramipexole, ropirinole) | Dopamine | [4] D00559D00559, D00633D00633, D05575D05575, D07870D07870 💬 | DRD1[5] DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 273 | Dose of 60 mg/kg alpha1-proteinase inhibitor | Alpha-1-proteinase inhibitor | - | - | - | 231[1] 231 💬 | 
| 274 | Dose of 60 mg/kg fraction iv-1 alpha1-proteinase inhibitor | Alpha-1-proteinase inhibitor | - | - | - | 231[1] 231 💬 | 
| 275 | Doxepin | Doxepin | [2] D00814D00814, D07875D07875 💬 | HRH1[3] HRH1, SLC6A2, SLC6A4 💬 | Calcium signaling pathway[5] Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle | 006[1]  6  💬 | 
| 276 | Doxepin and zopiclone | Doxepin | [3] D00814D00814, D01372D01372, D07875D07875 💬 | GABRA1[19] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, SLC6A2, SLC6A4 💬 | Calcium signaling pathway[10] Calcium signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction | 006[1]  6  💬 | 
| 277 | Dual release hydrocortisone (plenadren) | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 278 | Dupilumab prefilled syringe | Dupilumab | [1] D10354D10354 💬 | IL4R[1] IL4R 💬 | Cytokine-cytokine receptor interaction[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation | 160[1] 160 💬 | 
| 279 | Egg white protein | Egg | - | - | - | 096[1] 96 💬 | 
| 280 | Egg yolk preparation with cholesterol | Cholesterol | [1] D00040D00040 💬 | - | - | 310[1] 310 💬 | 
| 281 | Eltrombopag | Eltrombopag | [1] D03978D03978 💬 | - | - | 060[5] 60, 63, 65, 284, 285 💬 | 
| 282 | Eltrombopag (revolade) | Eltrombopag | [1] D03978D03978 💬 | - | - | 063[1] 63 💬 | 
| 283 | Eltrombopag 12.5 mg | Eltrombopag | [1] D03978D03978 💬 | - | - | 060[1] 60 💬 | 
| 284 | Eltrombopag 25 mg | Eltrombopag | [1] D03978D03978 💬 | - | - | 060[1] 60 💬 | 
| 285 | Eltrombopag combining rituximab | Eltrombopag | [2] D02994D02994, D03978D03978 💬 | MS4A1[1] MS4A1 💬 | Hematopoietic cell lineage[1] Hematopoietic cell lineage | 063[1] 63 💬 | 
| 286 | Eltrombopag olamine | Eltrombopag | [1] D03978D03978 💬 | - | - | 060[2] 60, 63 💬 | 
| 287 | Eltrombopag olamine (sb-497115-gr) | Eltrombopag | [1] D03978D03978 💬 | - | - | 063[1] 63 💬 | 
| 288 | Eltrombopag olamine, revolade, promacta | Eltrombopag | [1] D03978D03978 💬 | - | - | 063[1] 63 💬 | 
| 289 | Eltrombopag oral tablets | Eltrombopag | [1] D03978D03978 💬 | - | - | 063[1] 63 💬 | 
| 290 | Enbrel - 50 mg soluzione iniettabile in siringa (vetro da 1 ml) preriempita - uso sottocutaneo 12 siringhe preriempite + 24 tamponi imbevuti di alcol | - | - | - | - | 046[1] 46 💬 | 
| 291 | Enbrel 50 mg solution for injection in pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 292 | Enbrel 50mg pre-filled pen | - | - | - | - | 046[1] 46 💬 | 
| 293 | Enbrel 50mg pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 294 | Enbrel pre-filled pen | - | - | - | - | 046[1] 46 💬 | 
| 295 | Enbrel pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 296 | Enbrel® 50 mg solution for injection in pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 297 | Engineerd protein inhibitor of human neutrophil elastase | - | - | - | - | 299[1] 299 💬 | 
| 298 | Engineered protein inhibitor of human neutrophil elastase | - | - | - | - | 299[1] 299 💬 | 
| 299 | Ensure high protein | - | - | - | - | 299[1] 299 💬 | 
| 300 | Epinephrine | Epinephrine | [3] D00095D00095, D00996D00996, D02149D02149 💬 | ADRA1A[9] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | AMPK signaling pathway[13] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 046[2] 46, 96 💬 | 
| 301 | Epoprostenol | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 302 | Epoprostenol for injection | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 303 | Epoprostenol sodico | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 304 | Epoprostenol sodium | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 305 | Epoprostenol-actelion | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 306 | Erythromycin | Erythromycin | [9] D00140D00140, D00851D00851, D01361D01361, D02009D02009, D02184D02184, D02523D02523, D02524D02524, D02525D02525, D04054D04054 💬 | - | - | 006[5]  6 , 36, 164, 228, 291 💬 | 
| 307 | Erythropoietin | Erythropoietin | [1] D03231D03231 💬 | EPOR[1] EPOR 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer | 002[9]  2 ,  6 , 13, 18, 22, 47, 70, 95, 96 💬 | 
| 308 | Erythropoietin human recombinant (eporh) | Erythropoietin | [1] D03231D03231 💬 | EPOR[1] EPOR 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer | 006[1]  6  💬 | 
| 309 | Etanercept pre-filled syringe | Etanercept | [1] D00742D00742 💬 | LTA[2] LTA, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 310 | Etanercept pre-filled syringe sq injection | Etanercept | [1] D00742D00742 💬 | LTA[2] LTA, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 311 | Etanercept, methotrexate, prednisolone | Etanercept | [11] D00142D00142, D00472D00472, D00742D00742, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02115D02115, D02156D02156, D03301D03301 💬 | DHFR[5] DHFR, DHFR2, LTA, NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[70] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 056[1] 56 💬 | 
| 312 | Eus procedure with drug injection | - | - | - | - | 298[1] 298 💬 | 
| 313 | Evaluation of biological predictive factors of clinical response to ustekinumab | Ustekinumab | [1] D09214D09214 💬 | IL12A[3] IL12A, IL12B, IL23A 💬 | African trypanosomiasis[26] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus | 096[1] 96 💬 | 
| 314 | Everolimus oral product | Everolimus | [1] D02714D02714 💬 | MTOR[1] MTOR 💬 | AMPK signaling pathway[50] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway | 089[2] 89, 158 💬 | 
| 315 | Exelon patch (rivastigmine transdermal system) | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 316 | Fampyra - 10 mg - compressa a rilascio prolungato - uso orale - flacone (hdpe) 56 compresse (4 flaconi da 14) | - | - | - | - | 013[1] 13 💬 | 
| 317 | Fampyra 10 mg prolonged-release tablets | - | - | - | - | 013[1] 13 💬 | 
| 318 | Fampyra 10mg prolonged release tablets | - | - | - | - | 013[1] 13 💬 | 
| 319 | Fentanyl (low dose) + dexmedetomidine | Dexmedetomidine | [4] D00320D00320, D00514D00514, D01205D01205, D01399D01399 💬 | ADRA2A[4] ADRA2A, ADRA2B, ADRA2C, OPRM1 💬 | Estrogen signaling pathway[4] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 215[1] 215 💬 | 
| 320 | Finasteride | Finasteride | [1] D00321D00321 💬 | SRD5A2[1] SRD5A2 💬 | Prostate cancer[2] Prostate cancer, Steroid hormone biosynthesis | 006[1]  6  💬 | 
| 321 | Fixed dose combination ciprofloxacin/celecoxib | Celecoxib | [3] D00186D00186, D00567D00567, D02216D02216 💬 | PTGS2[1] PTGS2 💬 | Alzheimer disease[22] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway | 002[1]  2  💬 | 
| 322 | Fluconazole | Fluconazole | [2] D00322D00322, D01429D01429 💬 | - | - | 096[2] 96, 225 💬 | 
| 323 | Fluoxetine | Fluoxetine | [2] D00326D00326, D00823D00823 💬 | SLC6A4[1] SLC6A4 💬 | Serotonergic synapse[2] Serotonergic synapse, Synaptic vesicle cycle | 013[4] 13, 17, 78, 86 💬 | 
| 324 | Fluoxetine hydrochloride | Fluoxetine | [2] D00326D00326, D00823D00823 💬 | SLC6A4[1] SLC6A4 💬 | Serotonergic synapse[2] Serotonergic synapse, Synaptic vesicle cycle | 013[1] 13 💬 | 
| 325 | Fluticasone propionate | Fluticasone | [2] D01708D01708, D07981D07981 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 098[2] 98, 228 💬 | 
| 326 | Fluticasone propionate, 800 mcg twice daily (post 4fed failure) | Fluticasone | [2] D01708D01708, D07981D07981 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 098[1] 98 💬 | 
| 327 | Fluticasone propionate, 880 mcg twice daily (after 6fed failure) | Fluticasone | [2] D01708D01708, D07981D07981 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 098[1] 98 💬 | 
| 328 | Fluticasone propionate, usp | Fluticasone | [2] D01708D01708, D07981D07981 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 098[1] 98 💬 | 
| 329 | Freshly-pressed extra virgin olive oil | Olea europaea leaf | [1] D03311D03311 💬 | - | - | 013[1] 13 💬 | 
| 330 | G2-sfm (ifn-beta-1a from clone 484-39,fbs-free process) | - | - | - | - | 013[1] 13 💬 | 
| 331 | Gabapentin prescriptions | Gabapentin | [1] D00332D00332 💬 | CACNA2D1[5] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | Adrenergic signaling in cardiomyocytes[9] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle | 298[1] 298 💬 | 
| 332 | Gadoteridol | Gadoteridol | [1] D01137D01137 💬 | - | - | 013[1] 13 💬 | 
| 333 | Gadovist 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado | - | - | - | - | 013[1] 13 💬 | 
| 334 | Ganaxolone, spt3162, md 9150000, ccd-1042, mepalon 1042, (3a-hydroxy-3beta-methyl-5a-pregnan-20-one) | Ganaxolone | [1] D04300D04300 💬 | GABRA1[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | GABAergic synapse[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction | 152[1] 152 💬 | 
| 335 | Ganaxolone, spt3162, md 9150000, ccd-1042, mepalon 1042, (3a-hydroxy-3ß-methyl-5a-pregnan-20-one) | Ganaxolone | [1] D04300D04300 💬 | GABRA1[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | GABAergic synapse[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction | 152[1] 152 💬 | 
| 336 | Genetic: protein expression analysis | - | - | - | - | 028[2] 28, 60 💬 | 
| 337 | Genetically engineered hematopoietic stem progenitor cells | - | - | - | - | 285[1] 285 💬 | 
| 338 | Genetically engineered hematopoietic stem/progenitor cells | - | - | - | - | 285[1] 285 💬 | 
| 339 | Glucocorticoid (prednisone or prednisolone) | Prednisolone | [9] D00472D00472, D00473D00473, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 084[1] 84 💬 | 
| 340 | Glycomacropeptide-based protein substitute | - | - | - | - | 240[1] 240 💬 | 
| 341 | Golimumab final vialed product (fvp) | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 342 | Golimumab liquid in prefilled pen | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 343 | Golimumab liquid in prefilled pen or prefilled syringe | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 344 | Golimumab liquid in prefilled syringe | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[3] 46, 84, 97 💬 | 
| 345 | Golimumab pre-filled syringe | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[2] 46, 271 💬 | 
| 346 | Golimumab prefilled pen | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 347 | Golimumab prefilled pen or prefilled syringe | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 348 | Golimumab prefilled syringe | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 097[1] 97 💬 | 
| 349 | Gp2013 - a proposed biosimilar rituximab | Rituximab | [1] D02994D02994 💬 | MS4A1[1] MS4A1 💬 | Hematopoietic cell lineage[1] Hematopoietic cell lineage | 046[1] 46 💬 | 
| 350 | Granulocyte-colony stimulating factor (g-csf) and prednisone | Filgrastim | [2] D00473D00473, D03235D03235 💬 | CSF3R[2] CSF3R, NR3C1 💬 | Cytokine-cytokine receptor interaction[6] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pathways in cancer | 013[1] 13 💬 | 
| 351 | Group a sle prospective study | - | - | - | - | 049[1] 49 💬 | 
| 352 | Gsk1605786 gsk modified-process: formulation d | - | - | - | - | 096[1] 96 💬 | 
| 353 | Gvhd prophylaxis | - | - | - | - | 060[2] 60, 65 💬 | 
| 354 | Heparin & alkalinized lidocaine bladder instillation | Heparin | [4] D00358D00358, D02086D02086, D07510D07510, D08127D08127 💬 | SCN1A[6] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 | Adrenergic signaling in cardiomyocytes[4] Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction | 226[1] 226 💬 | 
| 355 | Hepatitis b virus surface antigen recombinant (s protein) | - | - | - | - | 046[1] 46 💬 | 
| 356 | Heterologous human adult liver-derived progenitor cells | - | - | - | - | 251[1] 251 💬 | 
| 357 | Heterologous human adult liver-derived progenitor cells (hhalpc) | - | - | - | - | 251[1] 251 💬 | 
| 358 | High dose dexamethasone pulses | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 063[1] 63 💬 | 
| 359 | High protein high fiber diet | - | - | - | - | 093[2] 93, 95 💬 | 
| 360 | High protein. t-diet plus range | - | - | - | - | 006[1]  6  💬 | 
| 361 | Hormonal profile | - | - | - | - | 113[1] 113 💬 | 
| 362 | Hormone (prednisone) | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 363 | Hpv prophylactic vaccine gardasil | - | - | - | - | 049[1] 49 💬 | 
| 364 | Human anti-promyostatin monoclonal antibody | - | - | - | - | 003[1]  3  💬 | 
| 365 | Human glucocerebrosidase (prgcd) | Taliglucerase alfa | [1] D09675D09675 💬 | GBA[1] GBA 💬 | Lysosome[4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism | 019[1] 19 💬 | 
| 366 | Human monoclonal antibody directed against complement 5 protein | - | - | - | - | 062[1] 62 💬 | 
| 367 | Human primary retinal pigment epithelial (hurpe) cells | - | - | - | - | 090[1] 90 💬 | 
| 368 | Human recombinant tissue non-specific alkaline phosphatase fusion protein | Alkaline Phosphatase | - | - | - | 172[1] 172 💬 | 
| 369 | Human retinal progenitor cells | - | - | - | - | 090[1] 90 💬 | 
| 370 | Human retinal progenitor cells drug product | - | - | - | - | 090[1] 90 💬 | 
| 371 | Humira 20 mg solution for injection in pre-filled syringe | - | - | - | - | 096[1] 96 💬 | 
| 372 | Humira 40 mg injekcní roztok v predplnené injekcní stríkacce | - | - | - | - | 096[1] 96 💬 | 
| 373 | Humira 40 mg solución inyectable en jeringa precargada | - | - | - | - | 046[2] 46, 96 💬 | 
| 374 | Humira 40 mg solution for injection in pre-filled pen | - | - | - | - | 096[1] 96 💬 | 
| 375 | Humira 40 mg solution for injection in pre-filled syringe | - | - | - | - | 046[3] 46, 96, 97 💬 | 
| 376 | Humira 40 mg solution for injection in pre-filled syringes | - | - | - | - | 097[1] 97 💬 | 
| 377 | Humira 40mg solution for injection in pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 378 | Humira 40mg solution for injection in pre-filled syringe (adalimumab) | Adalimumab | [1] D02597D02597 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 379 | Humira 40mg/0.4ml pre-filled syringe | - | - | - | - | 096[1] 96 💬 | 
| 380 | Humira 40mg/0.8ml solution for injection in pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 381 | Humira pre-filled pen | - | - | - | - | 096[1] 96 💬 | 
| 382 | Humira ® (adalimumab) 40mg/0.8ml pre-filled syringe | Adalimumab | [1] D02597D02597 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 383 | Humira, 40 mg solution for injection in pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 384 | Humira® 40 mg solution for injection in pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 385 | Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 386 | Hydrocortisone | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 006[9]  6 , 46, 53, 75, 78, 81, 83, 97, 299 💬 | 
| 387 | Hydrocortisone (solucortef) | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 388 | Hydrocortisone 100mg/ml | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 083[1] 83 💬 | 
| 389 | Hydrocortisone 10mg | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 390 | Hydrocortisone 10mg tablet | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 391 | Hydrocortisone 10mg tablets | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 392 | Hydrocortisone 20mg tablets | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 393 | Hydrocortisone acetate | Acetate | [2] D00088D00088, D00165D00165 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 394 | Hydrocortisone cream | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 006[1]  6  💬 | 
| 395 | Hydrocortisone cream 1% | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 006[1]  6  💬 | 
| 396 | Hydrocortisone cream 10mg/g fna fagron | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 006[1]  6  💬 | 
| 397 | Hydrocortisone hydrogen succinate | Hydrocortisone | [2] D00088D00088, D01442D01442 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 083[1] 83 💬 | 
| 398 | Hydrocortisone modified release capsules | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 399 | Hydrocortisone roussel | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 083[1] 83 💬 | 
| 400 | Hydrocortisone sodium acetate | Acetate | [2] D00088D00088, D01779D01779 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 401 | Hydrocortisone sodium phosphate | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 053[3] 53, 81, 83 💬 | 
| 402 | Hydrocortisone sodium succinate | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[3] 81, 83, 97 💬 | 
| 403 | Hydrocortisone tablet 2.5 mg | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 404 | Hydrocortisone takeda, tabletter | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 078[1] 78 💬 | 
| 405 | Hydroxychloroquine + prednisone | Hydroxychloroquine | [2] D00473D00473, D08050D08050 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 084[1] 84 💬 | 
| 406 | Imd preparative regimen | - | - | - | - | 019[5] 19, 20, 125, 234, 326 💬 | 
| 407 | Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy | - | - | - | - | 002[1]  2  💬 | 
| 408 | Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy chain), disulfide with human mus musculus monoclonal light chain, dimer | - | - | - | - | 002[1]  2  💬 | 
| 409 | Inactive reminder product | - | - | - | - | 019[1] 19 💬 | 
| 410 | Inflammatory profile | - | - | - | - | 113[1] 113 💬 | 
| 411 | Inhaled prostacyclin | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 412 | Inn not yet proposed | - | - | - | - | 193[1] 193 💬 | 
| 413 | Interferon beta-1a (current approved manufacturing process invloving fbs) | Human interferon beta | [1] D04554D04554 💬 | IFNAR1[2] IFNAR1, IFNAR2 💬 | Coronavirus disease - COVID-19[18] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway | 013[1] 13 💬 | 
| 414 | Interferon beta-1a (new process, manufactured without fbs) | Human interferon beta | [1] D04554D04554 💬 | IFNAR1[2] IFNAR1, IFNAR2 💬 | Coronavirus disease - COVID-19[18] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway | 013[1] 13 💬 | 
| 415 | Interferon beta-1b and tacrolimus | Human interferon beta | [3] D00107D00107, D00746D00746, D08556D08556 💬 | IFNAR1[7] IFNAR1, IFNAR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[47] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Epstein-Barr virus infection, Glucagon signaling pathway, Glutamatergic synapse, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 013[1] 13 💬 | 
| 416 | Interleukin-2 (aldesleukin). | Aldesleukin | [1] D00748D00748 💬 | IL2RA[3] IL2RA, IL2RB, IL2RG 💬 | Cytokine-cytokine receptor interaction[14] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor | 096[2] 96, 97 💬 | 
| 417 | Intervention for incipient patients at low risk of disease progression | - | - | - | - | 066[1] 66 💬 | 
| 418 | Intervention for patients at high risk of disease progression | - | - | - | - | 066[1] 66 💬 | 
| 419 | Intra plexus triamcinolone and bupivicaine injection | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 298[1] 298 💬 | 
| 420 | Intra-articular compound betamethasone | Betamethasone | [7] D00244D00244, D00972D00972, D01357D01357, D01402D01402, D01637D01637, D02032D02032, D02286D02286 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 421 | Intraarticular betamethasone | Betamethasone | [7] D00244D00244, D00972D00972, D01357D01357, D01402D01402, D01637D01637, D02032D02032, D02286D02286 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 422 | Intraarticular dexamethasone | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 423 | Intravenous dexamethasone 1 mg | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 424 | Intravenous methyl prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 043[1] 43 💬 | 
| 425 | Intubated with propofol (ip) | Propofol | [1] D00549D00549 💬 | GABRA1[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | GABAergic synapse[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction | 098[1] 98 💬 | 
| 426 | Ir prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 427 | Ivacaftor (proposed inn) | Ivacaftor | [1] D09916D09916 💬 | CFTR[1] CFTR 💬 | ABC transporters[8] ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway | 299[1] 299 💬 | 
| 428 | Kenalog injectable product | - | - | - | - | 070[1] 70 💬 | 
| 429 | Kinoquinone (proposed) | - | - | - | - | 006[1]  6  💬 | 
| 430 | L-lysyl-d-prolyl-l-threonine acetate | Acetate | [1] D00041D00041 💬 | - | - | 097[1] 97 💬 | 
| 431 | L-lysyl-d-prolyl-lthreonine acetate, lyophilisate | Acetate | - | - | - | 097[1] 97 💬 | 
| 432 | L01xe - protein kinase inhibitors | - | - | - | - | 085[1] 85 💬 | 
| 433 | Lactic acid producing organisms | Lactic acid | [1] D00111D00111 💬 | - | - | 299[1] 299 💬 | 
| 434 | Lamotrigine - generic product | Lamotrigine | [1] D00354D00354 💬 | SCN1A[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction | 038[1] 38 💬 | 
| 435 | Lansoprazole | Lansoprazole | [1] D00355D00355 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 063[7] 63, 71, 85, 98, 166, 222, 299 💬 | 
| 436 | Lansoprazole 30mg | Lansoprazole | [1] D00355D00355 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 166[1] 166 💬 | 
| 437 | Lansoprazole, amoxicillin, clarithromycin | Amoxicillin | [5] D00229D00229, D00276D00276, D00355D00355, D02925D02925, D07452D07452 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 222[1] 222 💬 | 
| 438 | Lansoprazole, clarithromycin, amoxycillin | Amoxicillin | [5] D00229D00229, D00276D00276, D00355D00355, D02925D02925, D07452D07452 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 063[1] 63 💬 | 
| 439 | Lantus® 100 units/ml solution for injection in a vial. lantus® 100 units/ml solution for injection in a cartridge. lantus® 100 units/ml solution for injection in a pre-filled pen | - | - | - | - | 299[1] 299 💬 | 
| 440 | Lap tap bupivacaine/epinephrine | Bupivacaine | [5] D00095D00095, D00996D00996, D01450D01450, D02149D02149, D07552D07552 💬 | ADRA1A[14] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | AMPK signaling pathway[15] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 096[1] 96 💬 | 
| 441 | Large protein molecule | - | - | - | - | 046[1] 46 💬 | 
| 442 | Lcp-tacro (tacrolimus) | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 095[1] 95 💬 | 
| 443 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | Leflunomide | [2] D00473D00473, D00749D00749 💬 | DHODH[2] DHODH, NR3C1 💬 | Biosynthesis of cofactors[4] Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism | 066[1] 66 💬 | 
| 444 | Lenalidomide and dexamethasone | Dexamethasone | [10] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D04687D04687 💬 | NR3C1[2] NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 016[1] 16 💬 | 
| 445 | Lenalidomide+dexamethasone | Dexamethasone | [10] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D04687D04687 💬 | NR3C1[2] NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 016[1] 16 💬 | 
| 446 | Lenalidomide, dexamethasone | Dexamethasone | [10] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D04687D04687 💬 | NR3C1[2] NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 016[1] 16 💬 | 
| 447 | Lenalidomide, dexamethasone and cyclophosphamide | Cyclophosphamide | [12] D00287D00287, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D04687D04687, D07760D07760 💬 | NR3C1[2] NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 028[1] 28 💬 | 
| 448 | Lenti-d drug product | - | - | - | - | 020[1] 20 💬 | 
| 449 | Letrozole | Letrozole | [1] D00964D00964 💬 | CYP19A1[1] CYP19A1 💬 | Metabolic pathways[3] Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis | 081[2] 81, 89 💬 | 
| 450 | Levemir 100 u/ml solution for injection in a cartridge, levemir 100 u/ml solution for injection in a pre-filled pen | - | - | - | - | 299[1] 299 💬 | 
| 451 | Levocarnitine | Levocarnitine | [3] D02030D02030, D02176D02176, D04713D04713 💬 | - | - | 003[3]  3 , 53, 97 💬 | 
| 452 | Levocarnitine propyl hydrochloride | Levocarnitine | [3] D02030D02030, D02176D02176, D04713D04713 💬 | - | - | 097[1] 97 💬 | 
| 453 | Licorice | Licorice | [1] D04365D04365 💬 | - | - | 053[1] 53 💬 | 
| 454 | Lidocaine | Lidocaine | [3] D00358D00358, D02086D02086, D08127D08127 💬 | SCN1A[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction | 006[10]  6 , 13, 34, 46, 51, 86, 168, 226, 231, 256 💬 | 
| 455 | Lidocaine 1% injectable solution | Lidocaine | [3] D00358D00358, D02086D02086, D08127D08127 💬 | SCN1A[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction | 034[1] 34 💬 | 
| 456 | Lidocaine 2% without vessel constrictor | Lidocaine | [3] D00358D00358, D02086D02086, D08127D08127 💬 | SCN1A[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction | 051[1] 51 💬 | 
| 457 | Lidocaine injection 2% | Lidocaine | [3] D00358D00358, D02086D02086, D08127D08127 💬 | SCN1A[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction | 168[1] 168 💬 | 
| 458 | Lidocaine patch 5% | Lidocaine | [3] D00358D00358, D02086D02086, D08127D08127 💬 | SCN1A[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction | 013[1] 13 💬 | 
| 459 | Lidocaine releasing intravesical system - liris® | Lidocaine | [3] D00358D00358, D02086D02086, D08127D08127 💬 | SCN1A[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction | 226[1] 226 💬 | 
| 460 | Lisinopril | Lisinopril | [2] D00362D00362, D08131D08131 💬 | ACE[1] ACE 💬 | Chagas disease[6] Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system | 019[7] 19, 46, 49, 66, 67, 113, 222 💬 | 
| 461 | Lisinopril pills | Lisinopril | [2] D00362D00362, D08131D08131 💬 | ACE[1] ACE 💬 | Chagas disease[6] Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system | 049[1] 49 💬 | 
| 462 | Lisinopril, losartan, and atorvastatin | Atorvastatin | [7] D00258D00258, D00357D00357, D00362D00362, D00887D00887, D07474D07474, D08131D08131, D08146D08146 💬 | ACE[3] ACE, AGTR1, HMGCR 💬 | AGE-RAGE signaling pathway in diabetic complications[22] AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Bile secretion, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Terpenoid backbone biosynthesis, Vascular smooth muscle contraction, cGMP-PKG signaling pathway | 222[1] 222 💬 | 
| 463 | Local anesthesia (lidocaine hydrochloride) | Lidocaine | [3] D00358D00358, D02086D02086, D08127D08127 💬 | SCN1A[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | Adrenergic signaling in cardiomyocytes[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction | 006[1]  6  💬 | 
| 464 | Lodotra (delayed release prednisolone) | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[1] 41 💬 | 
| 465 | Lonafarnib, zoledronic acid, and pravastatin | Lonafarnib | [7] D00893D00893, D01968D01968, D04768D04768, D06378D06378, D06379D06379, D08410D08410, D08689D08689 💬 | FDPS[4] FDPS, FNTA, FNTB, HMGCR 💬 | AMPK signaling pathway[6] AMPK signaling pathway, Bile secretion, Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis | 333[1] 333 💬 | 
| 466 | Long term follow up in all patients who received sar422459 in previous study tdu13583 | - | - | - | - | 301[1] 301 💬 | 
| 467 | Long-circulating liposomal prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 468 | Losartan and atenolol or propranolol | Atenolol | [5] D00235D00235, D00357D00357, D00483D00483, D08146D08146, D08443D08443 💬 | ADRB1[4] ADRB1, ADRB2, ADRB3, AGTR1 💬 | AGE-RAGE signaling pathway in diabetic complications[22] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 167[1] 167 💬 | 
| 469 | Low calorie protein substitute | - | - | - | - | 240[1] 240 💬 | 
| 470 | Low dose prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 084[1] 84 💬 | 
| 471 | Low-dose aldesleukin (proleukin®) | Aldesleukin | [1] D00748D00748 💬 | IL2RA[3] IL2RA, IL2RB, IL2RG 💬 | Cytokine-cytokine receptor interaction[14] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor | 049[1] 49 💬 | 
| 472 | Lysine-d-proline-threonine | D-Proline | [3] D00035D00035, D00041D00041, D02304D02304 💬 | - | - | 097[1] 97 💬 | 
| 473 | Mabthera or biosimilar rituximab product | Rituximab | [1] D02994D02994 💬 | MS4A1[1] MS4A1 💬 | Hematopoietic cell lineage[1] Hematopoietic cell lineage | 013[1] 13 💬 | 
| 474 | Medium dose prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 084[1] 84 💬 | 
| 475 | Melatonin pr | Melatonin | [1] D08170D08170 💬 | MTNR1A[2] MTNR1A, MTNR1B 💬 | Circadian entrainment[2] Circadian entrainment, Neuroactive ligand-receptor interaction | 006[1]  6  💬 | 
| 476 | Melphalan, thalidomide and dexamethasone | Dexamethasone | [11] D00292D00292, D00369D00369, D00754D00754, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[2] NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 028[1] 28 💬 | 
| 477 | Mesalazine with hydrocortisone sodium succinate | Hydrocortisone | [2] D00088D00088, D00377D00377 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 478 | Mesencephalic neuronal precursor cells | - | - | - | - | 006[1]  6  💬 | 
| 479 | Metabolic profile | - | - | - | - | 113[1] 113 💬 | 
| 480 | Methotrexate (metoject® prefilled pen) | Methotrexate | [2] D00142D00142, D02115D02115 💬 | DHFR[2] DHFR, DHFR2 💬 | Antifolate resistance[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 046[1] 46 💬 | 
| 481 | Methotrexate - etanercept - prednisolone arm | Etanercept | [11] D00142D00142, D00472D00472, D00742D00742, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02115D02115, D02156D02156, D03301D03301 💬 | DHFR[5] DHFR, DHFR2, LTA, NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[70] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 482 | Methotrexate 50mg/ml solution for injection, pre-filled syringe | Methotrexate | [2] D00142D00142, D02115D02115 💬 | DHFR[2] DHFR, DHFR2 💬 | Antifolate resistance[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 046[1] 46 💬 | 
| 483 | Methotrexate pre-filled pen | Methotrexate | [2] D00142D00142, D02115D02115 💬 | DHFR[2] DHFR, DHFR2 💬 | Antifolate resistance[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 046[1] 46 💬 | 
| 484 | Methotrexate prefilled pen | Methotrexate | [2] D00142D00142, D02115D02115 💬 | DHFR[2] DHFR, DHFR2 💬 | Antifolate resistance[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 046[1] 46 💬 | 
| 485 | Methotrexate prefilled syringe | Methotrexate | [2] D00142D00142, D02115D02115 💬 | DHFR[2] DHFR, DHFR2 💬 | Antifolate resistance[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 046[1] 46 💬 | 
| 486 | Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol | Methotrexate | [2] D00142D00142, D02115D02115 💬 | DHFR[2] DHFR, DHFR2 💬 | Antifolate resistance[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 046[1] 46 💬 | 
| 487 | Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol. | Methotrexate | [2] D00142D00142, D02115D02115 💬 | DHFR[2] DHFR, DHFR2 💬 | Antifolate resistance[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 046[1] 46 💬 | 
| 488 | Methyl prednisolonate | - | - | - | - | 013[1] 13 💬 | 
| 489 | Methyl prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 043[3] 43, 49, 96 💬 | 
| 490 | Methylene blue | Methylene blue | [2] D02312D02312, D10537D10537 💬 | - | - | 097[1] 97 💬 | 
| 491 | Methylene blue 25mg tablets | Methylene blue | [2] D02312D02312, D10537D10537 💬 | - | - | 097[1] 97 💬 | 
| 492 | Methylprednisolone (mp) or prednisone (pred) | Methylprednisolone | [7] D00407D00407, D00473D00473, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 493 | Methylprednisolone or prednisolone | Methylprednisolone | [14] D00407D00407, D00472D00472, D00751D00751, D00979D00979, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 065[1] 65 💬 | 
| 494 | Metoclopramide | Metoclopramide | [3] D00726D00726, D02213D02213, D05008D05008 💬 | DRD2[1] DRD2 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 051[1] 51 💬 | 
| 495 | Metoclopramide accord - 10 mg compresse 28 compresse in blister pvc/pvdc/al | Metoclopramide | [3] D00726D00726, D02213D02213, D05008D05008 💬 | DRD2[1] DRD2 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 051[1] 51 💬 | 
| 496 | Metoject 10 mg/ml, solution injectable en seringue pré-remplie | - | - | - | - | 044[1] 44 💬 | 
| 497 | Mezavant gastro-resistant, prolonged release tablets | - | - | - | - | 097[1] 97 💬 | 
| 498 | Mezavant xl 1200 mg gastro-resistant prolonged release tablets | - | - | - | - | 097[1] 97 💬 | 
| 499 | Mezavant xl 1200 mg gastro-resistant, prolonged release tablets | - | - | - | - | 097[1] 97 💬 | 
| 500 | Mezavant xl 1200 mg gastro-resistant, prolonged release tablets. | - | - | - | - | 097[1] 97 💬 | 
| 501 | Mezavant xl 1200mg gastro-resistant, prolonged release tablets | - | - | - | - | 097[1] 97 💬 | 
| 502 | Mezavant xl gastro-resistant, prolonged release tablets | - | - | - | - | 097[1] 97 💬 | 
| 503 | Midodrine | Midodrine | [2] D01307D01307, D08220D08220 💬 | ADRA1A[3] ADRA1A, ADRA1B, ADRA1D 💬 | AMPK signaling pathway[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway | 006[3]  6 , 17, 58 💬 | 
| 504 | Midodrine hydrochloride | Midodrine | [2] D01307D01307, D08220D08220 💬 | ADRA1A[3] ADRA1A, ADRA1B, ADRA1D 💬 | AMPK signaling pathway[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway | 058[1] 58 💬 | 
| 505 | Milrinone | Milrinone | [2] D00417D00417, D02085D02085 💬 | PDE3A[2] PDE3A, PDE3B 💬 | Apelin signaling pathway[11] Apelin signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 294[1] 294 💬 | 
| 506 | Mirapex (pramipexole) | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 507 | Mmf and dexamethasone | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 222[1] 222 💬 | 
| 508 | Mobilization of stem cells to prepare for leukapheresis | - | - | - | - | 096[1] 96 💬 | 
| 509 | Modafinil | Modafinil | [1] D01832D01832 💬 | - | - | 006[4]  6 , 13, 49, 93 💬 | 
| 510 | Modafinil 50mg | Modafinil | [1] D01832D01832 💬 | - | - | 006[1]  6  💬 | 
| 511 | Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142 | BMS-986142 | [11] D00298D00298, D00330D00330, D00529D00529, D00550D00550, D00696D00696, D00893D00893, D01475D01475, D02290D02290, D05028D05028, D08229D08229, D08410D08410 💬 | ATP1A1[24] ATP1A1, ATP1A2, ATP1A3, ATP1A4, CYSLTR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HMGCR, PTGS1, PTGS2 💬 | AMPK signaling pathway[49] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Terpenoid backbone biosynthesis, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway | 046[1] 46 💬 | 
| 512 | Moss-agal (recombinant human alpha-galactosidase a produced in moss) | Agalsidase alfa | [1] D02784D02784 💬 | GLA[1] GLA 💬 | Galactose metabolism[6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism | 019[1] 19 💬 | 
| 513 | Mr prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 514 | Multienzymes (lipase, protease etc.) | - | - | - | - | 298[2] 298, 299 💬 | 
| 515 | Mupirocin | Mupirocin | [2] D01076D01076, D02195D02195 💬 | - | - | 227[2] 227, 299 💬 | 
| 516 | Mupirocin intranasal creme | Mupirocin | [2] D01076D01076, D02195D02195 💬 | - | - | 299[1] 299 💬 | 
| 517 | Mycophenolate mofetil plus lower dose of prednisone | Mycophenolate mofetil | [5] D00473D00473, D00752D00752, D05094D05094, D05095D05095, D05096D05096 💬 | IMPDH1[3] IMPDH1, IMPDH2, NR3C1 💬 | Drug metabolism - other enzymes[4] Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism | 066[1] 66 💬 | 
| 518 | Myeloablative preparative regimen | - | - | - | - | 062[3] 62, 65, 284 💬 | 
| 519 | Myelostim - 34 1 flaconcino liofilizzato 33.6 miu + siringa preriempita solvente 1 ml | - | - | - | - | 019[2] 19, 65 💬 | 
| 520 | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | - | - | - | - | 013[1] 13 💬 | 
| 521 | Naproxen 500 mg tablets (pn 200 minus omeprazole) | Naproxen | [5] D00118D00118, D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[4] ATP4A, ATP4B, PTGS1, PTGS2 💬 | Alzheimer disease[26] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway | 046[2] 46, 271 💬 | 
| 522 | Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 013[1] 13 💬 | 
| 523 | Nebulized combination ipratropium bromide with salbutamol | Ipratropium | [2] D02147D02147, D02212D02212 💬 | ADRB2[6] ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Adrenergic signaling in cardiomyocytes[17] Adrenergic signaling in cardiomyocytes, Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway | 086[1] 86 💬 | 
| 524 | New thermo stable formulation of epoprostenol sodium | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 525 | Nifedipine | Nifedipine | [1] D00437D00437 💬 | CACNA1C[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | Adrenergic signaling in cardiomyocytes[36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 050[2] 50, 81 💬 | 
| 526 | Non propietry, therefore n/a | - | - | - | - | 051[1] 51 💬 | 
| 527 | Novorapid 100 u/ml, solution for injection in a vial. novorapid penfill 100 u/ml, solution for injection in a cartridge. novorapid flexpen 100 u/ml, solution for injection in a pre-filled pen. | - | - | - | - | 299[1] 299 💬 | 
| 528 | Nusinersen injectable product | Nusinersen | [1] D10881D10881 💬 | SMN2[1] SMN2 💬 | RNA transport[1] RNA transport | 003[1]  3  💬 | 
| 529 | Omega 3 premium | - | - | - | - | 299[1] 299 💬 | 
| 530 | Omeprazole | Omeprazole | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 006[16]  6 ,  8 , 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 💬 | 
| 531 | Omeprazole (uk licensed generic product) | Omeprazole | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 085[1] 85 💬 | 
| 532 | Omeprazole 20 mg | Omeprazole | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 096[2] 96, 97 💬 | 
| 533 | Omeprazole 20mg | Omeprazole | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 051[1] 51 💬 | 
| 534 | Omeprazole 20mg bid | Omeprazole | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 098[1] 98 💬 | 
| 535 | Omeprazole 40 mg | Omeprazole | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 096[1] 96 💬 | 
| 536 | Omeprazole 40mg capsule | Omeprazole | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 299[1] 299 💬 | 
| 537 | Omeprazole magnesium | Magnesium | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 225[1] 225 💬 | 
| 538 | Omeprazole rectally 1mg/kg | Omeprazole | [4] D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 294[1] 294 💬 | 
| 539 | Oms721 drug product 185 mg/ml | - | - | - | - | 109[1] 109 💬 | 
| 540 | Only medicinal products registered in austria will be used in this clinical trial. | - | - | - | - | 078[1] 78 💬 | 
| 541 | Only medicinal products registered in germany will be used in this clinical trial | - | - | - | - | 078[1] 78 💬 | 
| 542 | Oral ciprofloxacin | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 543 | Oral ciprofloxacin plus inhaled colistin | Ciprofloxacin | [4] D00186D00186, D02138D02138, D02216D02216, D07746D07746 💬 | - | - | 299[1] 299 💬 | 
| 544 | Oral erythromycin | Erythromycin | [9] D00140D00140, D00851D00851, D01361D01361, D02009D02009, D02184D02184, D02523D02523, D02524D02524, D02525D02525, D04054D04054 💬 | - | - | 036[1] 36 💬 | 
| 545 | Oral prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 049[2] 49, 145 💬 | 
| 546 | Oral prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 251[1] 251 💬 | 
| 547 | Oral prednisone 5mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 049[1] 49 💬 | 
| 548 | Oral probiotic | - | - | - | - | 291[1] 291 💬 | 
| 549 | Orencia 125 mg solution for injection in pre-filled syringe | - | - | - | - | 046[3] 46, 49, 53 💬 | 
| 550 | Orencia 125 mg, solution injectable en seringue préremplie | - | - | - | - | 046[1] 46 💬 | 
| 551 | Orencia® 125 mg solution for injection in pre-filled syringe | - | - | - | - | 065[1] 65 💬 | 
| 552 | Osteopetrosis haploidentical only preparative regimen | - | - | - | - | 019[5] 19, 20, 125, 234, 326 💬 | 
| 553 | Osteopetrosis only preparative regimen | - | - | - | - | 019[5] 19, 20, 125, 234, 326 💬 | 
| 554 | Other respiratory system products | - | - | - | - | 299[1] 299 💬 | 
| 555 | Other: a-step (new protocol) | - | - | - | - | 299[1] 299 💬 | 
| 556 | Other: best practice | - | - | - | - | 060[1] 60 💬 | 
| 557 | Other: classic, progressive endurance training | - | - | - | - | 013[1] 13 💬 | 
| 558 | Other: controls primary cervical dystonia (trihexyphenidyl) | Trihexyphenidyl | [2] D00787D00787, D08638D08638 💬 | CHRM1[5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Alzheimer disease[13] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway | 006[1]  6  💬 | 
| 559 | Other: empiric use of calcium carbonate and calcitriol | Calcitriol | [3] D00129D00129, D00932D00932, D10802D10802 💬 | VDR[1] VDR 💬 | Endocrine and other factor-regulated calcium reabsorption[4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis | 235[1] 235 💬 | 
| 560 | Other: eus procedure | - | - | - | - | 298[1] 298 💬 | 
| 561 | Other: glucose profile for 2 weeks | Dextrose, unspecified form | - | - | - | 299[1] 299 💬 | 
| 562 | Other: high energy / protein diet. | - | - | - | - | 096[1] 96 💬 | 
| 563 | Other: histone acetylation profiles of cells of srt patients with crebbp mutations | - | - | - | - | 102[1] 102 💬 | 
| 564 | Other: hydrocortisone | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 075[1] 75 💬 | 
| 565 | Other: imitation surgical procedure (isp) | - | - | - | - | 006[1]  6  💬 | 
| 566 | Other: low blood pressure control | - | - | - | - | 067[1] 67 💬 | 
| 567 | Other: plasticity-based computerized cognitive remediation program | - | - | - | - | 013[1] 13 💬 | 
| 568 | Other: prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 569 | Other: pretreatment antibiotics | - | - | - | - | 097[1] 97 💬 | 
| 570 | Other: progressive exercise | - | - | - | - | 013[1] 13 💬 | 
| 571 | Other: propensity score | - | - | - | - | 013[1] 13 💬 | 
| 572 | Other: prospective observational registry | - | - | - | - | 003[1]  3  💬 | 
| 573 | Other: pth based calcium carbonate and calcitriol repletion | Calcitriol | [3] D00129D00129, D00932D00932, D10802D10802 💬 | VDR[1] VDR 💬 | Endocrine and other factor-regulated calcium reabsorption[4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis | 235[1] 235 💬 | 
| 574 | Other: pulmonary rehabilitation program | - | - | - | - | 085[1] 85 💬 | 
| 575 | Other: refered to general practice | - | - | - | - | 046[1] 46 💬 | 
| 576 | Other: resistance exercise program | - | - | - | - | 046[1] 46 💬 | 
| 577 | Other: salbutamol nebulisation and with cpap | Salbutamol | [1] D02147D02147 💬 | ADRB2[1] ADRB2 💬 | Adrenergic signaling in cardiomyocytes[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 228[1] 228 💬 | 
| 578 | Other: screening to prevent falls | - | - | - | - | 006[1]  6  💬 | 
| 579 | Other: sham procedure | - | - | - | - | 090[1] 90 💬 | 
| 580 | Other: sham-procedure (dose cohort 1&2 only) | - | - | - | - | 090[2] 90, 303 💬 | 
| 581 | Other: specifically design 6 month resistance training program | - | - | - | - | 013[1] 13 💬 | 
| 582 | Other: standard blood pressure control | - | - | - | - | 067[1] 67 💬 | 
| 583 | Other: standard treatment according to the clinical protocols | - | - | - | - | 049[1] 49 💬 | 
| 584 | Other: water prescription | Water | [1] D00001D00001 💬 | - | - | 067[1] 67 💬 | 
| 585 | Over encapsulated prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[1] 41 💬 | 
| 586 | Over-encapsulated modafinil | Modafinil | [1] D01832D01832 💬 | - | - | 006[1]  6  💬 | 
| 587 | Overencapsulated prednisolone tablets | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 588 | Oxn 10 mg / 5 mg pr | - | - | - | - | 006[1]  6  💬 | 
| 589 | Oxn 10/5 mg pr | - | - | - | - | 226[1] 226 💬 | 
| 590 | Oxn 20 mg / 10 mg pr | - | - | - | - | 006[1]  6  💬 | 
| 591 | Oxn 20/10 mg pr | - | - | - | - | 226[1] 226 💬 | 
| 592 | Oxn 5 mg/2.5 mg pr | - | - | - | - | 006[1]  6  💬 | 
| 593 | Oxn 5/2.5 mg pr | - | - | - | - | 226[1] 226 💬 | 
| 594 | Oxycodone naloxone prolonged release tablets | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 226[1] 226 💬 | 
| 595 | Oxycodone/naloxone prolonged release t | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 226[1] 226 💬 | 
| 596 | Oxycodone/naloxone prolonged release tablets | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 006[1]  6  💬 | 
| 597 | Oxycodone/naloxone prolonged release tablets 10 mg /5 mg | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 006[1]  6  💬 | 
| 598 | Oxycodone/naloxone prolonged release tablets 10/5 mg | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 226[1] 226 💬 | 
| 599 | Oxycodone/naloxone prolonged release tablets 20 mg /10 mg | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 006[1]  6  💬 | 
| 600 | Oxycodone/naloxone prolonged release tablets 20/10 mg | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 226[1] 226 💬 | 
| 601 | Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 006[1]  6  💬 | 
| 602 | Oxycodone/naloxone prolonged release tablets 5/2.5 mg | Naloxone | [5] D01340D01340, D03783D03783, D05312D05312, D05462D05462, D08249D08249 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 226[1] 226 💬 | 
| 603 | P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | Pramipexole | [5] D00559D00559, D02562D02562, D05575D05575, D08469D08469, D10829D10829 💬 | DRD2[4] DRD2, DRD3, DRD4, MAOB 💬 | Alcoholism[18] Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway | 006[1]  6  💬 | 
| 604 | P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), | Pramipexole | [5] D00559D00559, D02562D02562, D05575D05575, D08469D08469, D10829D10829 💬 | DRD2[4] DRD2, DRD3, DRD4, MAOB 💬 | Alcoholism[18] Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway | 006[1]  6  💬 | 
| 605 | Pantoprazole | Pantoprazole | [2] D02593D02593, D05353D05353 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 013[2] 13, 65 💬 | 
| 606 | Paroxetine & prednisolone | Paroxetine | [12] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D02260D02260, D02362D02362, D03301D03301, D05374D05374, D05375D05375 💬 | NR3C1[2] NR3C1, SLC6A4 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle | 046[1] 46 💬 | 
| 607 | Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp | Paroxetine | [12] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D02260D02260, D02362D02362, D03301D03301, D05374D05374, D05375D05375 💬 | NR3C1[2] NR3C1, SLC6A4 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle | 046[1] 46 💬 | 
| 608 | Paroxetine hydrochloride tablets 10 & 20 mg and prednisolone 1 mg bp | Paroxetine | [12] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D02260D02260, D02362D02362, D03301D03301, D05374D05374, D05375D05375 💬 | NR3C1[2] NR3C1, SLC6A4 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle | 046[1] 46 💬 | 
| 609 | Peg-liposomal prednisolone sodium phosphate | Phosphate ion | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 013[2] 13, 97 💬 | 
| 610 | Pentasa 2g sachet prolonged release granules (95%) | - | - | - | - | 097[1] 97 💬 | 
| 611 | Pentasa compact 2g, granulate with prolonged release | - | - | - | - | 097[1] 97 💬 | 
| 612 | Pentasa compact 4g, granulate with prolonged release | - | - | - | - | 097[1] 97 💬 | 
| 613 | Pentasa prolonged release granules 2g | - | - | - | - | 097[1] 97 💬 | 
| 614 | Pentasa sachet 1 g prolonged release granules | - | - | - | - | 096[1] 96 💬 | 
| 615 | Peptidic+probiotic | - | - | - | - | 096[1] 96 💬 | 
| 616 | Peri-neural dexamethasone 1 mg | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 617 | Ph. eur.: (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | Propanoic acid | [1] D02310D02310 💬 | - | - | 006[1]  6  💬 | 
| 618 | Phenylalanine-free protein substitute in tablet form (xphe minis) | Phenylalanine | [1] D00021D00021 💬 | - | - | 240[1] 240 💬 | 
| 619 | Phenylalanine-free protein substitute tablets | Phenylalanine | [1] D00021D00021 💬 | - | - | 240[1] 240 💬 | 
| 620 | Pheur.: (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | Propanoic acid | [1] D02310D02310 💬 | - | - | 006[1]  6  💬 | 
| 621 | Phosphate and betamethasone acetate, 2 ml. | Acetate | [7] D00244D00244, D00972D00972, D01357D01357, D01402D01402, D01637D01637, D02032D02032, D02286D02286 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 235[1] 235 💬 | 
| 622 | Piperacillin-tazobactam combination product | Piperacillin | [4] D00466D00466, D00660D00660, D02251D02251, D08380D08380 💬 | - | - | 299[1] 299 💬 | 
| 623 | Pla-pru-pla-pru | - | - | - | - | 099[1] 99 💬 | 
| 624 | Pla-pru-pru-pla | - | - | - | - | 099[1] 99 💬 | 
| 625 | Plant cell expressed recombinant glucocerebrosidase (prgcd) | Taliglucerase alfa | [1] D09675D09675 💬 | GBA[1] GBA 💬 | Lysosome[4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism | 019[1] 19 💬 | 
| 626 | Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología prgf-system (bti) | - | - | - | - | 096[1] 96 💬 | 
| 627 | Plegridy - 125 mcg - soluzione iniettabile - uso sottocutaneo - penna preriempita - 0,5 ml - 6 penne preriempite | - | - | - | - | 013[1] 13 💬 | 
| 628 | Pn 200 tablets (500 mg naproxen and 20 mg omeprazole) | Naproxen | [5] D00118D00118, D00455D00455, D01207D01207, D05259D05259, D05261D05261 💬 | ATP4A[4] ATP4A, ATP4B, PTGS1, PTGS2 💬 | Alzheimer disease[26] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway | 046[2] 46, 271 💬 | 
| 629 | Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) conjugated to crm197 carrier protein and adsorbed on aluminium phosphate | Aluminium | - | - | - | 046[1] 46 💬 | 
| 630 | Po ciprofloxacin | Ciprofloxacin | [2] D00186D00186, D02216D02216 💬 | - | - | 299[1] 299 💬 | 
| 631 | Polaprezinc | Polaprezinc | [1] D01611D01611 💬 | - | - | 096[2] 96, 97 💬 | 
| 632 | Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with n-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1) | Diethyl ether | [2] D01772D01772, D06078D06078 💬 | PTH1R[1] PTH1R 💬 | Endocrine and other factor-regulated calcium reabsorption[3] Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action | 235[1] 235 💬 | 
| 633 | Pomalidomide and dexamethasone | Dexamethasone | [10] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D08976D08976 💬 | IL6[3] IL6, NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[79] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 028[1] 28 💬 | 
| 634 | Pomalidomide oral product | Pomalidomide | [1] D08976D08976 💬 | IL6[2] IL6, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[78] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 227[1] 227 💬 | 
| 635 | Pr | - | - | - | - | 041[1] 41 💬 | 
| 636 | Pr oxycodone | Oxycodone | [3] D03783D03783, D05312D05312, D05462D05462 💬 | OPRD1[3] OPRD1, OPRK1, OPRM1 💬 | Estrogen signaling pathway[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway | 006[1]  6  💬 | 
| 637 | Pr-06410293 | - | - | - | - | 046[1] 46 💬 | 
| 638 | Pr001 | - | - | - | - | 019[1] 19 💬 | 
| 639 | Pr001a | - | - | - | - | 006[1]  6  💬 | 
| 640 | Pr006 | - | - | - | - | 127[1] 127 💬 | 
| 641 | Pr1 | - | - | - | - | 051[1] 51 💬 | 
| 642 | Pralia 60 mg subcutaneous injection syringe(denosumab) | Denosumab | [1] D03684D03684 💬 | TNFSF11[1] TNFSF11 💬 | Breast cancer[7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis | 046[1] 46 💬 | 
| 643 | Pralia 60mg subcutaneous injection syringe(denosumab) | Denosumab | [1] D03684D03684 💬 | TNFSF11[1] TNFSF11 💬 | Breast cancer[7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis | 046[1] 46 💬 | 
| 644 | Praluent | - | - | - | - | 079[1] 79 💬 | 
| 645 | Pramipexol | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 646 | Pramipexol extended release | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 647 | Pramipexol immediate release | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 648 | Pramipexole | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 002[2]  2 ,  6  💬 | 
| 649 | Pramipexole 0.125 mg tablets | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 650 | Pramipexole 0.5 mg tablets | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 651 | Pramipexole dihydrochloride | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 652 | Pramipexole dihydrochloride extended-release tablets | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 653 | Pramipexole dihydrochloride monohydrate | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 654 | Pramipexole dihydrochloride monohydrate extended release | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 655 | Pramipexole er | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 656 | Pramipexole extended release | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 657 | Pramipexole extended release tablet | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 658 | Pramipexole hydrochloride sustained-release tablet (siforl®) specification: 0.26mg/ tablet (in pramipexole) | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 659 | Pramipexole immediate release | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 660 | Pramipexole immediate release tablet | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 661 | Pramipexole ir | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 662 | Pramipexole or ropinirole | Pramipexole | [4] D00559D00559, D00784D00784, D05575D05575, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 663 | Pramipexole sr | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 664 | Prasterone | Prasterone | [1] D08409D08409 💬 | AR[3] AR, ESR1, ESR2 💬 | Breast cancer[11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway | 049[1] 49 💬 | 
| 665 | Prasterone (gl701) | Prasterone | [1] D08409D08409 💬 | AR[3] AR, ESR1, ESR2 💬 | Breast cancer[11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway | 049[1] 49 💬 | 
| 666 | Pravastatin | Pravastatin | [2] D00893D00893, D08410D08410 💬 | HMGCR[1] HMGCR 💬 | AMPK signaling pathway[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis | 013[9] 13, 46, 49, 67, 79, 96, 164, 265, 333 💬 | 
| 667 | Pravastatin sodium | Pravastatin | [2] D00893D00893, D08410D08410 💬 | HMGCR[1] HMGCR 💬 | AMPK signaling pathway[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis | 265[1] 265 💬 | 
| 668 | Praxol hydrochloride sustained release tablet specification: 0.375mg/ tablet (in pramipexole hydrochloride) | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 669 | Prd2175434 | - | - | - | - | 113[1] 113 💬 | 
| 670 | Prd4862257 | - | - | - | - | 046[1] 46 💬 | 
| 671 | Prd5973697 | - | - | - | - | 097[1] 97 💬 | 
| 672 | Prd806998 | - | - | - | - | 013[1] 13 💬 | 
| 673 | Pre-filled syringe | - | - | - | - | 046[1] 46 💬 | 
| 674 | Prebiotics | - | - | - | - | 096[1] 96 💬 | 
| 675 | Prebiotics (prebiotin prebiotic fiber stick pac) | - | - | - | - | 013[1] 13 💬 | 
| 676 | Pred | - | - | - | - | 046[1] 46 💬 | 
| 677 | Pred + meth | - | - | - | - | 046[1] 46 💬 | 
| 678 | Predinose oral | - | - | - | - | 070[1] 70 💬 | 
| 679 | Prednihexal | - | - | - | - | 046[1] 46 💬 | 
| 680 | Prednihexal® 10mg tabletten | - | - | - | - | 046[1] 46 💬 | 
| 681 | Prednihexal® 20mg tabletten | - | - | - | - | 046[1] 46 💬 | 
| 682 | Prednihexal® 5mg tabletten | - | - | - | - | 046[1] 46 💬 | 
| 683 | Prednihexal® 5mg tabletten, prednihexal® 10mg tabletten | - | - | - | - | 046[1] 46 💬 | 
| 684 | Prednihexal® 5mg tabletten, prednihexal® 20mg tabletten | - | - | - | - | 046[1] 46 💬 | 
| 685 | Predniso | - | - | - | - | 046[1] 46 💬 | 
| 686 | Prednisolene tablets bp 1 mg | - | - | - | - | 046[1] 46 💬 | 
| 687 | Prednisolon | - | - | - | - | 046[6] 46, 50, 51, 66, 96, 97 💬 | 
| 688 | Prednisolon 1 mg jenapharm | - | - | - | - | 041[1] 41 💬 | 
| 689 | Prednisolon 5 mg jenapharm | - | - | - | - | 041[1] 41 💬 | 
| 690 | Prednisolon jenapharm | - | - | - | - | 096[2] 96, 97 💬 | 
| 691 | Prednisolon pfizer | - | - | - | - | 050[1] 50 💬 | 
| 692 | Prednisolona | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 051[1] 51 💬 | 
| 693 | Prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 011[40] 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬 | 
| 694 | Prednisolone & dipyridamole | Dipyridamole | [9] D00302D00302, D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[3] NR3C1, PDE4A, PDE5A 💬 | Metabolic pathways[7] Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway | 046[1] 46 💬 | 
| 695 | Prednisolone + mabthera | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 061[1] 61 💬 | 
| 696 | Prednisolone 1mg tablets | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 697 | Prednisolone 2,5 mg tablets | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 698 | Prednisolone 20 mg | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 699 | Prednisolone 40 mg | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 700 | Prednisolone 5 mg | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[2] 46, 51 💬 | 
| 701 | Prednisolone 5 mg jenapharm | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[1] 41 💬 | 
| 702 | Prednisolone 5 mg tablets | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 703 | Prednisolone 5mg gastro-resistant tablets | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 051[1] 51 💬 | 
| 704 | Prednisolone 5mg tablet | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 705 | Prednisolone acetate | Acetate | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 222[1] 222 💬 | 
| 706 | Prednisolone and chlorambucil | Chlorambucil | [9] D00266D00266, D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 222[1] 222 💬 | 
| 707 | Prednisolone and mycophenolate mofetil | Mycophenolate mofetil | [12] D00472D00472, D00752D00752, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301, D05094D05094, D05095D05095, D05096D05096 💬 | IMPDH1[3] IMPDH1, IMPDH2, NR3C1 💬 | Drug metabolism - other enzymes[4] Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism | 222[1] 222 💬 | 
| 708 | Prednisolone and taper | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 051[1] 51 💬 | 
| 709 | Prednisolone labesfal | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 710 | Prednisolone sodium metasulphobenzoate | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 711 | Prednisolone sodium phosphate | Phosphate ion | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 013[2] 13, 97 💬 | 
| 712 | Prednisolone sodium succinate | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 095[1] 95 💬 | 
| 713 | Prednisolone tablets b.p. 5mg | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 097[1] 97 💬 | 
| 714 | Prednisolone tablets bp | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 715 | Prednisolone tablets bp 1 mg | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 716 | Prednisolone tablets usp 5 mg | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 717 | Prednisolone-dipyridamole | Dipyridamole | [9] D00302D00302, D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[3] NR3C1, PDE4A, PDE5A 💬 | Metabolic pathways[7] Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway | 046[1] 46 💬 | 
| 718 | Prednisolone/prednisone | Prednisolone | [9] D00472D00472, D00473D00473, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 049[1] 49 💬 | 
| 719 | Prednisoloni | - | - | - | - | 051[1] 51 💬 | 
| 720 | Prednisolonum | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 051[1] 51 💬 | 
| 721 | Prednison | - | - | - | - | 046[3] 46, 84, 113 💬 | 
| 722 | Prednison 5, 20 léciva por. tablet nob | - | - | - | - | 050[1] 50 💬 | 
| 723 | Prednison 5, 20 léciva por. tablet nob. | - | - | - | - | 050[1] 50 💬 | 
| 724 | Prednison acis® 20 mg | - | - | - | - | 043[2] 43, 44 💬 | 
| 725 | Prednison acis® 5 mg | - | - | - | - | 043[2] 43, 44 💬 | 
| 726 | Prednisona | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[3] 46, 49, 222 💬 | 
| 727 | Prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 002[47]  2 ,  6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 | 
| 728 | Prednisone (and methylprednisolone) | Methylprednisolone | [7] D00407D00407, D00473D00473, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 043[1] 43 💬 | 
| 729 | Prednisone + inhibace/cozaar | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 730 | Prednisone - azathioprine | Azathioprine | [3] D00238D00238, D00473D00473, D03033D03033 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 011[1] 11 💬 | 
| 731 | Prednisone 0,5 mg/kg orally on alternate days | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 222[1] 222 💬 | 
| 732 | Prednisone 1 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 733 | Prednisone 15 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 734 | Prednisone 2 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 735 | Prednisone 3 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 736 | Prednisone 4 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 737 | Prednisone 5 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[2] 46, 66 💬 | 
| 738 | Prednisone 5 mg tablets | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 113[1] 113 💬 | 
| 739 | Prednisone 7.5 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 740 | Prednisone acetate | Acetate | [2] D00473D00473, D08416D08416 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 040[3] 40, 49, 224 💬 | 
| 741 | Prednisone acetate tablets | Acetate | [2] D00473D00473, D08416D08416 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 224[1] 224 💬 | 
| 742 | Prednisone alone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 011[2] 11, 66 💬 | 
| 743 | Prednisone and belimumab | Belimumab | [2] D00473D00473, D03068D03068 💬 | NR3C1[2] NR3C1, TNFSF13B 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Rheumatoid arthritis | 300[1] 300 💬 | 
| 744 | Prednisone and cyclophosphamide | Cyclophosphamide | [3] D00287D00287, D00473D00473, D07760D07760 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 745 | Prednisone and mycophenolate mofetil | Mycophenolate mofetil | [5] D00473D00473, D00752D00752, D05094D05094, D05095D05095, D05096D05096 💬 | IMPDH1[3] IMPDH1, IMPDH2, NR3C1 💬 | Drug metabolism - other enzymes[4] Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism | 300[1] 300 💬 | 
| 746 | Prednisone and ustekinumab treatment | Prednisone | [2] D00473D00473, D09214D09214 💬 | IL12A[4] IL12A, IL12B, IL23A, NR3C1 💬 | African trypanosomiasis[27] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Neuroactive ligand-receptor interaction, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus | 041[1] 41 💬 | 
| 747 | Prednisone arrow 20mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 748 | Prednisone arrow 5 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 749 | Prednisone capsules | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[1] 41 💬 | 
| 750 | Prednisone discontinuation | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 049[1] 49 💬 | 
| 751 | Prednisone in full dose | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 752 | Prednisone or prednisolone | Prednisolone | [9] D00472D00472, D00473D00473, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 753 | Prednisone plus cyclophosphamide | Cyclophosphamide | [3] D00287D00287, D00473D00473, D07760D07760 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 066[1] 66 💬 | 
| 754 | Prednisone tablets usp, 1 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[2] 41, 46 💬 | 
| 755 | Prednisone tablets usp, 2.5 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[1] 41 💬 | 
| 756 | Prednisone tablets usp, 5 mg | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[2] 41, 46 💬 | 
| 757 | Prednisone tablets, usp | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[3] 41, 43, 44 💬 | 
| 758 | Prednisone therapy and pharmacokinetic | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[1] 41 💬 | 
| 759 | Prednisone treatment | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 041[1] 41 💬 | 
| 760 | Prednisone, ciclosporin and mycophenolate mofetil | Cyclosporine | [6] D00184D00184, D00473D00473, D00752D00752, D05094D05094, D05095D05095, D05096D05096 💬 | IMPDH1[8] IMPDH1, IMPDH2, NR3C1, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[36] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 222[1] 222 💬 | 
| 761 | Prednisone, cyclophosphamide | Cyclophosphamide | [3] D00287D00287, D00473D00473, D07760D07760 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 040[1] 40 💬 | 
| 762 | Prednisone, fk506, mmf | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 222[1] 222 💬 | 
| 763 | Prednisone, low dose rituximab | Prednisone | [2] D00473D00473, D02994D02994 💬 | MS4A1[2] MS4A1, NR3C1 💬 | Hematopoietic cell lineage[2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction | 061[1] 61 💬 | 
| 764 | Prednisone, methylprednisolone,cyclophosphamides | Methylprednisolone | [7] D00407D00407, D00473D00473, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 042[3] 42, 43, 45 💬 | 
| 765 | Prednisone/prednisolone | Prednisolone | [9] D00472D00472, D00473D00473, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 035[1] 35 💬 | 
| 766 | Prednizolon | - | - | - | - | 051[1] 51 💬 | 
| 767 | Prednizolonas | - | - | - | - | 051[1] 51 💬 | 
| 768 | Prefilled liquid etanercept(yisaipu) | Etanercept | [1] D00742D00742 💬 | LTA[2] LTA, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 271[1] 271 💬 | 
| 769 | Prefilled syringe delivery of golimumab | Golimumab | [1] D04358D04358 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 097[1] 97 💬 | 
| 770 | Prefolic*30cpr gastror 15mg | - | - | - | - | 299[1] 299 💬 | 
| 771 | Pregabalin | Pregabalin | [1] D02716D02716 💬 | CACNA2D1[4] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 💬 | Adrenergic signaling in cardiomyocytes[7] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway | 013[5] 13, 36, 46, 70, 298 💬 | 
| 772 | Pregabalin 75mg | Pregabalin | [1] D02716D02716 💬 | CACNA2D1[4] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 💬 | Adrenergic signaling in cardiomyocytes[7] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway | 070[1] 70 💬 | 
| 773 | Preimplantation factor | Preimplantation factor | - | - | - | 095[1] 95 💬 | 
| 774 | Preladenant | Preladenant | [1] D09717D09717 💬 | ADORA2A[1] ADORA2A 💬 | Alcoholism[7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway | 006[1]  6  💬 | 
| 775 | Preladenant 10 mg tablet | Preladenant | [1] D09717D09717 💬 | ADORA2A[1] ADORA2A 💬 | Alcoholism[7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway | 006[1]  6  💬 | 
| 776 | Preladenant 2 mg tablet | Preladenant | [1] D09717D09717 💬 | ADORA2A[1] ADORA2A 💬 | Alcoholism[7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway | 006[1]  6  💬 | 
| 777 | Preladenant 5 mg tablet | Preladenant | [1] D09717D09717 💬 | ADORA2A[1] ADORA2A 💬 | Alcoholism[7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway | 006[1]  6  💬 | 
| 778 | Premarin and provera | - | - | - | - | 049[1] 49 💬 | 
| 779 | Premarin ® | - | - | - | - | 006[1]  6  💬 | 
| 780 | Preotact | - | - | - | - | 235[1] 235 💬 | 
| 781 | Preparative regimen 4-6 weeks after leukapheresis | - | - | - | - | 096[1] 96 💬 | 
| 782 | Prepulsid | - | - | - | - | 013[1] 13 💬 | 
| 783 | Preservative free artificial tear gel. | - | - | - | - | 157[1] 157 💬 | 
| 784 | Prevenar | - | - | - | - | 065[1] 65 💬 | 
| 785 | Prevenar 13 | - | - | - | - | 046[2] 46, 96 💬 | 
| 786 | Prevenar vaccination | - | - | - | - | 046[1] 46 💬 | 
| 787 | Prevenar vaccine | - | - | - | - | 046[1] 46 💬 | 
| 788 | Prevenar13 | - | - | - | - | 019[2] 19, 265 💬 | 
| 789 | Prevenar® and pneumo23® | - | - | - | - | 049[1] 49 💬 | 
| 790 | Previously known as r935788 | - | - | - | - | 046[1] 46 💬 | 
| 791 | Previously referred to as medi2070 and amg 139 | - | - | - | - | 096[2] 96, 97 💬 | 
| 792 | Previously referred to as medi2070 and amg 139, agn-151-598 | - | - | - | - | 096[1] 96 💬 | 
| 793 | Prgcd | Taliglucerase alfa | [1] D09675D09675 💬 | GBA[1] GBA 💬 | Lysosome[4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism | 019[1] 19 💬 | 
| 794 | Pridia (donepezil hydrochloride) 5mg | Donepezil | [2] D00670D00670, D07869D07869 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 795 | Pridia 10mg | - | - | - | - | 006[1]  6  💬 | 
| 796 | Pridia 5mg | - | - | - | - | 006[1]  6  💬 | 
| 797 | Pridiopidine | - | - | - | - | 008[1]  8  💬 | 
| 798 | Pridopidina | - | - | - | - | 008[1]  8  💬 | 
| 799 | Pridopidine | Pridopidine | [1] D09953D09953 💬 | DRD2[1] DRD2 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 002[3]  2 ,  6 ,  8  💬 | 
| 800 | Pridopidine (90 mg) | Pridopidine | [1] D09953D09953 💬 | DRD2[1] DRD2 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 008[1]  8  💬 | 
| 801 | Pridopidine hydrochloride | Pridopidine | [1] D09953D09953 💬 | DRD2[1] DRD2 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 008[1]  8  💬 | 
| 802 | Prim-dj2727 | - | - | - | - | 006[2]  6 , 97 💬 | 
| 803 | Primary cervical dystonia (trihexyphenidyl) | Trihexyphenidyl | [2] D00787D00787, D08638D08638 💬 | CHRM1[5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Alzheimer disease[13] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway | 006[1]  6  💬 | 
| 804 | Primavanserin tartrate | - | - | - | - | 006[1]  6  💬 | 
| 805 | Primus | Florasulam | - | - | - | 046[1] 46 💬 | 
| 806 | Prior donepezil 5mg | Donepezil | [2] D00670D00670, D07869D07869 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 807 | Prior donzepezil 10mg | - | - | - | - | 006[1]  6  💬 | 
| 808 | Privigen | - | - | - | - | 011[4] 11, 14, 51, 65 💬 | 
| 809 | Privigen 100 mg/ml, solution pour perfusion | - | - | - | - | 053[1] 53 💬 | 
| 810 | Privigen 100mg/ml | - | - | - | - | 085[1] 85 💬 | 
| 811 | Privigen® | - | - | - | - | 014[3] 14, 63, 65 💬 | 
| 812 | Privigen® 100mg/ml at the dose of 2g/kg of body weight | - | - | - | - | 053[1] 53 💬 | 
| 813 | Prm-151 | PRM-151 | - | - | - | 085[1] 85 💬 | 
| 814 | Prn1008 | - | - | - | - | 035[1] 35 💬 | 
| 815 | Prn1008 (rilzabrutinib) | - | - | - | - | 035[1] 35 💬 | 
| 816 | Prn1008 freebase | - | - | - | - | 035[1] 35 💬 | 
| 817 | Prn1008 oral tablet | - | - | - | - | 035[1] 35 💬 | 
| 818 | Prn2246 | - | - | - | - | 013[1] 13 💬 | 
| 819 | Pro044 | - | - | - | - | 113[1] 113 💬 | 
| 820 | Pro044 iv | - | - | - | - | 113[1] 113 💬 | 
| 821 | Pro044 iv 6 mg/kg | - | - | - | - | 113[1] 113 💬 | 
| 822 | Pro044 iv 9 mg/kg | - | - | - | - | 113[1] 113 💬 | 
| 823 | Pro044 sc | - | - | - | - | 113[1] 113 💬 | 
| 824 | Pro044 sc 6 mg/kg | - | - | - | - | 113[1] 113 💬 | 
| 825 | Pro045 | - | - | - | - | 113[1] 113 💬 | 
| 826 | Pro045, 0.15 mg/kg/week | - | - | - | - | 113[1] 113 💬 | 
| 827 | Pro045, 1.0 mg/kg/week | - | - | - | - | 113[1] 113 💬 | 
| 828 | Pro045, 3.0 mg/kg/week | - | - | - | - | 113[1] 113 💬 | 
| 829 | Pro045, 6.0 mg/kg/week | - | - | - | - | 113[1] 113 💬 | 
| 830 | Pro045, 9.0 mg/kg/week | - | - | - | - | 113[1] 113 💬 | 
| 831 | Pro045, selected dose | - | - | - | - | 113[1] 113 💬 | 
| 832 | Pro051 | - | - | - | - | 113[1] 113 💬 | 
| 833 | Pro053 | - | - | - | - | 113[1] 113 💬 | 
| 834 | Pro145223 | - | - | - | - | 097[1] 97 💬 | 
| 835 | Pro145223 (ro5490261) | - | - | - | - | 097[1] 97 💬 | 
| 836 | Pro283698 | - | - | - | - | 046[1] 46 💬 | 
| 837 | Probenecid | Probenecid | [1] D00475D00475 💬 | - | - | 025[1] 25 💬 | 
| 838 | Probiotic | - | - | - | - | 002[7]  2 ,  6 , 93, 96, 97, 193, 266 💬 | 
| 839 | Probiotic - vsl#3 | - | - | - | - | 096[1] 96 💬 | 
| 840 | Probiotic capsule | - | - | - | - | 006[1]  6  💬 | 
| 841 | Probiotic capsules containing lactobacillus rhamnosus gr-1 and l. reuteri rc-14 | - | - | - | - | 046[1] 46 💬 | 
| 842 | Probiotic formula capsule | - | - | - | - | 097[1] 97 💬 | 
| 843 | Probiotic mixture | - | - | - | - | 096[2] 96, 97 💬 | 
| 844 | Probiotic product - cap | - | - | - | - | 053[1] 53 💬 | 
| 845 | Probiotic treatment | - | - | - | - | 294[1] 294 💬 | 
| 846 | Probiotic-lactobacillus plantarum ps128 | Lactobacillus plantarum | - | - | - | 156[1] 156 💬 | 
| 847 | Probiotics | - | - | - | - | 094[4] 94, 96, 97, 291 💬 | 
| 848 | Probiotics (visbiome®) | - | - | - | - | 013[1] 13 💬 | 
| 849 | Probiotics with prebiotic | - | - | - | - | 006[1]  6  💬 | 
| 850 | Probucol | Probucol | [1] D00476D00476 💬 | - | - | 066[1] 66 💬 | 
| 851 | Procedure: 12 lead electrocardiogram | - | - | - | - | 019[1] 19 💬 | 
| 852 | Procedure: 12-lead ecg | - | - | - | - | 140[2] 140, 144 💬 | 
| 853 | Procedure: 2 ml of whole blood sample will be collected on edta tube | Edetic acid | [8] D00052D00052, D00571D00571, D01802D01802, D03943D03943, D03944D03944, D03945D03945, D03946D03946, D03947D03947 💬 | - | - | 051[1] 51 💬 | 
| 854 | Procedure: 2-hour holter monitor | Methamidophos | - | - | - | 019[1] 19 💬 | 
| 855 | Procedure: 3d electrocardiographic mapping (ecm) | - | - | - | - | 058[1] 58 💬 | 
| 856 | Procedure: 9% sodium chloride (nacl) iv | Chloride ion | [1] D02056D02056 💬 | - | - | 078[1] 78 💬 | 
| 857 | Procedure: [123i]-ibzm imaging | - | - | - | - | 006[1]  6  💬 | 
| 858 | Procedure: [123i]beta-cit and spect imaging | - | - | - | - | 006[1]  6  💬 | 
| 859 | Procedure: [123i]ß-cit and spect imaging | - | - | - | - | 006[1]  6  💬 | 
| 860 | Procedure: acupuncture | - | - | - | - | 046[2] 46, 70 💬 | 
| 861 | Procedure: ad-msc transdifferentiated hscs (ad-hscs) | - | - | - | - | 060[1] 60 💬 | 
| 862 | Procedure: adipose derived mesenchymal stem cells ( ad-mscs) | - | - | - | - | 060[1] 60 💬 | 
| 863 | Procedure: adipose tissue harvest | - | - | - | - | 051[1] 51 💬 | 
| 864 | Procedure: air stacking manuever | - | - | - | - | 003[1]  3  💬 | 
| 865 | Procedure: airway clearance technique | - | - | - | - | 299[1] 299 💬 | 
| 866 | Procedure: alcohol wipes vs. no alcohol wipes | Ethanol | [4] D00068D00068, D02798D02798, D04855D04855, D06542D06542 💬 | - | - | 013[1] 13 💬 | 
| 867 | Procedure: allo bmt | - | - | - | - | 065[1] 65 💬 | 
| 868 | Procedure: allogeneic bone marrow transplantation | - | - | - | - | 060[6] 60, 65, 96, 164, 284, 285 💬 | 
| 869 | Procedure: allogeneic hematopoietic stem cell transplantation | - | - | - | - | 028[8] 28, 51, 60, 62, 65, 164, 284, 285 💬 | 
| 870 | Procedure: allogeneic hsc | - | - | - | - | 065[1] 65 💬 | 
| 871 | Procedure: allogeneic hsct | - | - | - | - | 065[1] 65 💬 | 
| 872 | Procedure: allogeneic stem cell transplant | - | - | - | - | 060[1] 60 💬 | 
| 873 | Procedure: allogeneic stem cell transplantation | - | - | - | - | 019[3] 19, 20, 62 💬 | 
| 874 | Procedure: allogenic stem cell transplantation | - | - | - | - | 060[1] 60 💬 | 
| 875 | Procedure: allograft | - | - | - | - | 070[1] 70 💬 | 
| 876 | Procedure: antiviral therapy | - | - | - | - | 028[2] 28, 60 💬 | 
| 877 | Procedure: apheresis | - | - | - | - | 060[1] 60 💬 | 
| 878 | Procedure: apheresis catheter placement | - | - | - | - | 096[1] 96 💬 | 
| 879 | Procedure: arginine and clonidine stimulation testing | Arginine | [3] D00281D00281, D00604D00604, D02982D02982 💬 | ADRA2A[3] ADRA2A, ADRA2B, ADRA2C 💬 | Neuroactive ligand-receptor interaction[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway | 078[1] 78 💬 | 
| 880 | Procedure: arginine stimulation test after each limb | Arginine | [1] D02982D02982 💬 | - | - | 078[1] 78 💬 | 
| 881 | Procedure: arthroscopic synovial tissue biopsy | - | - | - | - | 046[1] 46 💬 | 
| 882 | Procedure: assessment of therapy complications | - | - | - | - | 060[1] 60 💬 | 
| 883 | Procedure: audiological and ear, nose and throat examination | - | - | - | - | 078[1] 78 💬 | 
| 884 | Procedure: autologous bone marrow transplantation | - | - | - | - | 013[2] 13, 28 💬 | 
| 885 | Procedure: autologous cd34+hpc transplantation (hsct) | - | - | - | - | 049[1] 49 💬 | 
| 886 | Procedure: autologous hematopoietic stem cell transplant | - | - | - | - | 013[1] 13 💬 | 
| 887 | Procedure: autologous hematopoietic stem cell transplantation | - | - | - | - | 011[6] 11, 13, 14, 28, 49, 51 💬 | 
| 888 | Procedure: autologous hematopoietic stem cell transplantation (asct) | - | - | - | - | 028[1] 28 💬 | 
| 889 | Procedure: autologous peripheral blood stem cell transplantation | - | - | - | - | 028[8] 28, 40, 41, 42, 45, 46, 49, 283 💬 | 
| 890 | Procedure: autologous stem cell transplant | - | - | - | - | 028[2] 28, 96 💬 | 
| 891 | Procedure: autologous stem cell transplantation | - | - | - | - | 013[2] 13, 28 💬 | 
| 892 | Procedure: autologous-autologous tandem hematopoietic stem cell transplantation | - | - | - | - | 028[1] 28 💬 | 
| 893 | Procedure: b-lines se | - | - | - | - | 058[3] 58, 86, 215 💬 | 
| 894 | Procedure: ballon pulmonary angioplasty | - | - | - | - | 088[1] 88 💬 | 
| 895 | Procedure: balloon pulmonary angioplasty (bpa) | - | - | - | - | 088[1] 88 💬 | 
| 896 | Procedure: bee venom pharmacopuncture | - | - | - | - | 070[1] 70 💬 | 
| 897 | Procedure: behavior and neuropsychometric evaluations | - | - | - | - | 078[1] 78 💬 | 
| 898 | Procedure: biliary stent | - | - | - | - | 300[1] 300 💬 | 
| 899 | Procedure: biofluid samplings | - | - | - | - | 006[1]  6  💬 | 
| 900 | Procedure: biopsies | - | - | - | - | 097[1] 97 💬 | 
| 901 | Procedure: biopsy | - | - | - | - | 051[3] 51, 78, 193 💬 | 
| 902 | Procedure: biospecimen collection | - | - | - | - | 159[1] 159 💬 | 
| 903 | Procedure: blood analysis | - | - | - | - | 006[1]  6  💬 | 
| 904 | Procedure: blood collection for pk testing (15 mins before injection) | - | - | - | - | 046[1] 46 💬 | 
| 905 | Procedure: blood collection for pk testing (15 minutes post injection) | - | - | - | - | 046[1] 46 💬 | 
| 906 | Procedure: blood collection for pk testing (18-20 hours post injection) | - | - | - | - | 046[1] 46 💬 | 
| 907 | Procedure: blood collection for pk testing (180 minutes post injection) | - | - | - | - | 046[1] 46 💬 | 
| 908 | Procedure: blood collection for pk testing (60 minutes post injection) | - | - | - | - | 046[1] 46 💬 | 
| 909 | Procedure: blood collection for pk testing (after injection) | - | - | - | - | 046[1] 46 💬 | 
| 910 | Procedure: blood draw | - | - | - | - | 006[5]  6 , 19, 65, 231, 299 💬 | 
| 911 | Procedure: blood draw. | - | - | - | - | 231[2] 231, 299 💬 | 
| 912 | Procedure: blood draws | - | - | - | - | 078[1] 78 💬 | 
| 913 | Procedure: blood sample | - | - | - | - | 065[1] 65 💬 | 
| 914 | Procedure: blood sampling for determination of serum zn | - | - | - | - | 299[1] 299 💬 | 
| 915 | Procedure: blood sampling from infant | - | - | - | - | 046[3] 46, 96, 271 💬 | 
| 916 | Procedure: blood sampling from mother | - | - | - | - | 046[3] 46, 96, 271 💬 | 
| 917 | Procedure: blood sampling from umbilical cord | - | - | - | - | 046[3] 46, 96, 271 💬 | 
| 918 | Procedure: blood sampling, endoscopy | - | - | - | - | 097[1] 97 💬 | 
| 919 | Procedure: blue light photopheresis | - | - | - | - | 096[1] 96 💬 | 
| 920 | Procedure: bone densitometry | - | - | - | - | 162[1] 162 💬 | 
| 921 | Procedure: bone marrow ablation with stem cell support | - | - | - | - | 028[2] 28, 60 💬 | 
| 922 | Procedure: bone marrow aspiration | - | - | - | - | 060[2] 60, 285 💬 | 
| 923 | Procedure: bone marrow infusion | - | - | - | - | 036[1] 36 💬 | 
| 924 | Procedure: bone marrow mononuclear cells | - | - | - | - | 057[1] 57 💬 | 
| 925 | Procedure: bone marrow or umbilical cord blood (ucg) stem cell transplantation | - | - | - | - | 036[1] 36 💬 | 
| 926 | Procedure: bone marrow transplant | - | - | - | - | 060[1] 60 💬 | 
| 927 | Procedure: bone marrow transplantation | - | - | - | - | 051[4] 51, 60, 284, 285 💬 | 
| 928 | Procedure: brain magnetic resonance imaging (mri) | - | - | - | - | 017[1] 17 💬 | 
| 929 | Procedure: brain mri/mrs/fmri | - | - | - | - | 019[1] 19 💬 | 
| 930 | Procedure: brain pet scan | - | - | - | - | 005[3]  5 ,  7 , 127 💬 | 
| 931 | Procedure: breast milk sampling | - | - | - | - | 046[3] 46, 96, 271 💬 | 
| 932 | Procedure: bronchoalveolar lavage (bal) | - | - | - | - | 084[1] 84 💬 | 
| 933 | Procedure: bronchoscopy with bal | - | - | - | - | 299[1] 299 💬 | 
| 934 | Procedure: bronchoscopy with bronchoalveolar lavage | - | - | - | - | 084[1] 84 💬 | 
| 935 | Procedure: cardiac monitoring | - | - | - | - | 006[1]  6  💬 | 
| 936 | Procedure: carotid ultrasound | - | - | - | - | 078[1] 78 💬 | 
| 937 | Procedure: cd3-depleted hematopoietic cell transplantation | - | - | - | - | 060[1] 60 💬 | 
| 938 | Procedure: cd34 selected haploidentical pbsct | - | - | - | - | 285[1] 285 💬 | 
| 939 | Procedure: cd34+ peripheral blood stem cell reinfusion | - | - | - | - | 049[1] 49 💬 | 
| 940 | Procedure: cd3±cd19 depleted hematopoietic stem cell transplantation | - | - | - | - | 060[1] 60 💬 | 
| 941 | Procedure: celiac block with triamcinolone and bupivicaine | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 298[1] 298 💬 | 
| 942 | Procedure: chuna manipulation | - | - | - | - | 070[1] 70 💬 | 
| 943 | Procedure: chuna manual medicine | - | - | - | - | 070[1] 70 💬 | 
| 944 | Procedure: clobetasol propionate | Clobetasol | [2] D01272D01272, D07715D07715 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 162[1] 162 💬 | 
| 945 | Procedure: colectomy | - | - | - | - | 097[1] 97 💬 | 
| 946 | Procedure: collagenase | Collagenase clostridium histolyticum | [1] D09596D09596 💬 | - | - | 162[1] 162 💬 | 
| 947 | Procedure: colonoscopy | - | - | - | - | 097[1] 97 💬 | 
| 948 | Procedure: colorectal biopsies | - | - | - | - | 097[1] 97 💬 | 
| 949 | Procedure: computed tomography | - | - | - | - | 034[5] 34, 40, 46, 49, 96 💬 | 
| 950 | Procedure: continuous glucose monitoring system (cgms) | Dextrose, unspecified form | - | - | - | 299[1] 299 💬 | 
| 951 | Procedure: continuous mononuclear cell collection (cmnc) | - | - | - | - | 096[1] 96 💬 | 
| 952 | Procedure: contrast sensitivity measurement | - | - | - | - | 019[1] 19 💬 | 
| 953 | Procedure: control group | - | - | - | - | 034[1] 34 💬 | 
| 954 | Procedure: conventional surgery | - | - | - | - | 034[1] 34 💬 | 
| 955 | Procedure: cord blood | - | - | - | - | 060[1] 60 💬 | 
| 956 | Procedure: cord blood infusion | - | - | - | - | 060[1] 60 💬 | 
| 957 | Procedure: coronary flow reserve se | - | - | - | - | 058[3] 58, 86, 215 💬 | 
| 958 | Procedure: ct scan | - | - | - | - | 065[1] 65 💬 | 
| 959 | Procedure: cupping | - | - | - | - | 070[1] 70 💬 | 
| 960 | Procedure: cyclophosphamide | Cyclophosphamide | [2] D00287D00287, D07760D07760 💬 | - | - | 065[1] 65 💬 | 
| 961 | Procedure: datscan and spect imaging | - | - | - | - | 006[1]  6  💬 | 
| 962 | Procedure: dental evaluation | - | - | - | - | 078[1] 78 💬 | 
| 963 | Procedure: determination of growth hormone status | Somatotropin | [1] D02691D02691 💬 | GHR[1] GHR 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway | 078[1] 78 💬 | 
| 964 | Procedure: determination of objective and subjective pain threshold | - | - | - | - | 017[1] 17 💬 | 
| 965 | Procedure: dexa scan | - | - | - | - | 019[3] 19, 46, 96 💬 | 
| 966 | Procedure: dexa, blood tests, h.g.p.o, osseous age. | - | - | - | - | 078[2] 78, 193 💬 | 
| 967 | Procedure: diastolic function se | - | - | - | - | 058[3] 58, 86, 215 💬 | 
| 968 | Procedure: digital substraction angiography (dsa) | - | - | - | - | 040[1] 40 💬 | 
| 969 | Procedure: drug coated balloon (dcb) | - | - | - | - | 040[1] 40 💬 | 
| 970 | Procedure: dual energy x-ray absorptiometry (dexa) | - | - | - | - | 299[1] 299 💬 | 
| 971 | Procedure: dynamic contrast-enhanced magnetic resonance imaging | - | - | - | - | 013[1] 13 💬 | 
| 972 | Procedure: dysmorphology evaluation | - | - | - | - | 078[1] 78 💬 | 
| 973 | Procedure: ebb + tblb + bal | - | - | - | - | 084[1] 84 💬 | 
| 974 | Procedure: ebus guided transbronchial forceps biopsy (ebus-tbfb) | - | - | - | - | 084[1] 84 💬 | 
| 975 | Procedure: ebus guided transbronchial needle aspiration (ebus-tbna) | - | - | - | - | 084[1] 84 💬 | 
| 976 | Procedure: echocardiogram | - | - | - | - | 019[1] 19 💬 | 
| 977 | Procedure: echocardiography (tee) | - | - | - | - | 058[1] 58 💬 | 
| 978 | Procedure: electroacupuncture | - | - | - | - | 006[2]  6 , 70 💬 | 
| 979 | Procedure: electrophysiologic study | - | - | - | - | 001[1]  1  💬 | 
| 980 | Procedure: embryonic dopamine cell implant surgery | Dopamine | [2] D00633D00633, D07870D07870 💬 | DRD1[5] DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 981 | Procedure: endobronchial forceps biopsy | - | - | - | - | 084[1] 84 💬 | 
| 982 | Procedure: endoscopic balloon dilatation | - | - | - | - | 096[1] 96 💬 | 
| 983 | Procedure: endoscopic drainage of the main pancreatic duct | - | - | - | - | 298[1] 298 💬 | 
| 984 | Procedure: endoscopic repair of myelomeningocele before 26 sa | - | - | - | - | 118[1] 118 💬 | 
| 985 | Procedure: endoscopic trans-sphenoidal adenoma resection | - | - | - | - | 074[1] 74 💬 | 
| 986 | Procedure: endothelial cell biopsy | - | - | - | - | 078[1] 78 💬 | 
| 987 | Procedure: enema | - | - | - | - | 097[1] 97 💬 | 
| 988 | Procedure: epidural local anesthetic injection | - | - | - | - | 070[1] 70 💬 | 
| 989 | Procedure: epidural steroid (dexamethasone) injection | Dexamethasone | [9] D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 070[1] 70 💬 | 
| 990 | Procedure: epidural steroid injection | - | - | - | - | 070[1] 70 💬 | 
| 991 | Procedure: epidural steroid with local anesthetic injection | - | - | - | - | 070[1] 70 💬 | 
| 992 | Procedure: esophageal dilation | - | - | - | - | 098[1] 98 💬 | 
| 993 | Procedure: esophagogastroduodenoscopy | - | - | - | - | 098[1] 98 💬 | 
| 994 | Procedure: eua with seton placement if necessary | - | - | - | - | 096[1] 96 💬 | 
| 995 | Procedure: eus | - | - | - | - | 096[1] 96 💬 | 
| 996 | Procedure: eus-fna/ebus-tbna + bal | - | - | - | - | 084[1] 84 💬 | 
| 997 | Procedure: ex vivo immunotherapy | - | - | - | - | 060[1] 60 💬 | 
| 998 | Procedure: exergame | - | - | - | - | 006[2]  6 , 13 💬 | 
| 999 | Procedure: exhaled nitric oxide | Nitric Oxide | [1] D00074D00074 💬 | - | - | 299[1] 299 💬 | 
| 1000 | Procedure: exhaled nitric oxide assessment | Nitric Oxide | [1] D00074D00074 💬 | - | - | 046[1] 46 💬 | 
| 1001 | Procedure: extracorporeal photopheresis | - | - | - | - | 046[2] 46, 96 💬 | 
| 1002 | Procedure: extracorporeal shock wave lithotripsy | - | - | - | - | 298[1] 298 💬 | 
| 1003 | Procedure: fdg-pet | - | - | - | - | 299[1] 299 💬 | 
| 1004 | Procedure: fecal microbiota transplantation | - | - | - | - | 097[1] 97 💬 | 
| 1005 | Procedure: fecal microbiota transplantation (fmt) of fmp30 donor stool | - | - | - | - | 013[1] 13 💬 | 
| 1006 | Procedure: fetal surgery for mmc repair | - | - | - | - | 118[1] 118 💬 | 
| 1007 | Procedure: fibroscan | - | - | - | - | 171[1] 171 💬 | 
| 1008 | Procedure: fluoroscopic swallow evaluation | - | - | - | - | 006[1]  6  💬 | 
| 1009 | Procedure: fmt | - | - | - | - | 096[2] 96, 97 💬 | 
| 1010 | Procedure: fmt+mtx | - | - | - | - | 046[1] 46 💬 | 
| 1011 | Procedure: functional hepatic nitrogen clearance | Nitrogen | [1] D00083D00083 💬 | - | - | 171[1] 171 💬 | 
| 1012 | Procedure: gastrointestinal evaluation | - | - | - | - | 078[1] 78 💬 | 
| 1013 | Procedure: gastroscopy | - | - | - | - | 097[1] 97 💬 | 
| 1014 | Procedure: general anesthesia with tourniquet | - | - | - | - | 046[1] 46 💬 | 
| 1015 | Procedure: general anesthesia without tourniquet | - | - | - | - | 046[1] 46 💬 | 
| 1016 | Procedure: ghrh/arginine stimulation testing | Arginine | [2] D02982D02982, D08523D08523 💬 | GHRHR[1] GHRHR 💬 | Growth hormone synthesis, secretion and action[2] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction | 078[1] 78 💬 | 
| 1017 | Procedure: glucagon stimulation test and insulin tolerance test | Glucagon | [2] D00116D00116, D02118D02118 💬 | GCGR[1] GCGR 💬 | Glucagon signaling pathway[2] Glucagon signaling pathway, Neuroactive ligand-receptor interaction | 078[1] 78 💬 | 
| 1018 | Procedure: growth factors laboratory testing | - | - | - | - | 078[1] 78 💬 | 
| 1019 | Procedure: growth hormone stimulation test | Somatotropin | [1] D02691D02691 💬 | GHR[1] GHR 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway | 299[1] 299 💬 | 
| 1020 | Procedure: haplo hsct | - | - | - | - | 060[1] 60 💬 | 
| 1021 | Procedure: hematopoietic bone marrow transplantation | - | - | - | - | 036[1] 36 💬 | 
| 1022 | Procedure: hematopoietic stem cell therapy | - | - | - | - | 013[1] 13 💬 | 
| 1023 | Procedure: hematopoietic stem cell transplant | - | - | - | - | 285[1] 285 💬 | 
| 1024 | Procedure: hematopoietic stem cell transplantation | - | - | - | - | 013[3] 13, 65, 285 💬 | 
| 1025 | Procedure: hematopoietic stem cell transplantation (hsct) | - | - | - | - | 013[1] 13 💬 | 
| 1026 | Procedure: hepatocyte transplant | - | - | - | - | 240[1] 240 💬 | 
| 1027 | Procedure: hgpiv diagnosis test | - | - | - | - | 299[1] 299 💬 | 
| 1028 | Procedure: high frequency ultrasonography | - | - | - | - | 046[1] 46 💬 | 
| 1029 | Procedure: history and physical | - | - | - | - | 231[1] 231 💬 | 
| 1030 | Procedure: history and physical exam. | - | - | - | - | 231[2] 231, 299 💬 | 
| 1031 | Procedure: homar-ir diagnosis test | - | - | - | - | 299[1] 299 💬 | 
| 1032 | Procedure: home based balance training | Isoxaflutole | - | - | - | 006[2]  6 , 13 💬 | 
| 1033 | Procedure: hydrocortisone withdrawal | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 1034 | Procedure: hyperbaric oxygen | Oxygen | [1] D00003D00003 💬 | - | - | 097[1] 97 💬 | 
| 1035 | Procedure: hyperbaric oxygen therapy | Oxygen | [1] D00003D00003 💬 | - | - | 090[1] 90 💬 | 
| 1036 | Procedure: hypercortisolism | - | - | - | - | 075[1] 75 💬 | 
| 1037 | Procedure: ileocecal resection | - | - | - | - | 096[1] 96 💬 | 
| 1038 | Procedure: ileocolonoscopy | - | - | - | - | 096[1] 96 💬 | 
| 1039 | Procedure: immunoadsorption | - | - | - | - | 013[1] 13 💬 | 
| 1040 | Procedure: immunosuppressive therapy (ist) | - | - | - | - | 060[1] 60 💬 | 
| 1041 | Procedure: impedance analysis | - | - | - | - | 162[1] 162 💬 | 
| 1042 | Procedure: implant procedure | - | - | - | - | 046[1] 46 💬 | 
| 1043 | Procedure: in vitro-treated bone marrow transplantation | - | - | - | - | 060[1] 60 💬 | 
| 1044 | Procedure: in vitro-treated peripheral blood stem cell transplantation | - | - | - | - | 060[2] 60, 65 💬 | 
| 1045 | Procedure: increased exercise intensity | - | - | - | - | 113[1] 113 💬 | 
| 1046 | Procedure: indirect calorimetry | - | - | - | - | 299[1] 299 💬 | 
| 1047 | Procedure: infection prophylaxis and management | - | - | - | - | 028[2] 28, 60 💬 | 
| 1048 | Procedure: infusion of saline | - | - | - | - | 097[1] 97 💬 | 
| 1049 | Procedure: injection of salivary glands | - | - | - | - | 002[1]  2  💬 | 
| 1050 | Procedure: injections on posterior bladder wall excluding the trigone | - | - | - | - | 226[1] 226 💬 | 
| 1051 | Procedure: injections upper aspect of trigone of urinary bladder | - | - | - | - | 226[1] 226 💬 | 
| 1052 | Procedure: instillation of fibrin glue | - | - | - | - | 096[1] 96 💬 | 
| 1053 | Procedure: intestinal surgery for crohn's disease | - | - | - | - | 096[1] 96 💬 | 
| 1054 | Procedure: intra-articular injection of etanercept | Etanercept | [1] D00742D00742 💬 | LTA[2] LTA, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 1055 | Procedure: intra-articular injection of steroid | - | - | - | - | 046[1] 46 💬 | 
| 1056 | Procedure: intraluminal impedance | - | - | - | - | 098[1] 98 💬 | 
| 1057 | Procedure: intravenous catheter | - | - | - | - | 231[1] 231 💬 | 
| 1058 | Procedure: irradiation | - | - | - | - | 013[1] 13 💬 | 
| 1059 | Procedure: iv administration of genetically engineered hematopoietic stem/progenitors cells (hspcs) | - | - | - | - | 285[1] 285 💬 | 
| 1060 | Procedure: iv deployment of csvf in sterile normal saline iv solution | - | - | - | - | 085[2] 85, 229 💬 | 
| 1061 | Procedure: iv glucose tolerance test | Dextrose, unspecified form | - | - | - | 299[1] 299 💬 | 
| 1062 | Procedure: land exercises | - | - | - | - | 046[1] 46 💬 | 
| 1063 | Procedure: large bore (19g) histologic needle biopsy of the mediastinal lymph nodes | - | - | - | - | 084[1] 84 💬 | 
| 1064 | Procedure: lateral transperitoneal la | - | - | - | - | 075[1] 75 💬 | 
| 1065 | Procedure: left ventricular contractile reserve se | - | - | - | - | 058[3] 58, 86, 215 💬 | 
| 1066 | Procedure: left ventricular outflow tract gradient se | - | - | - | - | 058[3] 58, 86, 215 💬 | 
| 1067 | Procedure: leukapheresis | - | - | - | - | 049[5] 49, 51, 96, 284, 285 💬 | 
| 1068 | Procedure: leukopheresis | - | - | - | - | 051[1] 51 💬 | 
| 1069 | Procedure: liver biopsy | - | - | - | - | 171[3] 171, 231, 240 💬 | 
| 1070 | Procedure: liver transplantation | - | - | - | - | 094[1] 94 💬 | 
| 1071 | Procedure: long term oxygen therapy | Oxygen | [1] D00003D00003 💬 | - | - | 088[1] 88 💬 | 
| 1072 | Procedure: lumbar epidural injection | - | - | - | - | 070[1] 70 💬 | 
| 1073 | Procedure: lumbar interlaminar epidural steroid injection | - | - | - | - | 070[1] 70 💬 | 
| 1074 | Procedure: lumbar puncture | - | - | - | - | 006[5]  6 , 13, 19, 96, 97 💬 | 
| 1075 | Procedure: magnetic resonance imaging | - | - | - | - | 019[1] 19 💬 | 
| 1076 | Procedure: magnetic resonance imaging of the brain | - | - | - | - | 078[1] 78 💬 | 
| 1077 | Procedure: management of therapy complications | - | - | - | - | 028[2] 28, 60 💬 | 
| 1078 | Procedure: manual therapy | - | - | - | - | 070[1] 70 💬 | 
| 1079 | Procedure: marrow graft transplantation | - | - | - | - | 326[1] 326 💬 | 
| 1080 | Procedure: matched unrelated donor hematopoietic stem cell transplant | - | - | - | - | 060[1] 60 💬 | 
| 1081 | Procedure: measurement of growth, thyroid and sex hormone levels | - | - | - | - | 078[1] 78 💬 | 
| 1082 | Procedure: measurement of serum infliximab and anti-infliximab antibodies | Infliximab | [1] D02598D02598 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 096[1] 96 💬 | 
| 1083 | Procedure: meg | - | - | - | - | 006[1]  6  💬 | 
| 1084 | Procedure: mesenchymal stem cell transplantation | - | - | - | - | 036[2] 36, 274 💬 | 
| 1085 | Procedure: microcannula harvest adipose derived tissue stromal vascular fraction (tsvf) | - | - | - | - | 085[2] 85, 229 💬 | 
| 1086 | Procedure: mild procedure | - | - | - | - | 070[1] 70 💬 | 
| 1087 | Procedure: minor salivary gland (labial) biopsy | - | - | - | - | 053[1] 53 💬 | 
| 1088 | Procedure: mitral regurgitation se | - | - | - | - | 058[3] 58, 86, 215 💬 | 
| 1089 | Procedure: motion analysis | - | - | - | - | 006[1]  6  💬 | 
| 1090 | Procedure: mri | - | - | - | - | 013[2] 13, 78 💬 | 
| 1091 | Procedure: mri imaging with intravenous contrast with gadoterate meglumine | Gadoteric acid | [2] D01796D01796, D08007D08007 💬 | - | - | 053[1] 53 💬 | 
| 1092 | Procedure: mri, fdg-pet/ct scans | - | - | - | - | 034[1] 34 💬 | 
| 1093 | Procedure: mri, venipuncture | - | - | - | - | 049[1] 49 💬 | 
| 1094 | Procedure: narrow band imaging | - | - | - | - | 097[1] 97 💬 | 
| 1095 | Procedure: neurology examination | - | - | - | - | 078[1] 78 💬 | 
| 1096 | Procedure: neuropsychological testing | - | - | - | - | 078[1] 78 💬 | 
| 1097 | Procedure: no celiac block | - | - | - | - | 298[1] 298 💬 | 
| 1098 | Procedure: no gas | - | - | - | - | 086[2] 86, 88 💬 | 
| 1099 | Procedure: non-myeloablative high dose immunosuppressive therapy conditioning (hdit) | - | - | - | - | 049[1] 49 💬 | 
| 1100 | Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation | - | - | - | - | 028[6] 28, 51, 60, 62, 65, 285 💬 | 
| 1101 | Procedure: ophthalmologic evaluation | - | - | - | - | 078[1] 78 💬 | 
| 1102 | Procedure: ophthalmology exam | - | - | - | - | 019[1] 19 💬 | 
| 1103 | Procedure: oral glucose tolerance test | Dextrose, unspecified form | - | - | - | 299[1] 299 💬 | 
| 1104 | Procedure: order of two elements of surgical procedure | - | - | - | - | 051[1] 51 💬 | 
| 1105 | Procedure: orthopedic evaluation | - | - | - | - | 078[1] 78 💬 | 
| 1106 | Procedure: other intervention(s) | - | - | - | - | 070[1] 70 💬 | 
| 1107 | Procedure: oxygen flow at the optic nerve head measurement | Oxygen | [1] D00003D00003 💬 | - | - | 019[1] 19 💬 | 
| 1108 | Procedure: padn | - | - | - | - | 086[1] 86 💬 | 
| 1109 | Procedure: pelvic floor physical therapy | - | - | - | - | 226[1] 226 💬 | 
| 1110 | Procedure: percutaneous endoscopic gastrostomy with jejunal extension (peg-j) | - | - | - | - | 006[1]  6  💬 | 
| 1111 | Procedure: percutaneous lumbar decompression | - | - | - | - | 070[1] 70 💬 | 
| 1112 | Procedure: peripheral blood stem cell transplantation | - | - | - | - | 011[11] 11, 13, 14, 28, 51, 60, 62, 65, 283, 284, 285 💬 | 
| 1113 | Procedure: peripheral blood stem cell transplantation (pbsct) | - | - | - | - | 060[1] 60 💬 | 
| 1114 | Procedure: pet/ct | - | - | - | - | 006[1]  6  💬 | 
| 1115 | Procedure: pft | - | - | - | - | 089[1] 89 💬 | 
| 1116 | Procedure: pharmacopuncture | - | - | - | - | 070[1] 70 💬 | 
| 1117 | Procedure: phlebotomy | - | - | - | - | 254[1] 254 💬 | 
| 1118 | Procedure: physical exam and updrs part iii assessment | - | - | - | - | 006[1]  6  💬 | 
| 1119 | Procedure: physiotherapy, exercise, percutaneous gastrostomy feeds | - | - | - | - | 299[1] 299 💬 | 
| 1120 | Procedure: pilocarpine | Pilocarpine | [3] D00525D00525, D02200D02200, D05478D05478 💬 | CHRM2[2] CHRM2, CHRM3 💬 | Alzheimer disease[13] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway | 053[1] 53 💬 | 
| 1121 | Procedure: planar image with both hands in field of view | - | - | - | - | 046[1] 46 💬 | 
| 1122 | Procedure: plasma exchange | - | - | - | - | 013[5] 13, 43, 44, 64, 222 💬 | 
| 1123 | Procedure: plasma exchange (pe) | - | - | - | - | 066[2] 66, 220 💬 | 
| 1124 | Procedure: plasmapheresis | - | - | - | - | 011[3] 11, 49, 222 💬 | 
| 1125 | Procedure: plex | - | - | - | - | 011[1] 11 💬 | 
| 1126 | Procedure: plf with autograft | - | - | - | - | 070[1] 70 💬 | 
| 1127 | Procedure: positron emission tomography | - | - | - | - | 040[4] 40, 46, 49, 96 💬 | 
| 1128 | Procedure: posterior ra | - | - | - | - | 075[1] 75 💬 | 
| 1129 | Procedure: posterolateral spinal fusion with instrumentation | - | - | - | - | 070[1] 70 💬 | 
| 1130 | Procedure: power doppler ultrasonography | - | - | - | - | 046[1] 46 💬 | 
| 1131 | Procedure: pre liver transplantation laparoscopic hand assisted staging | - | - | - | - | 094[1] 94 💬 | 
| 1132 | Procedure: psychiatric evaluation | - | - | - | - | 078[1] 78 💬 | 
| 1133 | Procedure: pulmonary endarterectomy | - | - | - | - | 088[1] 88 💬 | 
| 1134 | Procedure: pulmonary endarteriectomy | - | - | - | - | 088[1] 88 💬 | 
| 1135 | Procedure: pulmonary function testing | - | - | - | - | 002[3]  2 , 228, 299 💬 | 
| 1136 | Procedure: pulmonary function testing. | - | - | - | - | 231[2] 231, 299 💬 | 
| 1137 | Procedure: pulmonary hemodynamics se | - | - | - | - | 058[3] 58, 86, 215 💬 | 
| 1138 | Procedure: quality-of-life assessment | - | - | - | - | 028[3] 28, 34, 51 💬 | 
| 1139 | Procedure: quantiferon-tb gold assay | Gold | - | - | - | 046[1] 46 💬 | 
| 1140 | Procedure: quantitative chemical shift imaging (qcsi) | - | - | - | - | 019[1] 19 💬 | 
| 1141 | Procedure: radiation therapy | - | - | - | - | 013[3] 13, 284, 285 💬 | 
| 1142 | Procedure: radiographs of the thoracic and lumbar spine | - | - | - | - | 162[1] 162 💬 | 
| 1143 | Procedure: rectal dialysis | - | - | - | - | 097[1] 97 💬 | 
| 1144 | Procedure: rectosigmoidoscopy | - | - | - | - | 097[1] 97 💬 | 
| 1145 | Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation | - | - | - | - | 051[1] 51 💬 | 
| 1146 | Procedure: reduced intensity allogeneic transplant | - | - | - | - | 049[2] 49, 51 💬 | 
| 1147 | Procedure: renal sympathetic denervation | - | - | - | - | 067[1] 67 💬 | 
| 1148 | Procedure: repair of cdh w/alloderm | - | - | - | - | 294[1] 294 💬 | 
| 1149 | Procedure: repair of cdh w/sis gold | Gold | - | - | - | 294[1] 294 💬 | 
| 1150 | Procedure: rf catheter ablation | - | - | - | - | 058[1] 58 💬 | 
| 1151 | Procedure: routine drainage surgery | - | - | - | - | 096[1] 96 💬 | 
| 1152 | Procedure: saline injection | - | - | - | - | 113[1] 113 💬 | 
| 1153 | Procedure: sedation with iv propofol | Propofol | [1] D00549D00549 💬 | GABRA1[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | GABAergic synapse[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction | 006[1]  6  💬 | 
| 1154 | Procedure: self bone marrow transplant | - | - | - | - | 051[1] 51 💬 | 
| 1155 | Procedure: sham | - | - | - | - | 090[2] 90, 303 💬 | 
| 1156 | Procedure: sham cystoscopy procedure | - | - | - | - | 226[1] 226 💬 | 
| 1157 | Procedure: sham hyperbaric air | - | - | - | - | 097[1] 97 💬 | 
| 1158 | Procedure: sham padn | - | - | - | - | 086[1] 86 💬 | 
| 1159 | Procedure: sham procedure | - | - | - | - | 003[1]  3  💬 | 
| 1160 | Procedure: sham surgery | - | - | - | - | 006[1]  6  💬 | 
| 1161 | Procedure: sialoendoscopy | - | - | - | - | 053[1] 53 💬 | 
| 1162 | Procedure: sigmoidoscopy | - | - | - | - | 097[1] 97 💬 | 
| 1163 | Procedure: single photon emission computed tomography | - | - | - | - | 034[1] 34 💬 | 
| 1164 | Procedure: skeletal survey | - | - | - | - | 019[1] 19 💬 | 
| 1165 | Procedure: skin biopsy | - | - | - | - | 019[2] 19, 84 💬 | 
| 1166 | Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 srt patients included. | - | - | - | - | 102[1] 102 💬 | 
| 1167 | Procedure: slit lamp assessment and intra-ocular pressure measurement | - | - | - | - | 019[1] 19 💬 | 
| 1168 | Procedure: small bowel follow trough | - | - | - | - | 096[1] 96 💬 | 
| 1169 | Procedure: sodium bicarbonate | Sodium bicarbonate | [1] D01203D01203 💬 | - | - | 299[1] 299 💬 | 
| 1170 | Procedure: spect imaging (180 minutes post-injection) | - | - | - | - | 046[1] 46 💬 | 
| 1171 | Procedure: spect imaging (60 minutes post-injection) | - | - | - | - | 046[1] 46 💬 | 
| 1172 | Procedure: speech and modified barium swallow study | Barium | - | - | - | 019[1] 19 💬 | 
| 1173 | Procedure: speech pathology evaluation | - | - | - | - | 078[1] 78 💬 | 
| 1174 | Procedure: spinal anesthesia with tourniquet | - | - | - | - | 046[1] 46 💬 | 
| 1175 | Procedure: spinal anesthesia without tourniquet | - | - | - | - | 046[1] 46 💬 | 
| 1176 | Procedure: spirometry | - | - | - | - | 299[1] 299 💬 | 
| 1177 | Procedure: spleen sample | - | - | - | - | 061[1] 61 💬 | 
| 1178 | Procedure: sputum collection | - | - | - | - | 299[1] 299 💬 | 
| 1179 | Procedure: stage ii surgical repair | - | - | - | - | 211[1] 211 💬 | 
| 1180 | Procedure: standardized fmt | - | - | - | - | 097[1] 97 💬 | 
| 1181 | Procedure: static, dynamic and functional balance exercises | Isoxaflutole | - | - | - | 006[1]  6  💬 | 
| 1182 | Procedure: static, dynamic and functional balance exercises with dual task | Isoxaflutole | - | - | - | 006[1]  6  💬 | 
| 1183 | Procedure: status post lung transplant | - | - | - | - | 228[1] 228 💬 | 
| 1184 | Procedure: stem cell collection | - | - | - | - | 028[1] 28 💬 | 
| 1185 | Procedure: stem cell infusion | - | - | - | - | 028[5] 28, 60, 65, 284, 285 💬 | 
| 1186 | Procedure: stem cell or umbilical cord blood transplantation | - | - | - | - | 326[1] 326 💬 | 
| 1187 | Procedure: stem cell transplant | - | - | - | - | 019[5] 19, 20, 65, 164, 284 💬 | 
| 1188 | Procedure: stem cell transplantation | - | - | - | - | 019[6] 19, 51, 60, 62, 65, 326 💬 | 
| 1189 | Procedure: stool samples | - | - | - | - | 097[1] 97 💬 | 
| 1190 | Procedure: supplemental oxygen via a mask | Oxygen | [1] D00003D00003 💬 | - | - | 088[1] 88 💬 | 
| 1191 | Procedure: surgery to implant human cns stem cells (hucns-sc) | - | - | - | - | 019[1] 19 💬 | 
| 1192 | Procedure: surgery treatment | - | - | - | - | 291[1] 291 💬 | 
| 1193 | Procedure: syngeneic bone marrow transplantation | - | - | - | - | 011[3] 11, 13, 14 💬 | 
| 1194 | Procedure: synovial biopsy | - | - | - | - | 046[1] 46 💬 | 
| 1195 | Procedure: taking of blood | - | - | - | - | 113[1] 113 💬 | 
| 1196 | Procedure: testosterone injection | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 265[1] 265 💬 | 
| 1197 | Procedure: thymectomy plus prednisone | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 011[1] 11 💬 | 
| 1198 | Procedure: thymic shielding during radiation | - | - | - | - | 285[1] 285 💬 | 
| 1199 | Procedure: tissue biopsy | - | - | - | - | 001[1]  1  💬 | 
| 1200 | Procedure: tissue samplings | - | - | - | - | 006[1]  6  💬 | 
| 1201 | Procedure: tof repair with trans-annular patch vs preservation of pv | - | - | - | - | 215[1] 215 💬 | 
| 1202 | Procedure: total body irradiation | - | - | - | - | 019[6] 19, 20, 51, 60, 65, 285 💬 | 
| 1203 | Procedure: total lymphoid irradiation | - | - | - | - | 065[3] 65, 284, 326 💬 | 
| 1204 | Procedure: total thyroidectomy | - | - | - | - | 235[1] 235 💬 | 
| 1205 | Procedure: total-body irradiation | - | - | - | - | 051[1] 51 💬 | 
| 1206 | Procedure: trans-right ventricular alcohol septal ablation (trvasa) | Ethanol | [4] D00068D00068, D02798D02798, D04855D04855, D06542D06542 💬 | - | - | 058[1] 58 💬 | 
| 1207 | Procedure: transfusion | - | - | - | - | 096[1] 96 💬 | 
| 1208 | Procedure: transsphenoidal surgery treatment | - | - | - | - | 074[1] 74 💬 | 
| 1209 | Procedure: treatment according to current standards without knowledge of serum infliximab and anti-infliximab ab status | Infliximab | [1] D02598D02598 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 096[1] 96 💬 | 
| 1210 | Procedure: tuberculin skin test | - | - | - | - | 046[1] 46 💬 | 
| 1211 | Procedure: ultrasound | - | - | - | - | 171[1] 171 💬 | 
| 1212 | Procedure: umbilical cord blood therapy | Umbilical Cord Blood Hematopoietic Stem Cells | - | - | - | 002[2]  2 ,  6  💬 | 
| 1213 | Procedure: umbilical cord blood transplantation | - | - | - | - | 060[5] 60, 65, 284, 285, 326 💬 | 
| 1214 | Procedure: upper limb muscle block | - | - | - | - | 149[1] 149 💬 | 
| 1215 | Procedure: urinary collect | - | - | - | - | 299[1] 299 💬 | 
| 1216 | Procedure: urine collection | - | - | - | - | 019[1] 19 💬 | 
| 1217 | Procedure: urodynamic study | - | - | - | - | 226[1] 226 💬 | 
| 1218 | Procedure: use of an electronic data capture system by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in ra subjects. | Bifenthrin | - | - | - | 046[1] 46 💬 | 
| 1219 | Procedure: venipunctures | - | - | - | - | 084[1] 84 💬 | 
| 1220 | Procedure: videofluoroscopic swallowing study | - | - | - | - | 002[1]  2  💬 | 
| 1221 | Procedure: videofluoroscopic swallowing study (vfss) | - | - | - | - | 002[1]  2  💬 | 
| 1222 | Procedure: visual field testing | - | - | - | - | 019[1] 19 💬 | 
| 1223 | Procedure: warm compress prior to injection of glatiramer acetate | Acetate | [1] D04318D04318 💬 | HLA-A[20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | Allograft rejection[32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis | 013[1] 13 💬 | 
| 1224 | Procedure: water exercises | Water | [1] D00001D00001 💬 | - | - | 046[1] 46 💬 | 
| 1225 | Procedure: whole body planar spect imaging (15 minutes post-injection) | - | - | - | - | 046[1] 46 💬 | 
| 1226 | Procedure: whole body planar spect imaging (18-20 hours post-injection) | - | - | - | - | 046[1] 46 💬 | 
| 1227 | Procedure: whole body planar spect imaging (180 minutes post-injection) | - | - | - | - | 046[1] 46 💬 | 
| 1228 | Procedure: whole body planar spect imaging (60 minutes post-injection) | - | - | - | - | 046[1] 46 💬 | 
| 1229 | Procedure: whole body protein turnover | - | - | - | - | 019[4] 19, 46, 96, 299 💬 | 
| 1230 | Procedure: whole body protein turnover study | - | - | - | - | 299[1] 299 💬 | 
| 1231 | Procedure: whole lung lavage(wll) | - | - | - | - | 229[1] 229 💬 | 
| 1232 | Procedure: wll | - | - | - | - | 229[1] 229 💬 | 
| 1233 | Procedure: wmt | - | - | - | - | 096[1] 96 💬 | 
| 1234 | Prochymal (remestemcel-l) | Remestemcel-L | [1] D09719D09719 💬 | - | - | 096[1] 96 💬 | 
| 1235 | Prochymal adult human mesenchymal stem cells | Remestemcel-L | [1] D09719D09719 💬 | - | - | 096[1] 96 💬 | 
| 1236 | Prochymal™ adult human mesenchymal stem cells | Remestemcel-L | [1] D09719D09719 💬 | - | - | 096[1] 96 💬 | 
| 1237 | Procysbi | - | - | - | - | 019[1] 19 💬 | 
| 1238 | Prodarsan | - | - | - | - | 192[1] 192 💬 | 
| 1239 | Products containing aminosalicylate | - | - | - | - | 097[1] 97 💬 | 
| 1240 | Products containing azathioprine or 6-mercaptopurine | Azathioprine | [4] D00161D00161, D00238D00238, D03033D03033, D04931D04931 💬 | HPRT1[1] HPRT1 💬 | Drug metabolism - other enzymes[3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism | 097[1] 97 💬 | 
| 1241 | Progerinin | - | - | - | - | 191[2] 191, 333 💬 | 
| 1242 | Prograf | - | - | - | - | 060[3] 60, 222, 226 💬 | 
| 1243 | Prograft capsules | - | - | - | - | 299[1] 299 💬 | 
| 1244 | Progressive spacing of tnf-blocker injections | - | - | - | - | 046[1] 46 💬 | 
| 1245 | Prohance (gadoteridol) | Gadoteridol | [1] D01137D01137 💬 | - | - | 013[1] 13 💬 | 
| 1246 | Prolastin | - | - | - | - | 231[3] 231, 298, 299 💬 | 
| 1247 | Prolastin (drug) | - | - | - | - | 299[1] 299 💬 | 
| 1248 | Prolastin-c | - | - | - | - | 231[2] 231, 298 💬 | 
| 1249 | Prolastin-c, 120 mg/kg | - | - | - | - | 231[1] 231 💬 | 
| 1250 | Prolastin-c, 60 mg/kg | - | - | - | - | 231[1] 231 💬 | 
| 1251 | Proleukin | - | - | - | - | 002[3]  2 , 49, 65 💬 | 
| 1252 | Proleukin 18 mui | - | - | - | - | 002[1]  2  💬 | 
| 1253 | Proleukin® s | - | - | - | - | 065[1] 65 💬 | 
| 1254 | Prolia | - | - | - | - | 274[1] 274 💬 | 
| 1255 | Proline | Proline | [1] D00035D00035 💬 | - | - | 094[2] 94, 97 💬 | 
| 1256 | Prolonged release tablet | - | - | - | - | 006[1]  6  💬 | 
| 1257 | Prolonged-release fampridine | Dalfampridine | [1] D04127D04127 💬 | KCNA4[4] KCNA4, KCNC3, KCND2, KCND3 💬 | Cortisol synthesis and secretion[4] Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia | 013[1] 13 💬 | 
| 1258 | Prolopa® | - | - | - | - | 006[1]  6  💬 | 
| 1259 | Prolotherapy solution of 20% dextrose | Dextrose, unspecified form | - | - | - | 070[1] 70 💬 | 
| 1260 | Promacta | - | - | - | - | 063[2] 63, 65 💬 | 
| 1261 | Promethazine | Promethazine | [4] D00480D00480, D00494D00494, D01242D01242, D03290D03290 💬 | HRH1[1] HRH1 💬 | Calcium signaling pathway[3] Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction | 096[1] 96 💬 | 
| 1262 | Promethera hepastem | - | - | - | - | 251[1] 251 💬 | 
| 1263 | Prometic's immune globulin intravenous 10% | - | - | - | - | 065[1] 65 💬 | 
| 1264 | Promiten | - | - | - | - | 097[1] 97 💬 | 
| 1265 | Promixin | - | - | - | - | 299[1] 299 💬 | 
| 1266 | Promixin 1 million international units (iu) powder for nebuliser solution | - | - | - | - | 299[1] 299 💬 | 
| 1267 | Promixin*nebul 30monod 1mui | - | - | - | - | 299[1] 299 💬 | 
| 1268 | Promixin, 1 million international units (iu) powder for nebuliser solution | - | - | - | - | 299[1] 299 💬 | 
| 1269 | Promixin,1 millón de unidades internacionales,polvo para solución para inhalación por nebulizador | - | - | - | - | 299[1] 299 💬 | 
| 1270 | Promixin/tadim | - | - | - | - | 299[1] 299 💬 | 
| 1271 | Propagermanium | - | - | - | - | 222[1] 222 💬 | 
| 1272 | Propanoic acid | Propanoic acid | [1] D02310D02310 💬 | - | - | 006[2]  6 , 271 💬 | 
| 1273 | Propanolol | Propranolol | [2] D00483D00483, D08443D08443 💬 | ADRB1[3] ADRB1, ADRB2, ADRB3 💬 | Adrenergic signaling in cardiomyocytes[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway | 296[1] 296 💬 | 
| 1274 | Propantheline | Propantheline | [1] D00481D00481 💬 | CHRM1[5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Alzheimer disease[13] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway | 026[1] 26 💬 | 
| 1275 | Propantheline bromide | Propantheline | [1] D00481D00481 💬 | CHRM1[5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Alzheimer disease[13] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway | 026[1] 26 💬 | 
| 1276 | Prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis a, hepatitis b, tick-borne encephalitis, meningococcal, pneumococcal) | - | - | - | - | 013[1] 13 💬 | 
| 1277 | Propionyl l-carnitine | Levocarnitine | [3] D02030D02030, D02176D02176, D04713D04713 💬 | - | - | 097[1] 97 💬 | 
| 1278 | Propionyl l-carnitine hydrochloride | Levocarnitine | [3] D02030D02030, D02176D02176, D04713D04713 💬 | - | - | 097[1] 97 💬 | 
| 1279 | Propionyl-l-carnitine | Levocarnitine | [3] D02030D02030, D02176D02176, D04713D04713 💬 | - | - | 097[1] 97 💬 | 
| 1280 | Propionylcarnitinhydrochlorid | - | - | - | - | 097[1] 97 💬 | 
| 1281 | Propiverine | Propiverine | [1] D08441D08441 💬 | CACNA1C[9] CACNA1C, CACNA1D, CACNA1F, CACNA1S, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Adrenergic signaling in cardiomyocytes[42] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Regulation of actin cytoskeleton, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 226[1] 226 💬 | 
| 1282 | Propiverine hydrochloride | Propiverine | [1] D08441D08441 💬 | CACNA1C[9] CACNA1C, CACNA1D, CACNA1F, CACNA1S, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Adrenergic signaling in cardiomyocytes[42] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Regulation of actin cytoskeleton, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 226[1] 226 💬 | 
| 1283 | Propofol | Propofol | [1] D00549D00549 💬 | GABRA1[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | GABAergic synapse[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction | 006[8]  6 , 21, 22, 34, 46, 84, 98, 296 💬 | 
| 1284 | Propofol-lipuro | Propofol | [1] D00549D00549 💬 | GABRA1[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | GABAergic synapse[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction | 006[1]  6  💬 | 
| 1285 | Propolipid | - | - | - | - | 046[1] 46 💬 | 
| 1286 | Proposed inn - filgotinib | Filgotinib | [1] D10871D10871 💬 | JAK1[1] JAK1 💬 | Coronavirus disease - COVID-19[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 046[1] 46 💬 | 
| 1287 | Propranolol | Propranolol | [2] D00483D00483, D08443D08443 💬 | ADRB1[3] ADRB1, ADRB2, ADRB3 💬 | Adrenergic signaling in cardiomyocytes[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway | 006[5]  6 , 158, 167, 227, 278 💬 | 
| 1288 | Propranolol hcl cf 40 mg tablet | Propranolol | [2] D00483D00483, D08443D08443 💬 | ADRB1[3] ADRB1, ADRB2, ADRB3 💬 | Adrenergic signaling in cardiomyocytes[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway | 006[1]  6  💬 | 
| 1289 | Propranolol treatment | Propranolol | [2] D00483D00483, D08443D08443 💬 | ADRB1[3] ADRB1, ADRB2, ADRB3 💬 | Adrenergic signaling in cardiomyocytes[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway | 227[1] 227 💬 | 
| 1290 | Propsoed inn - filgotinib | Filgotinib | [1] D10871D10871 💬 | JAK1[1] JAK1 💬 | Coronavirus disease - COVID-19[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 046[1] 46 💬 | 
| 1291 | Propylene glycol | Propylene glycol | [1] D00078D00078 💬 | - | - | 028[2] 28, 51 💬 | 
| 1292 | Propylene glycol-free melphalan hydrochloride | Melphalan | [2] D00078D00078, D00369D00369 💬 | - | - | 028[1] 28 💬 | 
| 1293 | Prosavin | - | - | - | - | 006[1]  6  💬 | 
| 1294 | Proscar*30cpr riv 5mg | - | - | - | - | 006[1]  6  💬 | 
| 1295 | Prostacyclin | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 1296 | Prostanoids | - | - | - | - | 051[1] 51 💬 | 
| 1297 | Proteasa | - | - | - | - | 299[1] 299 💬 | 
| 1298 | Protease | - | - | - | - | 299[1] 299 💬 | 
| 1299 | Protease inhibitor | - | - | - | - | 265[1] 265 💬 | 
| 1300 | Protease inhibitors | - | - | - | - | 265[1] 265 💬 | 
| 1301 | Protectis | - | - | - | - | 066[1] 66 💬 | 
| 1302 | Protein | - | - | - | - | 046[2] 46, 67 💬 | 
| 1303 | Protein intake | - | - | - | - | 240[1] 240 💬 | 
| 1304 | Protein-carbohydrate supplementation | - | - | - | - | 113[1] 113 💬 | 
| 1305 | Proteína recombinante estimulante de la megacariopoyesis | - | - | - | - | 063[1] 63 💬 | 
| 1306 | Prothrombin | Prothrombin | - | - | - | 288[1] 288 💬 | 
| 1307 | Prothrombin complex concentrate | Factor IX Complex (Human) | - | - | - | 288[1] 288 💬 | 
| 1308 | Proton pump inhibitor (ppi) | - | - | - | - | 298[1] 298 💬 | 
| 1309 | Prototype capsule gdc-0134 | - | - | - | - | 002[1]  2  💬 | 
| 1310 | Provigil | - | - | - | - | 013[1] 13 💬 | 
| 1311 | Provigil (modafinil) | Modafinil | [1] D01832D01832 💬 | - | - | 013[1] 13 💬 | 
| 1312 | Prozac | - | - | - | - | 017[1] 17 💬 | 
| 1313 | Prp | - | - | - | - | 090[1] 90 💬 | 
| 1314 | Prp injection | - | - | - | - | 053[1] 53 💬 | 
| 1315 | Prtx-100 | - | - | - | - | 046[1] 46 💬 | 
| 1316 | Prtx-100 (staphylococcal protein a) | Bevifimod | - | - | - | 063[1] 63 💬 | 
| 1317 | Prtx-100 at 1.5 mcg/kg | - | - | - | - | 046[1] 46 💬 | 
| 1318 | Prtx-100 at 12.0 mcg/kg | - | - | - | - | 046[1] 46 💬 | 
| 1319 | Prtx-100 at 240 mcg | - | - | - | - | 046[1] 46 💬 | 
| 1320 | Prtx-100 at 3.0 mcg/kg | - | - | - | - | 046[1] 46 💬 | 
| 1321 | Prtx-100 at 420 mcg | - | - | - | - | 046[1] 46 💬 | 
| 1322 | Prtx-100 at 6.0 mcg/kg | - | - | - | - | 046[1] 46 💬 | 
| 1323 | Pru-pla-pla-pru | - | - | - | - | 099[1] 99 💬 | 
| 1324 | Pru-pla-pru-pla | - | - | - | - | 099[1] 99 💬 | 
| 1325 | Prucalopride | Prucalopride | [1] D09205D09205 💬 | HTR4[1] HTR4 💬 | Calcium signaling pathway[4] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway | 013[3] 13, 51, 96 💬 | 
| 1326 | Prucalopride succinate | Prucalopride | [1] D09205D09205 💬 | HTR4[1] HTR4 💬 | Calcium signaling pathway[4] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway | 051[1] 51 💬 | 
| 1327 | Prv-300 | - | - | - | - | 097[1] 97 💬 | 
| 1328 | Prv-6527 | - | - | - | - | 096[1] 96 💬 | 
| 1329 | Prv-6527 (jnj-40346527) | JNJ-40346527 | - | - | - | 096[1] 96 💬 | 
| 1330 | Prv-6527(jnj-40346527) | JNJ-40346527 | - | - | - | 096[1] 96 💬 | 
| 1331 | Prx-102 | - | - | - | - | 019[1] 19 💬 | 
| 1332 | Prx-102 (pegunigalsidase alfa) | Pegunigalsidase alfa | [1] D11685D11685 💬 | - | - | 019[1] 19 💬 | 
| 1333 | Prx-112 | - | - | - | - | 019[1] 19 💬 | 
| 1334 | Prx002 | - | - | - | - | 006[1]  6  💬 | 
| 1335 | Prx002, elt2, anti-alpha-synuclein monoclonal antibody | - | - | - | - | 006[1]  6  💬 | 
| 1336 | Prx102 | - | - | - | - | 019[1] 19 💬 | 
| 1337 | Psrs11.efs.il2rg.pre* retroviral vector | - | - | - | - | 065[1] 65 💬 | 
| 1338 | Psrs11.efs.il2rg.pre* retroviral vector transduce | - | - | - | - | 065[1] 65 💬 | 
| 1339 | Psrs11.efs.il2rg.pre* retroviral vector transduced cells | - | - | - | - | 065[1] 65 💬 | 
| 1340 | Pyridoxine plus prednisolone | Prednisolone | [10] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D02179D02179, D03301D03301, D08454D08454 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 145[1] 145 💬 | 
| 1341 | R(+) pramipexole dihydrochloride monohydrate | Pramipexole | [2] D00559D00559, D05575D05575 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 002[1]  2  💬 | 
| 1342 | R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride | Benzofuran | - | - | - | 006[1]  6  💬 | 
| 1343 | R-salbutamol | Levosalbutamol | [2] D02147D02147, D08124D08124 💬 | ADRB2[1] ADRB2 💬 | Adrenergic signaling in cardiomyocytes[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 049[1] 49 💬 | 
| 1344 | R-salbutamol sulphate | Levosalbutamol | [2] D02147D02147, D08124D08124 💬 | ADRB2[1] ADRB2 💬 | Adrenergic signaling in cardiomyocytes[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 049[1] 49 💬 | 
| 1345 | Radiation: preparative radiation therapy | - | - | - | - | 240[1] 240 💬 | 
| 1346 | Ranolazine 1000 mg pr tablets | Ranolazine | [2] D05700D05700, D05701D05701 💬 | - | - | 058[1] 58 💬 | 
| 1347 | Ranolazine 500 mg pr tablets | Ranolazine | [2] D05700D05700, D05701D05701 💬 | - | - | 058[1] 58 💬 | 
| 1348 | Ranolazine 750 mg pr tablets | Ranolazine | [2] D05700D05700, D05701D05701 💬 | - | - | 058[1] 58 💬 | 
| 1349 | Ranolazine pr (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die | Ranolazine | [2] D05700D05700, D05701D05701 💬 | - | - | 058[1] 58 💬 | 
| 1350 | Rayos (delayed-release prednisone) | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 1351 | Rebif 44 microgramos solución inyectable en jeringa precargada | - | - | - | - | 013[1] 13 💬 | 
| 1352 | Rebif 44 micrograms solution for injection in pre-filled syringe | - | - | - | - | 013[1] 13 💬 | 
| 1353 | Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack | - | - | - | - | 013[1] 13 💬 | 
| 1354 | Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack. | - | - | - | - | 013[1] 13 💬 | 
| 1355 | Rebif new formulation + ibuprofen prn | Ibuprofen | [4] D00126D00126, D01122D01122, D04490D04490, D06606D06606 💬 | PTGS1[2] PTGS1, PTGS2 💬 | Alzheimer disease[23] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway | 013[1] 13 💬 | 
| 1356 | Rebif new formulation + prophylactic ibuprofen | Ibuprofen | [4] D00126D00126, D01122D01122, D04490D04490, D06606D06606 💬 | PTGS1[2] PTGS1, PTGS2 💬 | Alzheimer disease[23] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway | 013[1] 13 💬 | 
| 1357 | Recifercept (proposed inn) | - | - | - | - | 276[1] 276 💬 | 
| 1358 | Recombinanat dna-derived human growth hormone produced in e.coli | Somatotropin | [1] D02691D02691 💬 | GHR[1] GHR 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway | 078[1] 78 💬 | 
| 1359 | Recombinant coagulation fviii fc – von willebrand factor – xten fusion protein | Von Willebrand Factor Human | - | - | - | 288[1] 288 💬 | 
| 1360 | Recombinant coagulation fviii fc – vonwillebrand factor – xten fusion protein | - | - | - | - | 288[1] 288 💬 | 
| 1361 | Recombinant dna-derived human growth hormone produced in e.coli | Somatotropin | [1] D02691D02691 💬 | GHR[1] GHR 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway | 078[1] 78 💬 | 
| 1362 | Recombinant factor fc fusion protein | - | - | - | - | 046[2] 46, 49 💬 | 
| 1363 | Recombinant human coagulation factor viii fc - von willebrand factor - xten fusion protein | Antihemophilic factor human | - | - | - | 288[1] 288 💬 | 
| 1364 | Recombinant human erythropoietin | Erythropoietin | [1] D03231D03231 💬 | EPOR[1] EPOR 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer | 013[1] 13 💬 | 
| 1365 | Recombinant human erythropoietin(rhepo) | Erythropoietin | [1] D03231D03231 💬 | EPOR[1] EPOR 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer | 002[1]  2  💬 | 
| 1366 | Recombinant human glucocerebrosidase (prgcd) | Taliglucerase alfa | [1] D09675D09675 💬 | GBA[1] GBA 💬 | Lysosome[4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism | 019[1] 19 💬 | 
| 1367 | Recombinant tnf-a receptor: igg fc fusion protein | - | - | - | - | 046[2] 46, 271 💬 | 
| 1368 | Recombinant truncated spint2 protease inhibitor | - | - | - | - | 299[1] 299 💬 | 
| 1369 | Rectal tacrolimus | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 097[1] 97 💬 | 
| 1370 | Reduced intensity preparative regimen | - | - | - | - | 062[3] 62, 65, 284 💬 | 
| 1371 | Rege pro dressing | - | - | - | - | 036[1] 36 💬 | 
| 1372 | Remestemcel-l | Remestemcel-L | [1] D09719D09719 💬 | - | - | 096[2] 96, 97 💬 | 
| 1373 | Reminder product | - | - | - | - | 019[1] 19 💬 | 
| 1374 | Repaglinide | Repaglinide | [1] D00594D00594 💬 | ABCC8[2] ABCC8, KCNJ11 💬 | ABC transporters[4] ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus | 006[3]  6 , 21, 299 💬 | 
| 1375 | Repaglinide and insulin | Repaglinide | [1] D00594D00594 💬 | ABCC8[2] ABCC8, KCNJ11 💬 | ABC transporters[4] ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus | 299[1] 299 💬 | 
| 1376 | Repatha 140 mg solution for injection in pre-filled pen | - | - | - | - | 079[1] 79 💬 | 
| 1377 | Requip pr | - | - | - | - | 006[1]  6  💬 | 
| 1378 | Requip prolonged release | - | - | - | - | 006[1]  6  💬 | 
| 1379 | Requip xl prolonged-release | - | - | - | - | 006[1]  6  💬 | 
| 1380 | Revolade, promacta | - | - | - | - | 063[1] 63 💬 | 
| 1381 | Rhumab beta7, anti beta 7, pro145223 | - | - | - | - | 097[1] 97 💬 | 
| 1382 | Rhumab beta7, anti beta7, pro145223 | - | - | - | - | 097[1] 97 💬 | 
| 1383 | Rifaximin+omeprazole+miralax | Omeprazole | [5] D00455D00455, D01207D01207, D02554D02554, D05259D05259, D05261D05261 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 096[1] 96 💬 | 
| 1384 | Riociguat oral product | Riociguat | [1] D09572D09572 💬 | GUCY1A1[3] GUCY1A1, GUCY1A2, GUCY1B1 💬 | Circadian entrainment[11] Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway | 086[1] 86 💬 | 
| 1385 | Rivastigmine | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 005[3]  5 ,  6 , 13 💬 | 
| 1386 | Rivastigmine capsule | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 1387 | Rivastigmine cf | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 1388 | Rivastigmine luye transdermal patch- 9.5mg/24h | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 1389 | Rivastigmine patch 9.5 cm2 | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 1390 | Rivastigmine transdermal patch | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[2]  6 , 13 💬 | 
| 1391 | Rivastigmine transdermal system | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 1392 | Rivastigmine transdermal system 13.3 mg/24 h | Rivastigmine | [2] D02558D02558, D03822D03822 💬 | ACHE[1] ACHE 💬 | Cholinergic synapse[2] Cholinergic synapse, Glycerophospholipid metabolism | 006[1]  6  💬 | 
| 1393 | Roactemra 162 mg solution for injection in pre-filled syringe | - | - | - | - | 041[1] 41 💬 | 
| 1394 | Roactemra 162 mg solution injectable en seringue préremplie | - | - | - | - | 046[1] 46 💬 | 
| 1395 | Roactemra®ev product code: prd82321 | - | - | - | - | 046[1] 46 💬 | 
| 1396 | Ropinirole hydrochloride prolonged release | Ropinirole | [2] D00784D00784, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1397 | Ropinirole oral product | Ropinirole | [2] D00784D00784, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1398 | Ropinirole pr | Ropinirole | [2] D00784D00784, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1399 | Ropinirole pr, 2mg | Ropinirole | [2] D00784D00784, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1400 | Ropinirole pr/xr | Ropinirole | [2] D00784D00784, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1401 | Ropinirole pr/xr tablets | Ropinirole | [2] D00784D00784, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1402 | Ropinirole prolonged release | Ropinirole | [2] D00784D00784, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1403 | Ropinirole prolonged release/extended release(pr/xr) | Ropinirole | [2] D00784D00784, D08489D08489 💬 | DRD2[3] DRD2, DRD3, DRD4 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1404 | Rotigotine (reference product pr 2.1.1) | Rotigotine | [1] D05768D05768 💬 | DRD2[1] DRD2 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1405 | Rotigotine (test product pr 2.3.1) | Rotigotine | [1] D05768D05768 💬 | DRD2[1] DRD2 💬 | Alcoholism[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 006[1]  6  💬 | 
| 1406 | Sait101 (proposed rituximab biosimilar) | Rituximab | [1] D02994D02994 💬 | MS4A1[1] MS4A1 💬 | Hematopoietic cell lineage[1] Hematopoietic cell lineage | 046[1] 46 💬 | 
| 1407 | Salbutamol | Salbutamol | [1] D02147D02147 💬 | ADRB2[1] ADRB2 💬 | Adrenergic signaling in cardiomyocytes[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 003[9]  3 , 11, 49, 85, 86, 111, 228, 256, 299 💬 | 
| 1408 | Salbutamol 4mg tablet | Salbutamol | [1] D02147D02147 💬 | ADRB2[1] ADRB2 💬 | Adrenergic signaling in cardiomyocytes[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 011[1] 11 💬 | 
| 1409 | Salbutamol sulfate | Salbutamol | [1] D02147D02147 💬 | ADRB2[1] ADRB2 💬 | Adrenergic signaling in cardiomyocytes[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 111[1] 111 💬 | 
| 1410 | Salbutamol sulfate ph. eur. | Salbutamol | [1] D02147D02147 💬 | ADRB2[1] ADRB2 💬 | Adrenergic signaling in cardiomyocytes[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 011[1] 11 💬 | 
| 1411 | Salbutamol wzf 4 mg | Salbutamol | [1] D02147D02147 💬 | ADRB2[1] ADRB2 💬 | Adrenergic signaling in cardiomyocytes[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway | 011[1] 11 💬 | 
| 1412 | Salofalk 3g gastro-resistant prolonged-release granules | - | - | - | - | 097[1] 97 💬 | 
| 1413 | Sandostatina - lar 20 mg/2.5 ml polvere e solvente per sospensione iniettabile flacone polvere + siringa preriempita 2.5 ml + 2 aghi | - | - | - | - | 067[1] 67 💬 | 
| 1414 | Sb12 (proposed eculizumab biosimilar) | Eculizumab | [1] D03940D03940 💬 | C5[1] C5 💬 | Complement and coagulation cascades[9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus | 062[1] 62 💬 | 
| 1415 | Sb2 (proposed biosimilar to infliximab) | Infliximab | [1] D02598D02598 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 1416 | Sb4 (proposed biosimilar to etanercept) | Etanercept | [1] D00742D00742 💬 | LTA[2] LTA, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 1417 | Sb5 (proposed biosimilar to adalimumab) | Adalimumab | [1] D02597D02597 💬 | TNF[1] TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 1418 | Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group) | Amitriptyline | [7] D00326D00326, D00809D00809, D00823D00823, D01355D01355, D02691D02691, D07448D07448, D08623D08623 💬 | GHR[4] GHR, OPRM1, SLC6A2, SLC6A4 💬 | Cytokine-cytokine receptor interaction[9] Cytokine-cytokine receptor interaction, Estrogen signaling pathway, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Serotonergic synapse, Synaptic vesicle cycle | 078[1] 78 💬 | 
| 1419 | Scopolamine, atropine, edaravone and dexmedetomidine | Atropine | [9] D00113D00113, D00138D00138, D00514D00514, D01077D01077, D01205D01205, D01552D01552, D02069D02069, D03011D03011, D03814D03814 💬 | ADRA2A[8] ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Alzheimer disease[14] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway | 002[1]  2  💬 | 
| 1420 | Secukinumab 150 mg provided in 1.0 ml pre-filled syringes (pfss) for sc injection. | Secukinumab | [1] D09967D09967 💬 | IL17A[1] IL17A 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation | 271[1] 271 💬 | 
| 1421 | Simponi 50 mg solución inyectable en pluma precargada | - | - | - | - | 046[1] 46 💬 | 
| 1422 | Sirolimus oral liquid product 1mg/ml | Sirolimus | [1] D00753D00753 💬 | MTOR[1] MTOR 💬 | AMPK signaling pathway[50] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway | 278[1] 278 💬 | 
| 1423 | Sirolimus oral product | Sirolimus | [1] D00753D00753 💬 | MTOR[1] MTOR 💬 | AMPK signaling pathway[50] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway | 089[2] 89, 158 💬 | 
| 1424 | Sitagliptin | Sitagliptin | [1] D08516D08516 💬 | DPP4[1] DPP4 💬 | Protein digestion and absorption[1] Protein digestion and absorption | 006[4]  6 , 75, 233, 299 💬 | 
| 1425 | Sitagliptin and metformin | Metformin | [3] D00944D00944, D04966D04966, D08516D08516 💬 | DPP4[3] DPP4, PRKAA1, PRKAA2 💬 | AMPK signaling pathway[20] AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Protein digestion and absorption, Thermogenesis, Tight junction, mTOR signaling pathway | 233[1] 233 💬 | 
| 1426 | Solu-cortef (hydrocortisone) | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 083[1] 83 💬 | 
| 1427 | Soluble prednisolone tablets | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 145[1] 145 💬 | 
| 1428 | Sotatercept with prednisone boost | Prednisone | [2] D00473D00473, D09670D09670 💬 | ACVR2A[2] ACVR2A, NR3C1 💬 | Cytokine-cytokine receptor interaction[5] Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Neuroactive ligand-receptor interaction, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway | 284[1] 284 💬 | 
| 1429 | Soy protein | - | - | - | - | 006[2]  6 , 96 💬 | 
| 1430 | Soy protein isolate | - | - | - | - | 227[1] 227 💬 | 
| 1431 | Staphylococcal protein a | Bevifimod | - | - | - | 063[1] 63 💬 | 
| 1432 | Stelara 90 mg solution for injection in pre-filled syringe | - | - | - | - | 096[1] 96 💬 | 
| 1433 | Stem/progenitor cells transplantation | - | - | - | - | 090[2] 90, 301 💬 | 
| 1434 | Steroid and proton pump inhibitor therapy | - | - | - | - | 098[1] 98 💬 | 
| 1435 | Strontium ranelate | Strontium ranelate | [1] D08468D08468 💬 | - | - | 078[1] 78 💬 | 
| 1436 | Study of the gene expression profile | - | - | - | - | 051[1] 51 💬 | 
| 1437 | Subcutaneous and intravenous prostacyclin | Epoprostenol | [2] D00106D00106, D01337D01337 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 1438 | Subcutaneous hydrocortisone | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 081[1] 81 💬 | 
| 1439 | Subcutaneous hydrocortisone 10mg | Hydrocortisone | [1] D00088D00088 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 006[1]  6  💬 | 
| 1440 | Subretinal injection of umbilical cord blood platelet-rich plasma (cb-prp) | - | - | - | - | 090[1] 90 💬 | 
| 1441 | Sulphasalazine + hydroxychloroquine or prednisolone | Hydroxychloroquine | [9] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301, D08050D08050 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 1442 | Sustanon (testosterone) | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 113[1] 113 💬 | 
| 1443 | Symptomatic treatment, steroids, immunosuppressive agents( azathioprine, tacrolimus, mycophenolate mofetil) | Azathioprine | [8] D00107D00107, D00238D00238, D00752D00752, D03033D03033, D05094D05094, D05095D05095, D05096D05096, D08556D08556 💬 | IMPDH1[7] IMPDH1, IMPDH2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[35] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 011[1] 11 💬 | 
| 1444 | Synthetic preimplantation factor | Preimplantation factor | - | - | - | 095[1] 95 💬 | 
| 1445 | T-cell depleted & cd34+select/w/stemcell enriched product | - | - | - | - | 065[1] 65 💬 | 
| 1446 | Tabalumab prefilled syringe | Tabalumab | [1] D10083D10083 💬 | TNFSF13B[1] TNFSF13B 💬 | Cytokine-cytokine receptor interaction[4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis | 046[2] 46, 49 💬 | 
| 1447 | Tacrolimus | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 002[32]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 | 
| 1448 | Tacrolimus (advagraf) | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 227[1] 227 💬 | 
| 1449 | Tacrolimus (prograf®) | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 046[1] 46 💬 | 
| 1450 | Tacrolimus (tacro) | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 065[1] 65 💬 | 
| 1451 | Tacrolimus and mmf | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 299[1] 299 💬 | 
| 1452 | Tacrolimus capsule | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 011[1] 11 💬 | 
| 1453 | Tacrolimus capsule (low-dose) | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 227[1] 227 💬 | 
| 1454 | Tacrolimus capsules | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 222[2] 222, 299 💬 | 
| 1455 | Tacrolimus combined with prednisone | Prednisone | [3] D00107D00107, D00473D00473, D08556D08556 💬 | NR3C1[6] NR3C1, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[33] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 222[1] 222 💬 | 
| 1456 | Tacrolimus prolonged-release hard capsules | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 299[1] 299 💬 | 
| 1457 | Tacrolimus tablets | Tacrolimus | [2] D00107D00107, D08556D08556 💬 | PPP3CA[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 006[1]  6  💬 | 
| 1458 | Tacrolimus with methotrexate | Methotrexate | [4] D00107D00107, D00142D00142, D02115D02115, D08556D08556 💬 | DHFR[7] DHFR, DHFR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease[37] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Axon guidance, B cell receptor signaling pathway, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Folate biosynthesis, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, One carbon pool by folate, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 046[1] 46 💬 | 
| 1459 | Taltz (80 mg solution for injection in pre-filled syringe) | - | - | - | - | 271[1] 271 💬 | 
| 1460 | Targinact 10 mg/5 mg prolonged-release tablets | - | - | - | - | 006[2]  6 , 226 💬 | 
| 1461 | Targinact 20 mg/10 mg prolonged-release tablets | - | - | - | - | 006[1]  6  💬 | 
| 1462 | Targinact 20mg/10 mg prolonged-release tablets | - | - | - | - | 226[1] 226 💬 | 
| 1463 | Targinact 5 mg/2.5 mg prolonged-release tablets | - | - | - | - | 006[1]  6  💬 | 
| 1464 | Targinact 5mg/2.5 mg prolonged-release tablets | - | - | - | - | 226[1] 226 💬 | 
| 1465 | Tasocitinib (proposed inn) | Tofacitinib | [1] D09970D09970 💬 | JAK1[4] JAK1, JAK2, JAK3, TYK2 💬 | AGE-RAGE signaling pathway in diabetic complications[35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 046[1] 46 💬 | 
| 1466 | Tch346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) | Hydrogen | - | - | - | 006[1]  6  💬 | 
| 1467 | Testosterone | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 001[8]  1 ,  2 ,  3 , 13, 60, 78, 113, 265 💬 | 
| 1468 | Testosterone decanoate | Testosterone | [7] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087, D08573D08573 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 113[1] 113 💬 | 
| 1469 | Testosterone enanthate | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 113[1] 113 💬 | 
| 1470 | Testosterone isocaproate | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 113[1] 113 💬 | 
| 1471 | Testosterone phenylpropionate | Testosterone | [7] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087, D08574D08574 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 113[1] 113 💬 | 
| 1472 | Testosterone plus somatropin | Somatotropin | [7] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D02691D02691, D06085D06085, D06087D06087 💬 | AR[2] AR, GHR 💬 | Cytokine-cytokine receptor interaction[8] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Oocyte meiosis, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer | 078[1] 78 💬 | 
| 1473 | Testosterone propionate | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 113[1] 113 💬 | 
| 1474 | Testosterone undecanoate | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 013[2] 13, 60 💬 | 
| 1475 | Thalidomide, cyclophosphamide and prednisone | Cyclophosphamide | [4] D00287D00287, D00473D00473, D00754D00754, D07760D07760 💬 | NR3C1[2] NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 331[1] 331 💬 | 
| 1476 | The generic name is warfarin and many producers will be involved | Warfarin | [3] D00564D00564, D01280D01280, D08682D08682 💬 | NQO1[2] NQO1, VKORC1 💬 | Biosynthesis of cofactors[6] Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis | 049[1] 49 💬 | 
| 1477 | The gut mycobiota and microbiota profile | - | - | - | - | 299[1] 299 💬 | 
| 1478 | The investigational medicinal product (imp) may be labelled as either pf-04236921 106 mg/vial, clonal sc lyophilized form” or pf-04236921 powder for injection, 106 mg/vial”. supplies labelled with either nomenclature are equivalent. | - | - | - | - | 096[1] 96 💬 | 
| 1479 | The investigational medicinal product (imp) will be labeled as pf-04236921 106 mg/vial, clonal sc lyophilized form, which is equivalent to pf-04236921 powder for injection, 106 mg/vial as described in the enclosed cta | - | - | - | - | 096[1] 96 💬 | 
| 1480 | The investigational medicinal product (imp) will be labeled as pf-04236921 106 mg/vial, clonal sc lyophilized form, which is equivalent to pf-04236921 powder for injection, 106 mg/vial as described in the enclosed cta. | - | - | - | - | 096[1] 96 💬 | 
| 1481 | The lung mycobiota and microbiota profile | - | - | - | - | 299[1] 299 💬 | 
| 1482 | The pop02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: | - | - | - | - | 086[1] 86 💬 | 
| 1483 | The pops study is collecting pk data on children prescribed the following drugs of interest per standard of care: | - | - | - | - | 086[1] 86 💬 | 
| 1484 | Tildrakizumab prefilled syringe | Tildrakizumab | [1] D10400D10400 💬 | IL23A[1] IL23A 💬 | C-type lectin receptor signaling pathway[9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis | 162[1] 162 💬 | 
| 1485 | Tobi inhalant product | - | - | - | - | 299[1] 299 💬 | 
| 1486 | Tocilizumab prefilled syringe | Tocilizumab | [1] D02596D02596 💬 | IL6R[1] IL6R 💬 | Coronavirus disease - COVID-19[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor | 046[1] 46 💬 | 
| 1487 | Tocilizumab sc 162 mg/0.9 ml pre-filled syringe with safety device (pfs) | Tocilizumab | [1] D02596D02596 💬 | IL6R[1] IL6R 💬 | Coronavirus disease - COVID-19[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor | 046[1] 46 💬 | 
| 1488 | Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs) | Tocilizumab | [1] D02596D02596 💬 | IL6R[1] IL6R 💬 | Coronavirus disease - COVID-19[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor | 051[1] 51 💬 | 
| 1489 | Tofacitinib (xeljanz®) 11mg prolonged release tablet | Tofacitinib | [1] D09970D09970 💬 | JAK1[4] JAK1, JAK2, JAK3, TYK2 💬 | AGE-RAGE signaling pathway in diabetic complications[35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 046[1] 46 💬 | 
| 1490 | Tofacitinib citrate (proposed commercial formulation - debossed) | Tofacitinib | [1] D09970D09970 💬 | JAK1[4] JAK1, JAK2, JAK3, TYK2 💬 | AGE-RAGE signaling pathway in diabetic complications[35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 046[2] 46, 97 💬 | 
| 1491 | Tofacitinib citrate (proposed commercial formulation debossed) | Tofacitinib | [1] D09970D09970 💬 | JAK1[4] JAK1, JAK2, JAK3, TYK2 💬 | AGE-RAGE signaling pathway in diabetic complications[35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 046[1] 46 💬 | 
| 1492 | Tofacitinib citrate (proposed commercial formulation – debossed) | Tofacitinib | [1] D09970D09970 💬 | JAK1[4] JAK1, JAK2, JAK3, TYK2 💬 | AGE-RAGE signaling pathway in diabetic complications[35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 046[2] 46, 97 💬 | 
| 1493 | Tofacitinib citrate (proposed commercial formulation- debossed) | Tofacitinib | [1] D09970D09970 💬 | JAK1[4] JAK1, JAK2, JAK3, TYK2 💬 | AGE-RAGE signaling pathway in diabetic complications[35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 046[1] 46 💬 | 
| 1494 | Tofacitinib citrate (proposed commercialformulation - debossed) | Tofacitinib | [1] D09970D09970 💬 | JAK1[4] JAK1, JAK2, JAK3, TYK2 💬 | AGE-RAGE signaling pathway in diabetic complications[35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis | 097[1] 97 💬 | 
| 1495 | Topical preparation h arm | - | - | - | - | 013[1] 13 💬 | 
| 1496 | Trade name depends on the source of the product | - | - | - | - | 076[1] 76 💬 | 
| 1497 | Trade name depends on the source of the product’ | - | - | - | - | 076[1] 76 💬 | 
| 1498 | Transcon peg40 hgh, transiently pegylated hgh prodrug | - | - | - | - | 078[1] 78 💬 | 
| 1499 | Transdermal testosterone gel | Testosterone | [6] D00075D00075, D00957D00957, D00958D00958, D00959D00959, D06085D06085, D06087D06087 💬 | AR[1] AR 💬 | Oocyte meiosis[3] Oocyte meiosis, Pathways in cancer, Prostate cancer | 078[1] 78 💬 | 
| 1500 | Transiently pegylated hgh prodrug | - | - | - | - | 078[1] 78 💬 | 
| 1501 | Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan | Alemtuzumab | [5] D00369D00369, D00583D00583, D01907D01907, D02802D02802, D07966D07966 💬 | RRM1[1] RRM1 💬 | Drug metabolism - other enzymes[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 065[2] 65, 164 💬 | 
| 1502 | Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | Lansoprazole | [1] D00355D00355 💬 | ATP4A[2] ATP4A, ATP4B 💬 | Collecting duct acid secretion[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation | 098[1] 98 💬 | 
| 1503 | Treatment systemic therapy (prednisone) | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 162[1] 162 💬 | 
| 1504 | Treatment with systemic therapy (prednisone) | Prednisone | [1] D00473D00473 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 162[1] 162 💬 | 
| 1505 | Treprostinil injectable product | Treprostinil | [1] D06213D06213 💬 | PTGIR[1] PTGIR 💬 | Neuroactive ligand-receptor interaction[3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 086[1] 86 💬 | 
| 1506 | Trexan+salazopyrin+oxiklorin+prednisolone | Prednisolone | [8] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 1507 | Trexan+salazopyrin+oxiklorin+prednisolone + infliximab | Infliximab | [9] D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D02598D02598, D03301D03301 💬 | NR3C1[2] NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 046[1] 46 💬 | 
| 1508 | Triamcinolone | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 035[8] 35, 46, 56, 70, 90, 96, 226, 298 💬 | 
| 1509 | Triamcinolone 40 milligrams (kenacort, bristol myers squip) | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 1510 | Triamcinolone acetonide | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 035[3] 35, 46, 56 💬 | 
| 1511 | Triamcinolone acetonide and normal saline solution | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 070[1] 70 💬 | 
| 1512 | Triamcinolone hexacetonid (lederspan) | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 1513 | Triamcinolone hexacetonide | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 1514 | Triamcinolone hexacetonide (lederspan) | Triamcinolone | [5] D00385D00385, D00983D00983, D00984D00984, D00985D00985, D06216D06216 💬 | NR3C1[1] NR3C1 💬 | Neuroactive ligand-receptor interaction[1] Neuroactive ligand-receptor interaction | 046[1] 46 💬 | 
| 1515 | Trimethoprim | Trimethoprim | [2] D00145D00145, D06236D06236 💬 | - | - | 036[6] 36, 44, 49, 60, 85, 299 💬 | 
| 1516 | Trimethoprim and sulfamethoxazole | Sulfamethoxazole | [3] D00145D00145, D00447D00447, D06236D06236 💬 | - | - | 299[1] 299 💬 | 
| 1517 | Trimethoprim sulfamethoxazole | Sulfamethoxazole | [3] D00145D00145, D00447D00447, D06236D06236 💬 | - | - | 044[1] 44 💬 | 
| 1518 | Trimethoprim sulfamethoxazole (tmp/smx) | Sulfamethoxazole | [3] D00145D00145, D00447D00447, D06236D06236 💬 | - | - | 299[1] 299 💬 | 
| 1519 | Trimethoprim sulfate | Sulfate ion | [2] D00145D00145, D06236D06236 💬 | - | - | 060[1] 60 💬 | 
| 1520 | Trimethoprim-sulfamethoxazole | Sulfamethoxazole | [3] D00145D00145, D00447D00447, D06236D06236 💬 | - | - | 049[2] 49, 299 💬 | 
| 1521 | Trimethoprim/sulfamethoxazole | Sulfamethoxazole | [3] D00145D00145, D00447D00447, D06236D06236 💬 | - | - | 299[1] 299 💬 | 
| 1522 | Trimethoprim/sulfamethoxazole (tmp/smx) | Sulfamethoxazole | [3] D00145D00145, D00447D00447, D06236D06236 💬 | - | - | 299[1] 299 💬 | 
| 1523 | Ursodeoxycholic acid+low dose glucocorticoid(prednisone) | Prednisone | [2] D00473D00473, D00734D00734 💬 | NR1H4[2] NR1H4, NR3C1 💬 | Bile secretion[2] Bile secretion, Neuroactive ligand-receptor interaction | 093[1] 93 💬 | 
| 1524 | Us tap bupivacaine/epinephrine | Bupivacaine | [5] D00095D00095, D00996D00996, D01450D01450, D02149D02149, D07552D07552 💬 | ADRA1A[14] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | AMPK signaling pathway[15] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 096[1] 96 💬 | 
| 1525 | Ustekinumab liquid in prefilled syringe | Ustekinumab | [1] D09214D09214 💬 | IL12A[3] IL12A, IL12B, IL23A 💬 | African trypanosomiasis[26] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus | 084[1] 84 💬 | 
| 1526 | Valproate, levocarnitine | Levocarnitine | [4] D00399D00399, D02030D02030, D02176D02176, D04713D04713 💬 | ABAT[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | Alanine, aspartate and glutamate metabolism[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism | 003[1]  3  💬 | 
| 1527 | Valproic acid and levocarnitine | Levocarnitine | [4] D00399D00399, D02030D02030, D02176D02176, D04713D04713 💬 | ABAT[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | Alanine, aspartate and glutamate metabolism[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism | 003[1]  3  💬 | 
| 1528 | Vancomycin pre-treat | Vancomycin | [2] D00212D00212, D00926D00926 💬 | - | - | 097[1] 97 💬 | 
| 1529 | Vancomycin pre-treatment | Vancomycin | [2] D00212D00212, D00926D00926 💬 | - | - | 097[1] 97 💬 | 
| 1530 | Vivomixx probiotics | - | - | - | - | 051[1] 51 💬 | 
| 1531 | Vwf-containing products | - | - | - | - | 288[1] 288 💬 | 
| 1532 | Vwf/fviii products | - | - | - | - | 288[1] 288 💬 | 
| 1533 | Whey protein | - | - | - | - | 006[2]  6 , 96 💬 | 
| 1534 | Whey protein&prebiotic supplement | - | - | - | - | 046[1] 46 💬 | 
| 1535 | Z102 (prednisolone and dipyridamole). | Dipyridamole | [9] D00302D00302, D00472D00472, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | NR3C1[3] NR3C1, PDE4A, PDE5A 💬 | Metabolic pathways[7] Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway | 046[1] 46 💬 | 
| 1536 | Zavesca® prescription | - | - | - | - | 256[1] 256 💬 | 
| 1537 | Zoledronic acid kern pharma 4 mg/100 ml solution for infusion, generic medicinal product | Zoledronic acid | [4] D01968D01968, D06378D06378, D06379D06379, D08689D08689 💬 | FDPS[1] FDPS 💬 | Human T-cell leukemia virus 1 infection[4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis | 274[1] 274 💬 | 
| 1538 | Zoledronic acid kern pharma 4 mg/100 ml solution for infusion, generic medicinal product. | Zoledronic acid | [4] D01968D01968, D06378D06378, D06379D06379, D08689D08689 💬 | FDPS[1] FDPS 💬 | Human T-cell leukemia virus 1 infection[4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis | 274[1] 274 💬 | 
| 1539 | Zoledronic acid kern pharma 4 mg/100 ml solution for infusion,generic medicinal product | Zoledronic acid | [4] D01968D01968, D06378D06378, D06379D06379, D08689D08689 💬 | FDPS[1] FDPS 💬 | Human T-cell leukemia virus 1 infection[4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis | 274[1] 274 💬 | 
| 1540 | Zoledronic acid, pravastatin | Pravastatin | [6] D00893D00893, D01968D01968, D06378D06378, D06379D06379, D08410D08410, D08689D08689 💬 | FDPS[2] FDPS, HMGCR 💬 | AMPK signaling pathway[6] AMPK signaling pathway, Bile secretion, Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis | 333[1] 333 💬 |